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SYNOPSIS 
The use of fluorescein and rhodamine as donor and 
acceptor fluorescent labels in the development of energy 
transfer immunoassay (ETIA) methods was evaluated by developing 
an assay for human serum albumin. The sensitivity of the assay 
was found to depend on (i) the degrees of fluorophore labelling 
of antibody and antigen, (ii) concentrations of labelled 
antibody and antigen, (iii) the fluorimeter spectral bandwidth, 
and (iv) whether the donor (fluorescein) was conjugated to the 
antigen or the antibody. These results, including those relating 
to the stability of the labelled immune reactants on storage, 
lead to the conclusion that fluorescein and rhodamine are far 
from ideal as donor and acceptor. Nevertheless, the application 
of the assay to the analysis of test serum samples gave results 
that compared favourablY with those obtained by electroimmunoassay. 
Other potential donor and acceptor fluorescent labels 
were also investigated, viz. Ca) fluorescamine and fluorescein, 
(b) MDPF and fluorescein, (c) dansyl chloride and rhodamine, 
(d) quinacrine and fluorescein, and (e) quinacrine and rhodamine. 
Of these, only (a) and (b) were found to be suitable donor-acceptor 
pairs, and they were applied to the development of a number of 
assays for both low and high molecular-weight analytes • 
. Comparative studies of fluorescamine and MDPF as donor fluorescent 
labels together with fluorescein as the acceptor label were 
performed by developing immunoassay methods for the determination 
of human serum transferrin in four serum samples including a 
blood sample from the victim of a road traffic accident. Results 
ix 
obtained were generally in good agreement with those found by 
the radial immunodiffUsion method. An ETIA developed ·for 
nortriptyline and related tricyclic antidepressants was capable 
of detecting nanomolar concentrations of the drugs in pure 
solution and in spiked sera. Other ETIA's developed include a 
sandwich assay for the quantitation of human immunoglobulin A, 
and a direct assay for the determination of human immunoglobulin G. 
The Fluram as well as the MDPF enhancement phenomena 
were also studied in detail and applied suocessfUlly to the 
development of fluorescence enhancement immunoassays for 
nortriptyline, human serum transferrin and immunoglobulin G. 
Finally, the automation of an energy transfer 
irurrunoassay was successfUlly performed by using the principles of 
stopped-flow injeotion analysis with merging zones. 
'. 
CHAPTER 1 INTRODUCTION 
1.1 Energy Transfer 
1.1.1 Competitive processes affecting an electronically 
excited molecule. 
A molecule excited from the ground state So to an 
upper singlet energy level S2 may be deactivated by several 
competitive proc~sses as outlined in the energy-level diagram 
of Fig.1.1 
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Fig 1.1 Competitive processes affecting a molecule in an 
excited state S2 • Straight and wavy lines denote radiative 
and nonradiative processes, respectively. 
So = ground state; S, = lowest excited singlet state; 
S2 = initial excited state; T, = lowest triplet state 
k, = rate constant for chemical reaction 
ket= rate constant fo~ energy transfer 
k1c = rate constant for internal conversion 
klx = rate conetant for intersystem crossing 
k f = rate constant for fluorescence 
kp = rate constant for phosphorescence 
From the initial excited state S2' the molecule can 
1 
-13 -11 (i) return rapidly ( in ca. 10 to 10 s ) to the lowest einglet 
". 
state S, by a nonradiative procees called internal conversion, 
(ii) undergo a chemical reaction to yield products, or (iii) 
donate its excitation energy to a neighbouring molecule 
( acceptor ), a proceee called energy transfer. 
For a competitive process to compete effectively with the' 
spontaneous decay ( internal conversion) of the excited state, 
it must have a rate "constant kcp greater than the decay rate of 
the excited state from which it occurs, ie 
kcp ;:::: 
where T.is the lifetime of 
1 
Ta 
the state involved. Thue, in this case, 
the competing processes - chemical reaction and energy transfer -
2 
are not probable frem the excited state S2 because their occurrence 
would imply that these competing proceeses could not be diffusion-
9 -1 -1) 
controlled ( with rate constant -10 litre mol e ,but must 
11 -1 -1 
occur with a first order rate constant of at leaet 10 litre mol s 
(Hercules 1966). 
The molecule from the lowest excited singlet state S,may 
return to the ground state So by fluorescence or internal 
conversion; it may also go to the triplet state T, by a non-
radiative spin-inversion procees called intersystem crossing. 
-8 Since the lifetime of the molecule in S, is ca. 10 s (k f , k1c 
and klx for S,-;>SO approximately 10
8 
S-1) , the competing 
processee of energy transfer and chemical reaction can also oc,cur 
from S, • 
From the lowest triplet state T, , the molecule can return 
to the ground state So by internal conversion or phosphorescence. 
-, 
Furthermore, with T, having a comparatively long lifetime ( 10 to 
'. 
10 s) the competitive processes of energy transfer and chemical 
reaction can also take place from the triplet state. Thus, 
energy transfer from both the lowest excited singlet S, and 
triplet T, states of a molecule ( donor ) to another molecule 
( acceptor ) can occur, and the following possible types of 
energy transfer between donor and acceptor molecules will be 
discussed in the appropriate sections below: 
" 
singlet-singlet energy transfer 
triplet-singlet energy transfer 
singlet-triplet energy transfer 
triplet-triplet energy transfer 
1.1.2 Collisional deactivation of an electronically excited 
molecule 
This is a diffusion-controlled process that involves a 
collisional contact between the excited donor D* and the 
ground state acceptor A. The steps involved in a collisional 
deactivation of an excited donor may be represented as follows. 
* (excitation) (1.2) D + hv~ D 
D* + A~ D + A + kT (deactivation without (1.3) 
energy transfer to A) 
D* * (energy transfer) (1.4) + A~ D + A 
The donor absorbs a photon hv and becomes an excited 
* state molecule D which can then be deactivated to its ground 
* state by emitting a photon hv' ( fluorescence: D -+D + hv') 
or dissipating its excitation energy through interaction with 
a colliding acceptor molecule. The latter process is governed 
by the Stern-Volmer law (stern and Volmer 1919), 
~ 
F = 
3 
". 
4 
where Fo and F are the fluorescence intensi ties in the 
abBence and preBence of the acceptor respectively; Ld is the 
lifetime of the excited state of the donor and . k 11. 
proportionality constant. It can be deduced from the stern-
Volmer that the lifetime 'td decreases with an increase in [A]. 
More collisions will occur the longer the excited state exists 
and therefore donors with long lifetimes are more susceptible 
to colliBional deactivation. 
Although Equations (1.2) to (1.4) above provide an 
adequate mathematical description of collisional energy loss, 
the physical process necessitates an energy dissipation of ca. 
-1 210 _ 420 kJ mol ,which is much greater than what would have 
been expended in a simple bimolecular collision (Hercules 1966). 
Deactivation of the excited donor by the collisional procesB 
can be effected by the following mechanisms which mayor may not 
involve an energy transfer to the acceptor. 
1.1.2.1 Collisional deactivation mechanisms NOT involving 
energy transfer 
(a) Enhanced intersystem crossing ( .spin-orbit coupling the 
external heavy atom effect ). 
* 'D + A ___ 3D* A } intersystem crossing + in the presence of A 
/~ 
enhanced 
D + hv 
phosphorescence 
D + kT internal conversion to 
ground state 
(b) Enhanced internal conversion. The interaction with H-
bonding acceptor involving vibrational coupling between 
D* and A will lead to enhanced internal conversion of D* 
to the ground state. 
D* + A ~D + A + kT 
5 
(c) Exciplex formation followed by internal conversion to the 
ground state or diminished and red-shifted fluorescence. 
* * D + A - (D-A) ---> D + A + hv' 
exciplex 
1 
D + A + kT 
diminished fluorescence 
and red-shifted compared 
to monomeric donor 
fluorescence 
internal conversion to 
ground state 
(d) Charge-transfer complex formation (by the reversible 
electron transfer mechanism) 
In nonpolar solvents 
* * D + A~D-A ---+1 (D~A-)*--~I.D.+ A + hv' 
encounter 
complex 
charge-transfer diminished, 
complex red-shifted 1 fluorescence 
D+A+kT 
internal conversion to ground state 
In polar solvents 
D* + A * D-A 
encounter 
complex 
D! + 
solvated ions 
Triplets may also be produced via enhanced intersystem 
crossing in encounter complex: 
* 'D-A 3 * --_I D +A 
or by ion-recombination reactions: 
1.1.2.2 Collisional deactivation mechanislns involving 
energy transfer 
(a) Exchange mechanism (Dexter 1953) 
When the donor and acceptor are in close colllsional 
contact, the electron clouds of the colliding molecules will 
6 
coalesce resulting in the indistinguishability of the highest 
energy eleotrons of the donor and acoeptor. Exchange of electrons 
between donor and acceptor can take place so that, for example, 
an electron in a donor triplet state may become part of the 
electronic structure of the acceptor originally in the So state. 
While the donor is deactivated to the ground state So by 
acquiring an electron from the acceptor, simultaneously, the 
acceptor will be raised to the 8, state by the acquisition of 
an electron from the donor in the triplet state ( triplet -
singlet energy transfer). The exchange mechanism of energy 
transfer is most efficient when the equilibrated excited state 
of the donor lies slightly higher than the Frank-Condon excited 
state of the acceptor. Singlet-singlet and triplet-singlet 
energy transfer between donor and acceptor are pernlitted by 
the exchange mechanism. Furthermore; the exchange mechanism 
can also effect an energy transfer which may involve the spin-
forbidden transition of the acceptor, viz., singlet-~riplet 
(occasionally) and triplet-triplet (quite commonly), provided 
that the donor singlet or triplet state is in a higher energy 
state than the acceptor triplet state (Schulman 1977). This is 
in marked contrast to the resonance energy transfer mechanism 
which precludes a spin-forbidden transition in the acceptor. 
\ 
(See Section 1.1.4 for further discussion). Since collisional 
1 
contact between donor and acceptor is a prerequieite for 
energy transfer by the exchange mechanism, the process is 
diffusion-controlled and is dependent on the viscosity of 
the medium. 
(b) Delayed fluorescence 
In rigid and viscoue media, the phenomenon of delayed 
fluorescence is dccasionally observed in addition to 
phosphorescence. It occurs at the wavelength of "normal" 
fluorescence (provided the molecule is also fluorescent at the 
temperature of measurement) but has a lifetime comparable to 
that of phosphorescence. Delayed fluorescence is a result of 
the excitation of the molecule in the triplet state back to the 
lowest excited singlet state (ie reverse intersyetem croesing), 
and can be effected by two mechanisms. Delayed fluorescence 
brought about by thermal excitation (ie by warming) is exhibited 
only by certain molecules which have a small energy difference 
between the Sland T1states. This was first observed in eosin 
and hence the phenomenon has been classified as E-type delayed 
fluorescence. In the other mechanism for delayed fluorescence, 
two triplet molecules would collide resulting in the activation 
, 
of one to the Sl state and the deactivation of the other by 
internal conversion to the So state (triplet-triplet annihila-
tion). Since the phenomenon was first observed in pyrene it has 
been called P-type delayed fluorescence. The mechanism requires 
the simultaneous annihilation of two triplet molecules and so 
P-type delayed fluorescence is a biphotonic process which 
requires a sufficiently high concentration of the absorbing 
molecules. The intensity of P-type delayed fluorescence ie 
propo~ional to the square of the intensity of the exciting 
light. 
------------ ----- ---
8 
All the above mechanisms for the collisional 
deactivation of the excited donor would result in the 
fluorescence quenching of the donor ( if it is fluorescent) 
with or without a concomitant energy transfer to the acceptor. 
Ae only the excited state of the donor is involved, this type 
of fluorescence quenching ie diffusion-controlled and is called 
dynamic quenching. Donor fluorescence intensity can also be 
" 
quenched if the number of potential excited state donor is 
decreased ego by the complexation of ground state donor and 
acceptor ( D + A_D-A) or the formation of a ground state 
dimer ( D + D -- D-D ). The dimer or donor-acceptor complex 
when excited has a zero or negligible quantum yield, and even 
though it may dissociate in the excited state to produce the 
luminescing species, the dissociation process is usually less 
efficient than the nonradiative conversion of the excited 
complex to its ground state. This type of quenching is not 
diffusion dependent and is referred to as static quenching. 
1.1.3 Noncollisional energy transfer 
Energy transfer that occurs over distances larger than 
the contact distances of molecular collision is called a 
noncollisional energy transfer (Forster 1947,1959;Perrin 1932). 
In resonance transfer, the energy of the excited donor is lost 
via transfer to the acceptor without any emission of radiation 
or any collisional contact between the donor and acceptor. 
Various other equivalent terms have also been used in the 
literature to describe this class of energy transfer process: 
sensitized fluorescence ( if acceptor is also fluorescent), 
singlet-singlet nonradiative energy transfer, dipole-dipole 
--------
9 
resonance transfer, long-range radiationless energy transfer, 
" Fbreter-type energy transfer, etc. Resonance energy transfer 
ie the term used in this thesis to describe this type of non-
radiative energy transfer which should be distinguished from 
the "trivial" process of reabsorption of the donor emission by 
the acceptor. The efficiency of the trivial reabsorption 
process depends on (i) the spectral overlap between the donor 
" 
emission spectrum and the acceptor absorption spectrum, and 
(ii) the Beer-Lambert law which states 
I 
a = 
( 1.6) 
where I and I are the intensities of the incident and absorbed 
o a 
radiation, a is the (molar) absorption coefficient, b the 
optical pathlength, and c the concentration. The qualifying 
word "trivial" used to describe the process of radiative energy 
transfer is a misnomer: life on earth depends upon the radiant 
energy from the sun. Livingstone (1957) called the process 
"trivial not because it is unimportant but because it is easy 
to explain". 
1.1.4 Resonance energy transfer 
1.1.4.1 Historical background 
Historically, the first recorded observation of 
resonance energy transfer was made in 1923 by Cario and Frank 
who found that a gaseous mixture of mercury and thallium 
showed the emission spectra of both atoms even though the 
excitation radiation was set at the 254 nm mercury resonance 
wavelength. The experimental set-up in this case excluded the 
possibility of indirect excitation of thallium by reabsorption 
". 
10 
of the mercury emission. Subsequent work by Bowen and 
Brocklehurst in 1955 on energy transfer between 1-chloro-
anthracene and perylene showed very clearly that the non-
collisional energy transfer was not brought about by the 
process of trivial reabsorption. That the resonance energy 
transfer process was also not a consequsnce of a collisional 
mechanism had already been established in 1949 by Forster 
" (1949a,b) who found that the fluorescence quenching of trypa-
flavin by rhodamine B occurred over a distance of 7 nm, which 
was much greater than the collisional molecular dimensions. 
The effioiency of the resonance energy transfer process had 
been demonstrated earlier in 1947 by Bucher and Kaspers in 
their investigations on the transfer efficiency between the 
chromophoric groups in myoglobin. Their results were later 
confirmed by Weber and Teale ~1959) who found an almost 100% 
transfer efficiency in this particular system. Even though 
the first work on the quantitative aspects of resonance energy 
transfer was done by J. and F. Perrin (1925,1927 and 1932), it 
was For9ter who developed in 1948 a complete theory underlying 
the mechanism of the resonance transfer process. 
Transfer mechanism 
In the classical sense, an electron in a molecule 
which has been excited to a singlet or triplet state behaves 
like a charged oscillator with a characteristic frequency 
superimposed on its electrical field (which extends beyond the 
molecular dimension). Transfer of its excitation energy to a 
second molecule (acceptor) within this electrical field can 
take place if the electronic transition of the acceptor 
corresponds to the frequency imposed on the electrical 
field by the excited oscillator (donor). This would require 
that the transitional energy difference from the excited 
state to the ground state in the donor is the same as the 
11 
reverse process in the acceptor. However, an electronic 
transition in a molecular oscillator (cf. free atoms) with 
various vibrational transitions superimposed on it does not 
correspond to a fixed frequency. Instead, it is characterised 
by a whole distribution of frequencies. Consequently, a 
continuous spectrum of frequencies is also imposed on the 
electrical field in any one ~ of molecular electronic 
transition, and a certain frequency interval within this 
spectrwn can cause the excitation of the acceptor. Maximum 
spectral overlap between donor emission and acceptor absorption 
is therefore an important prerequisite for resonance energy 
transfer to occur. Furthermore, there must also be an optimum 
relative orientation to permit strong interaction 'between the 
oscillators. As will be shown in Equation (1.10) below, the 
rate of resonance energy transfer varies inversely as the sixth 
power of the distance between the donor and acceptor, and there 
must be a certain minimum distance (the critical distance r o ' 
See Equation(1.10» for efficient energy transfer (Stryer 1960). 
The mean intermolecular distance decreases with higher concentra-
tions of both donor and acceptor, so resonance energy trans~er 
is a concentration dependent phenomenon. Other parameters which 
determine the rate of resonance energy transfer include the 
lifetimes and therefore the spin multiplicities of the excited 
states of the donor, as well as the probabilities ( ie molar 
absorptivities) of the electronic transitions involved in the 
acceptor. The lowest excited singlet 
( -8 a shorter lifetime 10 s) than the 
state of the donor has 
triplet state (10-4 to 
12 
10 B). However, excitation to the lowest excited singlet state 
of an acceptor has a higher probability than transition from 
the ground to the triplet state (spin-forbidden transition). 
Thus, the acceptor can be excited to the excited singlet state via 
the resonance mechanism by a donor in the lowest excited singlet 
state (singlet-singlet energy transfer) or triplet state (triplet-
singlet energy transfer). However, because of the spin-forbidden 
transition from the ground to the triplet state of an acceptor, 
singlet-triplet and triplet-triplet resonance energy transfer 
resulting, respectively, in singlet- and triplet- sensitized 
phosphorescence have very low probabilities and such phenomena 
are not generally observed. 
The conditions for resonance energy transfer are. very 
similar to those for trivial reabsorption (Refer Section 1.1.3) 
and special precautions must be taken to minimize the contributory 
effect of one on the observation of the other. In most stUdies 
of resonance energy transfer, trivial reabsorption can be obviated 
by keeping the absorbance (optical density) of the solution low 
( < 0.005 for 1 cm optical pathlength) or altering the optical 
layout for sample illumination (eg. front-surfance fluorescence 
measurements; smaller optical pathlength cuvette).Some of the 
characteristic properties associated with resonance transfer and 
trivial reabsorption had been identified by Forster (1959) and 
are surnrnari zed in '1'able 1.1 which can be used for distinguishing 
between the two mechanisms. 
'. 
Table 1.1 
Some characteristic properties of resonance energy transfer 
and trivial reabsorption (Forster 1959). 
Properties 
Dependence on sample volume 
Dependence on sample conc. 
Dependence on visoosity 
Donor lifetime 
Donor fluorescence spectrum 
Absorption spectrum 
Resonance transfer 
None 
Increase 
None 
Decreased 
Unchanged 
Unchanged 
Reabsorption 
Increase 
Increase 
None 
Unchanged 
Changed 
Unchanged 
1.1.4.3 Some guantitative aspects (Forster 1948,1951;Pesce 1971) 
The field strength ··E at a distance r from an excited 
electron oscillating at a point D is given by 
E = 
where q is the electronic charge, k the orientation factor, 
a the amplitude of oscillation at D, ~ the refractive index, 
and r the distance between the acceptor A and the donor at D. 
After time t of exact resonance, oscillator A has 
acquired the energy 
= (1.8 ) 
8m 
where m is the mass of the electron. Thus, the interaction 
energy between the oscillators is proportional to the inverse 
sixth power of the distanoe ( Equation (1.7) and (1.8) ) and 
the rate of energy transfer between donor and acceptor is 
- dW D 
dt 
= 
14 
= 
dt 
where ND-+A is the number of energy quanta (hv) transferred 
per unit time. 
For a given donor-acceptor system, a critical distance 
" 
ro has been defined: 
= (1.10) 
where To is the lifetime of the excited state of the donor in 
1 
the absence of transfer. (-;- is the rate of its deactivation 
o 
in the absence of acceptor). Consequently from Equation (1.10), 
r is the distance at which there is an equal probabUi ty for 
o 
resonanoe energy transfer and for intramoleoular deaotivation 
of the excited state of the donor (by radiative or nonradiative 
processes). An expression for ro had been derived by Forster 
(1951), viz., 
= 
6 2 2 9 x 10 (In 10) k 0 TO J_ 
v (1.11) 
where 0 = velooity of light, L = Avogadro's constant, v = o 
arithmetio mean of the wave-number of maximum absorption and 
emission of donor, and J- = overlap integral between 
v 
emission speotrum of donor and absorption speotrum of acceptor. 
The theoretioal r values of some donor-aoceptor pairs 
o 
had been oalculated (from Equation (1.11)) by Weber and Teale 
(1959) and Weber (1960) and these were generally in good 
, 
agreement with the experimental values - See Table 1.2 
(Pesce et al 1971). (An experimental method for the deter-
mination of r by fluorescence depolarization had been 
o 
described by Weber (1954,1960)). 
Table 1.2 ro values 
Donor-acceptor pair 
DNS - heme (ferrous) 
DNS - heme (ferric) 
Phenol-phenol 
Indole-indole 
Phenol-indole 
Tryptophan-:-DNS 
Theoretical 
from Eqn. (1.11) 
6.3 
5.8 
1.1 
2.3 
1.5 
2.6 
Experimental 
4.3 - 6.7 
3.7 - 6.9 
1.7 
1.6 
2.0 
2.4 
DNS = 1-Dimethylaminonaphthalene-5-sulphonate 
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1.2 Ligand Assay 
1.2.1 Classical and labelled immunochemical methods 
Immunochemical techniques which are widely used in 
the biomedical sciences exploit two outstanding properties 
of the immune response: sensitivity which refers to the ability 
, 
of immunologica~ reagents antibodies or cellular receptors, 
or the secondary receptors such as complement and histamine -
to respond to extremely minute quantities of the antigen; and 
the specificity of the immunological reaction which allows the 
detection of specific antigens in a matrix of potential 
interferences. The immunochemical methods differ, however, 
according to the mechanisms by which the antigen-antibody 
interaction is manifested. Classical methods such as 
precipitation, immunodiffusion, agglutination, complement 
fixation, anaphylaxis, etc are based on the gross or secondary 
and tertiary effects produced by the antigen-antibody inter-
actions which are usually visible to the naked eye. Other 
methods utilize the increased sensitivity of the immunological 
interaction when the antibody or the antigen is bound to a 
distinctive label ego isotope, enzyme. The use of labelled 
immune reactants converts to observable or detectable forms 
the primary antigen-antibody interactions which by themselves 
produce no visible effects at least in vitro. Labelled immuno-
chemical methods generally trace their origins to the studies 
performed by Coons et al (1941,1942 and 1950) who used 
fluorescein-labelled antibody as a topographical marker for 
the localization of antigen in tissue cells. Other applications 
have included the specific identification and localization 
I 
I' 
'. 
of precipitation lines in immunodiffusion and immunoelectro-
phoresis (eg. radio-IEP), and the distribution of labelled 
lymphoid cells in the body. Table 1.3 lists the different 
types of labels and the corresponding immunochemical methods 
which had been developed on the same principles as Coon's 
immunofluorescence method. All these methods are essentially 
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qualitative techniques which utilize the enhanced sensitivity 
associated with the use of labelled immune reactants for the 
detection and identification of antigens and antibodies in 
biological systems. 
Table 1.3 
Labelled immunochemical methods 
Method/Technique Label 
Immunofluorescence Fluorophore 
Passive hemagglut!nation Tanned red blood' 
cell; erythrocyte 
Immunoautoradiography 
Immunoelectron-
microscopy 
Immunoenzymatic 
method 
1.2.2 Ligand assay 
1.2.2.1 Introduction 
Radionuclide 
Electron-dense 
compounds ego 
ferritin 
Enzyme 
Reference 
Coons et al 1941, 
1942 and 1950 
Boyden 1951; 
Borduas 1953 
Fitzgerald 1953 
Singer 1951,1961 
Nakane 1966,1967; 
Avrameas 1966 
The most significant quantitative application of 
labelled immune reactants was based on the use of radio-
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isotopically labelled ligands in a technique called radio-
immunoassay which was introduced in 1959 by the late Solomon 
Berson and his collaborator, Rosalyn Yalow. The radioimmunoassay 
methodology offers a technique to assay materials otherwise 
unmeasurable or detectable only with difficulty. The subsequent 
developments and exhaustive exploitation of the original principles 
of the method and its widespread and diversified application in 
" the biomedical field stand as a testimony to the creative genius 
and industry of Berson and Yalow whose achievements were 
"accomplished by a spectacular combination of immunology, isotope 
research, mathematics and physics" (Nobel citation 1977). 
Radioimmunoassay (RIA) was the first of what are now 
known collectively as ligand assays (Marks 1978), even though 
the technique has been variously termed in the literature 
dep~nding on which aspect of the test principle is being 
emphasized in the definition. Thus radioimmunoassay has also been 
termed: 
saturation analysis 
displace~e~t analysis 
equilibrium analysis 
competitive binding assay 
competitive inhibition assay 
antigen excess technique 
limited reagent technique 
isotope dilution technique 
radioassay 
radio ligand assay 
radiosorbent assay 
Notwithstanding the semantics, ths general analytical 
concepts of radioimmunoassay are best expressed in the two terms 
competitive binding and saturation analysis (Zettner 1973), 
though the developments since the late 1960's have produced 
variants of the technique which are based on the principle of 
noncompetitive binding ie stoichiometric assays. See Section 1.2.2.3 
I. 
1.2.2.2 Competitive binding assay (CBA) 
The underlying theory of competitive binding assay 
is as follows: 
L = Ligand (material to be assayed; the analyte) 
L* = Ligand tagged with a distinctive label ego 
isotope 
B = Binding agent; the binder ego antibody Ab 
raised specifically against the ligand to be 
assayed; plasma binding proteins, etc. 
* On combining both L and L with B, the reaction of complex 
formation, which follows the law of mass action, can be 
represented as 
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( 1.12) 
where [L + L*] = the combined molar concentration of the 
mixture of labelled and unlabelled ligand; [B] = the molar· 
concentration of the specific binding agent;[BL + BL*] = the 
combined molar concentration of the complexes between the binder 
and the unlabelled and labelled ligands; k1 = the association 
constant; k2 = the dissociation constant; and ka = kylk2 is 
the affinity constant of the binder (Parker 1976). 
* The complexes BL and BL can be looked upon as the 
* bound fractions of L and L respectively, in contrast to the 
* free or unbound ligand L and L • If a fixed quantity of B and 
* L is used and·the amount of B is adjusted SO that it can bind 
(say) 50% of the total ligands, then at equilibrium the reaction 
system will contain both free unlabelled and labelled ligands 
( L and L* ) and both bound labelled and unlabelled ligands 
* (BL and BL ) • It is implicit in this type of assay that the 
'. 
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binding properties of the binder do not distinguish between 
the unlabelled and labelled ligands ie" the 
B possess identical affinity for L and 
binding sites of 
* L • (This assumption 
is not completely valid, but the problems arising there from 
are usually inconsequential in most assays). 
Reproducibility of results would require that the system 
be made to attain equilibrium which is usually accomplished by 
allowing the reagents to react for a sufficiently long time 
(the incubation time) under fixed conditions. The time required 
to achieve this equilibrium may vary from several hours to days 
depending on the assay system (Zettner 1973). However, so long 
as sufficient time is allowed for establishing the 
equilibrium conditions, the order of addition of the reagents 
is not critical in "equilibrium" competitive binding assay. 
(Cf. Non-equilibrium competitive binding assay which also 
comes under various terms: sequential saturation, delayed 
addition, two-step analysis, etc (Zettner 1914». 
From Equation (1.12), it can be seen that since the 
* * amount of L and B are fixed, then the proportion of L bound 
to the binding agent is inversely proportional to the amount of 
* unlabelled L. Conversely, the proportion of free L will be 
proportional to the amount of unlabelled L • ~~erefore, if 
* * various known amounts of L are added and BL or L is measured 
by the appropriate instrumentation, the relationship between 
the signal of the label and the concentration of L cah be 
established. From this a standard curve,can be obtained and used 
to quantitate the amount of L in an unknown sample. 
I 
I In a heterogeneous assay, the quantitation of L by detecting 
the signal of the label in EL* must be preceded by a I 
* 
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separation step to separate BL from the reagent mixthre 
containing the free L*. If, however, the PhYSiCOChemicll 
properties of the label in the free and bound L* are I 
sufficiently different, then the ch~e in the signal/detection 
implicit in the label may be used to quantitate L without a 
~ * I need to separate EL from L • This type of assay is called 
I 
homogeneous. 
1.2.2.3 Noncompetitive binding assay 
(a) stoichiometric assay (immunometrio; reagent-exdess; 
labelled antibody) I 
In contrast to the competitive binding assay as 
exemplified by the radioimmunoassay, stoichiometri1 assay 
involves the use of labelled binding agent ego labelled 
I 
* I 
antibody Ab. In this connection, it must be emphasized that 
labelled binding agents are by no means preclud~d ifrom use in 
some variants of competitive binding assay, just as it must 
not be inferred that labelled ligands pannot be u~ed in non-
competitive binding assay. See Sections 1.2.3.3 ahd 1.2.4 • 
The principal purpose of the stoichiometric assaj, which was 
first suggested by Miles an4 Hales in 1968, is tJ improve the 
I 
sensitivity which can be achieved with a given binding agent. 
In the reaction of the conventional RIA method (refer Equation 
I (1.12», there must be a limited number of bind1ng sites 
available such that only a proportion of the ligands, labelled 
as well as unlabelled, is bound. In the stoichiometric assay, 
I 
as exemplified by the immunoradiometric assay IBM! , a large 
I 
". 
excess of the labelled binding agent is used to increase the 
forward (association) reaction, and a greater sensitivity 
potential might be expected. The assay method involves the 
* addition of excess labelled binder B to standards ( and 
unknown samples) of the ligand. After incubation, an excess 
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of insolubilized ligand is added to bind the excess * B which 
* is removed by centr~fugation. The amount of B in the final 
supernatant is thus directly proportional to the ligand 
initially present in the solution. Since the assay involves a 
* * separation of excess unbound B from B L, it is heterogeneous. 
(b) Sandwich (two-site) assay 
The sandwich assay lAddison and Hales 1971) is a variant 
of the stoichiometric assay in which a solid-phase antibody (the 
binding agent) is first reacted with the antigen (the ligand) 
and an excess of labelled antibody then added. The amount of 
labelled antibody associated with the solid-phase component is 
proportional to the original antigen concentration. The assay is 
also heterogeneous. 
f-Ab + Ag_ I-AbAg 
Ab* * 
--.:::.:.--.... AbAgAb 
1st reaction 2nd reaction 
r- denotes solid-phase 
(c) Double sandwich assay (Beck and Hales 1975) 
The double sandwiGh assay resembles the preceding 
method but uses an unlabelled antibody from a second species 
for the second reaction, 
I-Ab,Ag Ab2 • I-Ab,AgAb2 
1 at reaction 2nd reaction 
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A labelled heterologous antibody to the y'-globulin of this 
speoies is then used to produoe the signal: 
* ~Ab,AgAb.Ab 
3rd reaotion 
(Ab, and Ab. represent 1st and 2nd antibody, respeotively) 
An attraotive feature of this assay system is that a single 
, 
labelled preparation may serve for any number of different assays, 
provided only that they all employ the same speoies antibody at 
the seoond stage. 
(d) Indireot sandwioh assay for antibody deteotion 
The most notable example of this approaoh is the 
radioallergosorbent test (RAST) of Wide et al(1967). Its greatest 
use ie in identifying the oonoentrations of antibodies of defined 
immunoglobulin types. 
It is unlikely that any of the stoichiometrio assays 
will be applicable to the analyses of haptens. Hapten-antibody 
oomplex dissooiates in the presenoe of solid-phase antigen, and 
sandwiches oannot be made with haptens beoause their small size 
would preolude the display of two independent binding sites. 
1.2.2.4 Classifioation of ligand assay methods: Prinoiples 
Ligand assay methods are usually olassified on the 
basis of one or more of the following prinoiples. 
(a) Separation methods (the original basis for olassifioation) 
ego ohromatoeleotrophoresis 
aloohol preoipitation 
oharooal and talo 
second antibody 
solid-phase Ab or Ag 
I. ,. 
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Refer Ratcliffe t1914) for a review of methods· for bound/free 
separation • 
(b) Binding agents 
ego antibody 
specific binding proteins (thyroid binding globulins 
with affinities for various circulating hormones; 
transcortin is a binding protein for cortisol). 
cell membtane or tiseue receptors (the uterine 
receptor for meaeuring estradiol) 
(c) Nature of label 
See Table 1.6 for a full list of the different types of 
labels that have been used in the development of ligand 
assays. 
(d) Labelled materials 
ego labelled ligand (antigen) 
labelled antibody (in stoichiometric and sandwich· assay) 
labelled 2nd Ab to 1st Ab (in indirect sandwich assay) 
(e) Analytical principles 
ego competitive binding or saturation analysis 
stoichiometric assay 
sandwich (two-site) assay 
indirect sandwich assay 
homogeneous and heterogeneous assay 
-. 
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1.2., Isotopic and nonisotopic immunoassay methods 
1.2.,.1 Developments in ligand assay technigues 
The principal developments in ligand assay techniques 
after the introduction of the radioimmunoassay method in 1959 
can be summarized as follows: 
(a) the substitution of other binding agents for antibodies ego 
" plasma binding proteins, cell membranes and tissue receptorsl 
(b) the use of other radionuclides in addition to 1311 such as 
1251 , 3H , 14C and 
(c) the modification of the separation techniques (Ratoliffe 
1974) which inolude the use of seoond antibody, solid-phase 
immune reactants (immunoadsorbents) on polystyrene tubes, 
beads and magnetizable particles; 
(d) the use of labelled antibodies in assay techniques whioh 
are based on stoiohiometrio prinoiples ego immunoradiometric 
assay (lEMA) and sandwich assay; 
(e) the use of nonisotopic labels as the tracer ego enzymes, 
fluorophores, etc. See Table 1.6 ; 
(f) the introduction of homogeneouB assays for haptens eg.EMIT 
(Rubenstein 1972) where the difference in the physico-
chemical properties of the label between the free and 
bound labelled ligands is utilized as a "substitution" 
for the separation step used in heterogeneous assays; 
(g) the extension of the homogeneous assay concept to the 
measurement of macromolecules in addition to haptens ego 
an EMIT assay for specific proteins (Gibbons et al 1979); 
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(h) the automation of heterogeneous ligand assays and the 
adaptation of the homogeneous assay technology to existing 
instrumentation; and 
(i) the development of ultra-sensitive immunoassays in which 
two types of labels are used simultaneously to improve 
sensitivity ego USERIA (Harris et al 1919) • 
Many reviews have been published on the developments 
in the techniques as well as the underlying principles of the 
different types of ligand immunoassay. See Table 1.4 • 
Table 1.4 
Published reviews on ligand immunoassay methods 
subject 
Radioimmunoassay 
Enzymeimmuoassay 
Fluorescence immunoassay 
Chemi- and Bio-
luminescence immunoassay 
Principles and Theory 
of Ligand Assay 
Reference 
Parker(1912); Skelley et al(1979) 
Scharpe et al(1916); Wisdom(1976); 
Schuurs et al(1911) 
O'Donnell and SUffin(1919); 
Saini and Hemmila(1919) 
Whitehead et al(1919) 
Zettner(1913,1914); Walker(1917); 
Odell and Daughaday(1911) 
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1.2.3.2 Isotopic immunoassay methods: 
Advantages and disadvantages 
The widespread and diversified applications of 
radio immunological methods in the biomedical field may be 
related to the following advantages. 
(a) High sensitivity (10-':" 10-'5M) and specificity which are 
" 
attainable with the use of radiolabelled materials. 
(b) Wide applicability ego analyses of hormonal and non-
hormonal peptides, drugs, enzymes, parasitic, microbial 
and viral agents, etc. It was estimated that some 50 - 60 
million radioimmunoassays were carried out worldwide in 
1976 alone (New Scientist, 20 October 1977, p 144) 
(0) Small sample size, usually from 10 - 100 ~l • 
(d) Speed of analysis and batch sampling capabilities, 
especially with the advent of multihead scintillation 
spectrometers for the analyses of several samples 
simultaneously. 
The technique suff'ers, however, from certain drawbacks. 
(1) Radiation hazards which impose several restrictions such 
as regulation of' production, transport, handling and 
disposal of radioactive materials. 
(2) The destructive process of' radioactive decay limits the 
useful lifetime of' assay kits and prevents long-term 
assay standardization. 
(3) Radiation damage to immune reactants. 
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(4) Relatively expensive instrumentation and reagents, and 
a need for a special laboratory. 
(5) The method being heterogeneous, the assay procedures are 
usually less amenable to automation. 
1.2.'.:5 Nonisotollio immunoassay methods 
To overcome some of the limitations of radioimmunoassay 
methods, alternative immunological techniques are being developed 
which do not require the use of radiolabelled materials. These 
nonisotopic immunoassay methods ( Table 1.6 ) take full advantage 
of the specificity and sensitivity that result from the applica-
tion of antibodies but avoid the use of radionuclides. Other 
advantages are listed in Table 1.5 • A number of these non-
isotopic immunoassays are already commercially available e·g. 
EMIT (Syva Corporation), IMMUNO-FLUOR (BIO-RAD Laboratories), 
and FIAX/STiQ (International Diagnostic Technology). However, 
the success of these new immunochemical approaches will depend 
ultimately on the attainment of the sensitivity and specificity 
equivalent to that already achieved by the use of radiolabelJ.ed 
materials. 
Some of the nonisotopic immunoassays listed in 
Table 1.6 are still in the developmental stage ego voltammetric 
immunoassay, while others already developed have been found to 
unsatisfactory for routine application for a number of reasons. 
Thus, the use of free radicals in spin-immunoassay requires 
expensive electron spin resonance spectrometers for measurement. 
The utility of phage immunoassay is limited by the long periods 
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Table 1.5 
Some advantages of nonisotopio immunoassay methods 
Equipment 
Reagents 
Label 
Assay 
procedure 
Hazards 
Widely available and relatively inexpensive 
ego uv/visible apeotrophotometers, filter 
fluorimeters 
: Comparatively oheap; long shelf-life ego 
enzyme- and fluoresoenoe-labelled materials 
: Wide range (See Table 1.6). Choice of labels 
may allow multiple, simultaneoue assays to be 
performed ego in enzyme immunoassays. Physico-
ohemical properties of labels may also be 
exploited in addition to their use as signal 
tracers. 
Simple. Labelling procedure easily performed. 
Separation step may be obviated and thus 
there is a potential for automation. 
No speoial hazards. 
of time required to oulture the bacteria for the assay of phage 
activity. At the moment, it would appear that only enzyme and 
fluorescence !mmunoassays are oapable of competing with, and 
possibly supplanting, RIA.in a number of areas even though 
there are inherent limitations in each of these two nonisotopic 
!mmunoassays. Table 1.7a & b summarize the various types of 
enzyme immunoassay methods already developed. Fluorescence 
immunoassay methods will be discussed in detail in Seotion 1.2.4 • 
;0 
Table 1.6 Ligand Immunoassay Technique 
Immunoassay technique 
Isotopic 
Radioimmunoassay RIA 
Nonisotopic 
Viroimmunoassay; 
Phage immunoassay 
" 
Hemagglutination 
inhibition technique HIT 
Enzyme immunoassay EIA 
Free radical assay 
technique FRAT; 
Spin immunoassay 
Fluorescenoe immunoassay 
FIA 
Bioluminescence 
immunoassay BLIA 
Chemiluminescence 
immunoassay CLIA 
Metalloimmunoassay 
MIA 
Vol tanunetric 
immunoassay VIA 
Isotopic & Nonisotopic 
Label 
Radionuclide 
Reference 
Yalow & Berson 
1959a,b and 1960 
Bacteriophage Haimovich 1966; 
Makela 1966 
Erythrocyte Adler & Liu 1971 
(cell) 
Enzyme Engvall 1971a,b; 
Van Weeman 1971 
Free radical Leute et al 
1972a, b 
Fluorophore Aalberse 197; 
'. eg.ATP-labelled Carrico et al 1976 
ligand with 
firefly luci-
ferase detection 
eg. Luminol Pratt et al 1978 
with H20/haem 
detection 
Metal ion Cais et al 1977 
complexes 
Eleotroactive 
group 
Weber & Purdy 1979; 
Heineman et a1 1979 
Ultra-sensitive enzymatic Enzyme and Harris et al 1979 
radioimmunoassay USERIA radionuclide 
}1 
Table 1.7. CI.sslflcatlon 01 EIA method. 
Enzyme 
Homogeneous 
EMIT 
Labelled Ag 
Ab on .olld ph •• e 
I.: Compellllve .88ay lor Ag 
detecllon. Cl. cla88lc.1 RIA 
Ib: Noncompelltlve a •• ay lor 
Ab detecllon: Ag* + Ab. 
Then exce.. i-Ab added 
I 
to react with remaining Ag* 
Immuno.ssay I EIA 
I 
1 
Heterogeneous 
ELISA 
r L.belled Ab I 
Ag on .olld ph •• e Ab on Bolld ph •• e 
lIa: Noncompellllve .... y lor Ag nl.: S.ndwlch ••• ay lor 
detecllon. AI.o c.lled Immuno- Ag detection 
enzymometrlc •••• y. CI.IRMA 
lib: Compelltlve •••• y lor Ab IIIb: Indirect •• ndwlch a •• ay 
detecllon: Hg + Ab + Ab* luslng labelled 2nd 
I-AgAb + I-AgAb" Ab I lor Ab detecllon. 
Cl. RAST 
Table 1.7b 
Enzyme immunoassay methods 
* Method/Technique 
Heterogeneous (ELISA) 
la 
Ib 
IIa 
IIb 
IIIa 
IIIb 
Homogeneous (EMIT ) 
Reference 
Engvall and Perlmann 1971 a, b; 
Van Weeman and Schuurs 1971 
Schuurs and Van Weeman 1972 
Maiolini et al 1975a 
Schuurs and Van Weeman 1972 
Maiolini et al 1975b 
Engvall and Perlmann 1 972 
--Rubenstein et al 1972 
Rowley et al 1975 
* Refer Table 1.7a. for a classifi.cation of EIA methods 
1.2.4 Fluorescence immunoassay 
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Quantitative analyses of ligands using fluorescence 
immunoassay methods may be accomplished in one of two ways 
(t) The fluorophores are used as labels or probes in the same 
way that radioactive isotopes are used in radioimmunoassays. 
Like RIA, these assays are heterogeneous, and similar methods 
to those used in RIA can be implemented as separation 
procedures ego precipitation with ammonium sulphate, poly-
ethylene glycol and various other organic solvents, double-
'. 
;; 
antibody precipitation and solid-phase separation. To date, 
solid-phase fluorescence immunoassay has received the most 
attention, and many variations of the technique have been 
developed and reported (See Table 1.8a and b) 
In the solid-phase system, once the separation 
has been achieved then the fluorescent label can either be 
stripped off the'solid-phase using a denaturant such as 
dilute alkali and measured in a standard fluorimeter,or the 
fluorescence can be recorded using a front surface attachment 
in a fluorimeter. With the latter method, the separation 
procedure is relatively straightforward and there is the added 
advantage of one less analysis step when reading the label 
attached to the solid-phase. FUrthermore, endogenous inter-
ferences from the eample can be removed or minimized after the 
separation step. Of course, the sensitivity of the assay in 
this case will be limited by the optical properties of the 
solid-phase material as well as light scattering interferences. 
These drawbacks can be overcome by using solid-phase materials 
which are not strongly absorbent at the excitation wavelength, 
or fluorescent at the emission region. Light scattering 
interferences can be removed by using cut-off filters, 
polarizers or specially designed instrumentation for front 
surface fluorescence measurements. Another major problem of 
the solid-phase system relates to the difficulty of producing 
reproducible reagents: the attachment of antibody on solid-
phase by physical adsorption is not very reproducible over 
long periods of time and subject to antibody loss on storage, 
and covalent coupling often results in the reduction of anti-
body binding capacity. The latter problem can be overcome by 
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using secondary antibody immobilized on the solid-phase 
which binds th~ primary antibody. However, the need to use 
considerable amounts of the secondary antibody will be a 
constraining factor as far as assay cost is concerned. 
* (2) When a fluorescent-labelled ligand L binds to the 
antibody (the binder B), a change in the physicochemical 
properties of th~fluorophore can occur as a result of the 
differences in the solvation effects, hydrophobic binding, 
hydrogen binding and ionic interactions within the micro-
environment of the antibody binding site. In particular, if 
the fluorescence properties of the bound labelled ligand 
* (BL ) are sufficiently different from those of the unbound 
* labelled ligand L , then this change in the fluorescence 
properties may be used to q~antitate the ligand (ie the 
analyte) in an immunoassay without a separation of BL* 
* and L • This type of assay is called homogeneous 
fluorescence immunoassay and the fluorescence properties 
which have been studied to date inclUde: 
Fluorescence polarization 
Fluorescence quenching and enhancement 
Fluorescence energy transfer 
Fluorescence lifetime (time-resolved fluorimetry) 
In addition, conjugates have also been used as labels which 
depend on additional enzymatic reactions to yield fluorescent 
products (Burd 1977). 
(a) Fluorescence polarization 
Polarization of fluorescence is based on the 
relative orientation of the excitation and emission oscillators. 
The degree of polarization p can be calculated from readily 
measurable quantities: 
p = 
where IV = the vertical component tie parallel to the 
excitation polarization) 
., 
~ = the horizontal component (ie perpendicular to the 
excitation polarization) 
G = the grating factor 
p is a function of the molecular size and' shape, the viscosity 
of the medium.~ , the decay time r of the excited state, and 
the temperature T. The Perrin equation for a spherical molecule 
as derived by Weber (1952a) is: 
1 
p 
1 
3 
= (~ _ .!.)(1 + RTr) Po 3 ~V 
where Po is the polarization observed in the absence of rotary 
Brownian motion, V the molar volume assuming a spherical 
molecule, and R is the gas constant. 
When a small fluorescent~labelled hapten or antigen 
L* reacts with the antibody, amongst other effects, the rotary 
* motion of L is retarded due to the increase in effective size. 
There will thus be a corresponding increase in the degree of 
polarization, which will be reversed by the addition of 
unlabelled ligand. The fluorescence polarization immunoassay 
requires a fluorophore with a relatively long decay time 
(>20 ns), and though it is a relatively simple technique its 
application in routine analysis is limited by the expense for 
instrumentation and endogenous background. 
(b) Fluorescence quenching and enhancement 
Following the formation of the ligand-antibody 
complex, the changed molecular environment within the immune 
complex will alter the electronic energy distribution of 
both the ligand and the fluorophore that is attached to it. 
"' In most cases, this will result in the label fluorescence 
being quenched (Sbaw 1977), while in others an enhancement 
phenomenon may be observed. Smith (1977) had reported that 
the fluorescence quantum yield of fluorescein-Iabelled 
thyroxine (T4) was increased approximately four-fold upon 
binding to antibody. Tbe increase in fluorescence was explained 
in terms of the quenching effect of iodine (the heavy atom 
effect), which was partly dispersed as the thyroxine binds to 
the antibody. Similar enhancement immunoassays using the more 
convenient fluorescamine (Fluram· , Roche Diagnostics Ltd) and 
its closely related analogue, 2-methoxy-2,4-diphenyl-~(2H)­
fUranone (MnPF), have also been developed. However, the 
mechanism underlying these fluorescamine-based assays (Miller 
1979) is not the same as that described above for fluorescein-
labelled T4 • Tbe "Fluram" enhancement phenomenon appears to 
be a general effect with all the fluorescamine-labelled 
antigens studied so far, and this has been applied to the 
development of fluorescence enhancement immunoassays for 
nortriptyline (Chapter 5 ) , human serum transferrin (Chapter 
6 ) alld immunoglobulin G (Chapter 7 ). 
In a general immunochemical method described by 
Zuk et al (1979), the formation of an immune complex of a 
~7 
fluorescent-labelled ligand sterically protects the fluoro-
phore from binding by antibodies to it. The addition of 
unlabelled ligand prevents the formation of the fluorescent-
labelled ligand immune complex, and allows the anti-
fluorophore antibodies to quench the fluorescence by binding 
to the fluorophore. This homogeneous assay technique has been 
variously termed in the literature, viz., fluorescence 
" protection immunoassay (Zuk et al 1979), indirect quenching 
fluoroimmunoassay (Nargessi et al 1978), and double-receptor 
fluorescence immunoassay (Ullman 191~). 
(c) Fluorescence energy transfer 
This is another general immunochemical method for 
the assay of haptens and proteins first described by Ullman 
et al-(1916). In this method, ligand labelled with the donor 
fluorescent molecule is reacted with its specific antibody 
labelled with the acceptor molecule. Since resonance energy 
transfer is based on a short-range ( < 5 nm) nonradiative 
mechanism (Refer Section 1.1.4), it is only within the 
molecular dimension of the immune complex formed that transfer 
of energy from the donor group to the acceptor group can take 
place. The energy transfer effects are manifested by the 
quenching of the donor fluorescenoe intensity and lpossibly) 
the enhancement of the acceptor fluorescence intensity. 
Competitive binding by added unlabelled ligand will inhibit 
the interaction between labelled ligand and antibody, and 
the consequent reversal of the quenching and enhancement 
effects may be used to quantitate the ligand ie the sample. 
'. 
Since the assay involves a change in the fluorescence 
properties of one or both of the labels, the assay does not 
require a separation step ie it is homogeneous. ~'Urthermore, 
the simultaneous observation of the quenching and enhancement 
effects may be used to distinguish specific ligand-antibody 
combination from non-specific environmental effects on the 
fluorescence intensity. The assay requires, however, the use 
" of pure ligand and mono specific antibody for the preparation 
of labelled immune reactants because the presence of non-
specific labelled materials in the assay system will increase 
the background fluorescence and thus limit sensitiVity. So, an 
al teroative sandwich type of assay may be used with a poly- . 
valent ligand in which separate portions of the antibody are 
labelled with the donor and acceptor groups. Unlabelled ligand 
causes the aggregation of the separately labelled antibody 
components and the effects of energy tIOansfer are again 
observed. With this approach, the use of pure or enriched 
ligand is not necessary. 
The development of energy transfer immunoassay 
methods for the analyses of low and. high molecular-weight 
ligands will be described in the appropriate chapters below. 
(d) Time-resolved fluorimetry 
In time-resolved fluorescence measurements, a fast 
light pulse «1ns) is used to excite the fluorescent label 
whose excited state has a lifetime T between 100 11S - 1 p.s. 
Measurement of fluorescence is started after a certain time 
". 
ii 
c 
~ 
U) 
Fig 1.2 
Short 
decay 
Diagram 
tE = 
tD = 
LH = 
Long decay 
.1.t ) Time 
of time resolved fluorescence measurements 
Excitation pulse time «1 ns) 
Delay time 
Counting time interval 
(the delay time t D) has elapsed when the background fluores-
cence with a decay time of less than 10 ns would have been 
reduced almost to zero (See Fig 1.2). The fluorescence of 
the label is measured at certain time intervals' ( at, the 
counting time), starting from time tD • Thus time resolved 
fluorimetry provides an elegant way of removing non-specifio 
background interferences with a consequent improvement in 
sensitivity. 
Two types of time resolved systems have been used 
to measure the decay times of fluorescent labels:(i) for short 
decay times up to 200 ne, and (ii) for long decay times up to 
1 MS • A time resolved fluorimeter for short decay time 
measurements requires a very fast P11T detector together with 
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either a nanosecond spark discharge lamp or a dye laser 
controlled by a nitrogen laser for excitation. These inetru-
ments are expensive and are oommonly used for such fluorophores 
as the pyrene derivatives, N-(3-pyrene)-maleimide and pyrene 
butyrate (with T ca. 100 ns), and some other organic labels 
with decay times less than 20 ne. Measurement of long decay 
times (1 ~s - 1 ms) can be performed with an inexpensive and 
" 
commercially available xenon-discharge lamp for excitation and 
an ordinary FMT detector equipped with an electronic switch 
(switching time 51 ~s). Such an instrument is suitable for 
work with the rare earth metal chelates ell'. europium and 
terbium complexed with various ~-diketones and salicylates 
exhibit very long decay times from 50 ~s to 1 ms. 
To date, there has been no published report of a time 
resolved fluorescence immWloassay. However, if suitable chelates 
are available and if these can be conjugated to the immune 
reactants without producing adverse immunological effects, then 
it can be envisaged that time-resolved fluorescence immWloassays 
may attain even greater sensitivity than RI! (Wieder 1978). 
(e) Enzymatic reaction to yield fluorescent products. 
* L ____ ~e=n=z~ym=e~ __ •• fluorescent products 
lI-~ ll-B + L ~ BL enzyme. no reaction 
* BL + L displacement 
* of L by L in 
• 
BL + L* _ fluorescent 
products 
competitive bind-
ing reactions 
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The assay is based on the enzymatic reaction with the 
substrate-Iabelled ligand to yield fluorescent products 
(Equation (1.15a». The reaction principles as given above 
show that the substrate-Iabelled ligand conjugate as an 
enzymatic substrate is inactivated when it is bound to the 
antibody (the binder B) - Equation(1.15b) This inactivation 
is relieved by the presence of unlabelled ligand in 
, 
competitive binding reactions (Equation (1.15c». Hence, the 
rate of production of fluorescence will be related to the 
ligand (sample) concentration. Since the assay utilizes a 
change in the physicochemical properties of the substrate-
labelled ligand upon binding to antibody, no separation step 
is required in the procedure. This fluorescence enzyme 
immunoassay (FEIA) has also been termed as homogeneous 
reactant-labelled fluorescence immunoassay (Burd 1977). 
Applications of this immunoassay method include the analyses 
of ge!ltamicin (Burd 1977) and phenytoin in serum (Wong 1979). 
A common drawback of all the homogeneous fluores-
cence assays described above is the difficulty of removing 
the endogenous background of the test sample. Though the assay 
sensitivities as low as 0.1 nmol have been reported in the 
literature, interferences may reduce this limit by several 
orders of magnitude. Nevertheless, the assays being homogeneous, 
the experimental procedures are more amenable to automation 
A classification of the various types of fluorescence 
irrmlunoassay together with the references are given in Table 1.8a 
and 1.8b • 
.. 
_. Table 1.8a Classification of "lA _ methods 
I 
Fluorolmmunoassay , FIA 
Labelled 
I Heterogeneous I 
-Ab on solid pha.e 
la: Compelltive as.ay for Ag 
detection. Cf. cta.slcal RIA 
Ib: Noncomp.lltivs assay lor 
Ab detection 111 
I 
Ag 
I Homogeneous 
lIa. Quenching 
lib: Enhancemenf 
lie: Protecllon; !Indirect 
quenching; double-
recaptor assay J 
lid: Polarlzallon 
lie: Lifetime; I Tlme-
r.solved fluorimetry I 
11f: Others 1 
Fluorescence Immunoassay 
Immunofluorlmetric assay,lFMA 
or Fluorolmmunometrlc a.say, FIMA 
Labelled Ab 
I .. I Heterogeneous 
-
Ag on solid phase 
ilia: Noncompetitive a •• ay for Ag 
detection. Cf. IRMA 
IIIb: Competitive as.ay for Ab 
detection 1. 
Ab on sOlld- pha.e 
IIIc: Sandwich assay for Ag detection. 
IIld: Indlroct s~ndwlch I using 
laballed 2nd Ab I for Ab 
dotoctlon 1 Cf. RAST 
Energy Transf.r 
immunoassay , ~TIA 
Labelled Ab & Ag 
Homogeneous or 
Heterogeneous 
lVa: Competitive as .. y. 
Ag and Ab labolled with 
donor and acceptor, 
respectively _ 
IVb: Sandwich assay: 
Separate port Ions of Ab 
labelled with donor 
and acceptor. 
IVc: Solid-ph.s. ETIA 
. 
Fluorescen t Enzyme 
immunoassay, FEIA 
Labelled Ag 
Homogeneous 
I Heterogeneous 1 I 
Va: Substrate -labelled 
Vb: Enzyme - labelled 
Vc : Cofactor -labelled 
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Table 1.8b Fluorescence immunoassay methods 
* Method/Technique 
Fluoroimmunoassay 
Heterogeneous 
la 
Ib 
Homogeneous 
lIa 
lIb 
lIo 
lId 
lIe,f 
Immunofluorimetrio assay 
IlIa 
IlIb 
IlIc 
IlId 
Energy Transfer 
Immunoassay 
IVa,b 
!VO 
Fluorescent Enzyme 
Immunoassay 
Va 
Vb 
Vc 
* Refer Table 1.8a 
Referenoe/Remarks 
Nargessi 1978a ; Kamel'1978 
? Analogous to type Ib of EIA;(see 
Table 1.7a & b ) 
Shaw et al 1977 
Snith 1977 
Ullman 1973 I double-reoeptor 
Zuk 1978 : fluoresoenoe protection 
Nargessi 1978b : indirect quenching 
Watson et al 1976 
? Time-resolved immuoassay may have 
the potential for even more sensi-
tivity than RIA (Wieder 1978) 
ego FIAX/STiQ system; Blanchard 1978 
? Analogous to type lIb of EIA; (see 
Table 1.7a,b) 
ego IMMUNO-FLUOR system; 
Aal berse 1973; Burgett 1977 
? Cf. RAST. Analogous to type lIIb 
of ElA (see Table 1.7a,b) 
Ullman et al 1976 
? See Chapter 7 
Burd et al 1977 
These assays generally make use of 
ohemi- and bioluminescenoe as the 
detection system. See Whitehead 1979 
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1.3 Fluorophores as Labels in Fluorescence Immunoassay 
1.3.1 General requirements for fluorescence labels 
Most labels utilized in fluorescence immunoassays 
were developed for other purposes (eg. as a topographical 
marker in immunofluorescence microscopy and as a probe in 
"-the . investigation of the structural changes in proteins, 
etc.), and there are defioiencies in these labels. The most 
significant drawback relates to the broad absorption and 
emission bandB because this reduces the specificity of the 
label. In resonance energy transfer studies, a principal 
criterion in the choice of suitable donor and acceptor 
fluoresoent labels is the absence of spectral overlap. 
between the excitation sp·ectra of both labels in addition 
to the prerequisite that there mUllt be optimwn spectral, 
overlap between the donor emission and acceptor excitation. 
This important factor is well illustrated by the dependence 
on the fluorimeter spectral bandwidth of the energy transfer 
efficiency between fluorescein and rhodamine when these are 
used as labels in energy transfer. immunoassays (See Chapter 
3 ; also refer Sohiller 1975). In the search for new 
fluorescent labels designed for specific types of assays, 
in particular for labels for time-resolved flUorimetry, 
attention has focussed on the fluorescing metal chelates 
which exhibit large Stoke's shifts and long decay times 
(Soini and Hemmila 1979). These emit well-defined, spectrally 
distinct peaks that would permit simultaneoull measurements 
· , 
'. 
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Table 1.9 Some properties of an ideal fluorescence label 
Property Desirable Characteristics 
Molar absorbance : As high as possible, > 104 
Quantum yield : As high as possible especially in buffered 
Excitation and 
emission wave-
lengths 
Stability 
Conjugation to 
ligand 
Solubility 
aqueous solutions at pH 7 - 8. 
The excitation and emission wavelengths 
must be a~ far removed as possible from 
those background regions where interferences 
are significant. In most immunoassays, these 
interferences arise from the serum srunples 
and the antiserum which have excitation and 
emission maxima at ca. ~40 run and 4'(0 run, 
respectively (Soini 1979). High protein 
concentration also causes scattering inter-
ferences (Rayleigh, Raman and 2nd order 
scattering). So, wavelength requirements are 
(a) XI between 500-700 run, (b) a Stoke's 
shUt ~ 50 run, and (c) \x in the visible 
region to avoid uv irradiation of the sample. 
Should be stable both under measurement 
conditions and on storage SO that long-term 
standardization of assay procedures can be 
performed. 
: Conjugation procedures must be simple and 
capable of producing reproducibly pure 
reagents. Labels must possess flexibility 
in functional group aocessibility and form 
stable covalent bonds to the compounds 
under investigation without producing any 
adverse immunological effects. 
High solubility in aqueous solutions 80 that 
even the use of heavily-labelled antibodies 
or entigene will not decrease the solubility 
of the conjugates. 
.. 
.. 
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without interferenoe. However, the widespread applioation of 
the existing and new fluoresoent labels in immunoassays is 
limited by the defioienoies in our knowledge of the eleotronio 
struotural details of the label and the intrioate changes in 
theeleotronio energy distribution when the labelled.inunune 
complex is formed. The desirable characteris'tics of an ideal 
fluoresoence label are summarized in Table 1.9 
1.3.2 Fluorophores and the ohemistry of their oonjugation to 
functional groups in ligands ego proteins 
HO '«Br OH 
J:~=o y 
NCS 
Fluorescein isothiooyanate FITC 
R-N=C=S + 
Hl-Protein _ R_NH_CS-NH_Protein 
HS-Protein- fl..NH-CS-S-Protein 
Fluorescein isothiooyanate is by far the most commonly 
used label in fluoresoenoe immunoassays beoause of its high 
quantum yield (0.85) and molar absorptivity (7.2 x 104 M-\m-1j. 
Its disadvantages include a small Stoke's shift (20-30 nm), the 
presence of two isomers in oonuneroial preparation which oauses 
heterogeneity in oonjugation (Brandtzaeg 1973; Goding 1976), 
and itB limited Bolubility in water though dimethylsulphoxide 
'. 
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(moo) may be used as the solvent (up to 3CY)/i mso in carbonate 
buffer) without causing any deleterious effects on gamma-
globulins (Bergquisl and Nilsson 1914; Goding 1916). Blakeslee 
and Baines (1916) had reported that the replacement of the 
isothiocyanate functional group with the dichlorotriazi.nyl 
group would produce substantially improved stability, homogeneity 
and simplicity of conjugation. 
" The next important group of fluorescent labels are 
the various rhodamines: tetramethylrhodamine isothiocyanate 
(TRITC), rhodamine-B-isothiocyanate (RBlTC), and Hssamin., 
rhodamine-B2'OO Bulphonyl chloride (RB200SC). Compared to FITC, 
the rhodamine emission wavelengths fall in the 585-595 nm reg.ion 
but their relative fluorescence intensities are less (Brandtzaeg 
1915; McKinney 1915). Advantages of the rhodamine labels include 
their stability and homogeneity (Brandtzaeg 1913; Chadwick 1958) 
ICH:Jl,N~O~ N1CH31, 
0~ 
0i
C
- d:O 
/1 
:-... 
NCS 
TRITC 
C25H21N303S = 443.51 
RB200SC 
C21H2911204S2Cl = 545.11 
~312 
~ 
SO,CI 
Dansyl Chloride 
C12H1~02SCl = 269.15 
• 
I 
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Ho_n_prot----R-SO-O-~Prot (1.17b) \d 2 ~ 
Dimethylaminonaphthalene-5-sulphonyl chloride (dansyl chloride; 
DN8-Cl) has a comparatively low quantum yield (0.3) and its 
, 
excitation and emission wavelengths overlap those of serum 
(Soini 1979). Its 'sensitivity to polarity changes has been 
utilized to investigate the formation of antigen-antibody 
complexes (Parker 1970). 
4-Phenylspiro[furan-2(3),1'-Phthalan-,,2-dione] 
tFluorescamine;Fluram) and its closely related analogue, 
2_methoxy_2,4_diphenyl_,(2H)_furanone (MDPF), react rapidly 
with'primary amino groups to yield fluorescent. products 
(Weigele 1972, 1973). The use of fluorescamine in Immunoassays 
,has been reported (Katsch et al 1974; Handley 1979), and 
although the fluorescent conjugate has a relatively small 
quantum yield (0.1), its sensitivity to polarity changes may 
be exploited (Miller 1979). 1t had been claimed (Handsehin 
and Ritsehard 1976) that the fluorescence of MDPF was more 
stable than that of fiuorescamine, but comparative studies 
performed by Cukor(1976) and EgW(1977) had shown that MDPF-
based assays did not compare favourably with the radioallergo-
,sorbent tests or with assays using fluorescein-labeJ.1ed IgG. 
Both fluorescamine and MDPF are readily hydrolysed to non-
fluorescent products so that separation to remove unreacted 
hydrolysed products from the labelled conjugates is optional 
(Handschin 1976). 
Hydrolysate 
(non-fluorescent) 
< H,O 
( H
2
0 
Fluorogenio reagent 
(non-fluorescent) 
H,N-proteln 
o 
Fluorescamine FL 
o 
) 
CH30 :;, 
-H2N-proteln 
MDPF 
C17H140, = 266., 
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Conjugate 
(Fluorescent) 
-Quinacrine [atebrine; 9-(4-diethylamino-1-methyl-
butyl amino ) -6-chloro-2-methoxy acridine] , a known fluorescent 
drug with antimalarial properties, has been used in cytological 
studies for investigating cellular components ego chromosomes 
and submitochondrial particles. Quinacrine mustard (QM) differs 
from the parent compound in that the N-methyl groups are replaced 
by chloroethyl moieties that are capable of reacting with 
primary amino groups under alkaline conditions (Price et al 
1968). The potential application of quinacrine and its mustard 
as fluorescent labels has been evaluated by Chen(1976). The 
.. 
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advantages appear to be that QM labels proteins readily, 
has good light stability, is water soluble, and the mustard 
conjugates are useful for polarization studies. However, the 
quantum yields of mustard conjugates are generally low, 
varying from 0.1 to 0.3 depending on the protein. Absorption 
bands at 250, 350 and 450 nm offer a choice of excitation 
wavelengths but the broad emission spectrum (see Fig.4.1a&b) , 
may limit the applicability of the label. 
CH30 
Cl 
.2HCI 
NHCHICH3 i-1CH.I3' NIC. H.CII. 
Quinacrine mustard dihydrochloride 
C23H28CI3N30.2HC~.= 541.76 
The reaction of mustards with proteins occurs via a cyclic 
intermediate (Dandliker and Portman. 1971) 
CH ~/~ ) R-j CH2 
CH:iCI!2CI 
The intermediate is readily hydrolysed in aqueous media, but 
it reacts even more readily with a variety of protein groups, 
the second reactive group on the open chain being hydrolysed 
and not leading to cross-linking (Herriot 1946; Fraenkel-
Conrat 1959; Webb 1966) 
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/
CH, 
+ '" X-protein ) 
R 
I 
HOCtt,C~N-CH,CH2y-prot8In R-N CH, + 
I 
CH,CH,CI 
x y 
HOOC-
-O-CO-
H5-
-5-
HO@- -O-@-
-NH-
1~Anilino-8-naphthalenesulphonic acid (ANS) and toluidino-
naphthalene aulphonic acid (TNS) are used extensively as 
fluorescent probes for'the polarity of their environment 
because the quantum yield increases and the emission 
maximum shifts towards the shorter wavelengths as the 
environmental polarity decreases (stryer 1968; Brand 1912'; 
Kanaoka 1911). Being not covalently bound to proteina, these 
hydrophobic probes are not suitable for use as fluorescent 
labels in immunoassays. 
ANS TNS 
The pyrene derivatives such as N-(3-pyrene) maleimide (NPM), 
which combines the selective reactivity of maleimide towards 
N-(3-pyrene) maleimide, NPM 
C20~11N02 ~ 281.~1 
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thiols with the speotral properties of pyrene, are generally 
not suitable for conventional immunoassay (Weltman 1975). 
However, the long deoay time of the fluoresoenoe may have 
applications in time-resolved fluorimetry. The reaotion of 
N-substituted maleimide with the thiol functional group may 
be represented as follows. 
+ HS-Protein 
o H 
__ ~) R_N~~-protein 
)r1; 
pH >7 
hydrolysis 
R-NH-COCH2CH-S-Protein I 
COOH 
At pH 7 the reaotion is speoific for thiol groups; below pH 6 
the rate is slow, and above pH 7 the reagent begins to 
hydrolyse and groups other than thiol may also be attacked. 
other less commonly used fluorophores inolude the following: 
(a) 7-chloro-4-nitrobenzo-2-oxa-1,~-diazole (NBD-Cl) 
(Ghosh 1968) 
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H N-R 
2 ) 
NBD-Cl NBD-conjugate 
highly fluorescent 
non-nuorescen~ 
(b) 4_acetamido_4'_isothiocyanatostilbene_2,2'_disulphonic 
The utility of SITS as a fluorescent label is limited by the 
decrease in fluorescence intensity and the changes in absorp-
tion spectrum under prolonged excitation (Chen 1969) 
(c) Anthracene-2-isothiocyanate (Chen 1969) 
N=C=S 
~CHO 
~CHO 
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1.3.3 Luminescence propertie's; molar absorption coefficients 
of fluorophores conjugated to proteins. 
SOme luminescence properties of the commonly 
used fluorescent labels are listed in Table 1.10. Data on "ex 
and '" represent the most probable values as these may vary 
depending on (i) whether the label is bound or free, (ii) the 
species protein to which the label is bound, and (iii) the 
degree of labelling (F:P ratio) of the conjugate. The corrected 
excitation and emission spectra of the fluorescent conjugates 
used in the energy transfer immunoassay investigations can be 
found in the appropriate chapters. Concentrations of the bound 
fluorescent labels are assayed spectrophotometrically using the 
molar absorption coefficients given in Table 1.10 • FUrther 
comments on these generally accepted values published in the 
"- . 
literature are given below. 
Comments on the molar abl!lorPtion coefficients • listed 
in Table 1.10 
(a) FITC : The value of 1.2 x 104 M-1cm-1 at 493 nm for the 
bound fluorescein thiocarbamide,group in conjugated 
proteins was calculated by Chen (1969) from the data of 
McKinney et al (1964) • 
(b) RBITC : The assumed value of 1.23 x 104 M-1cm-1 at 551 nm 
for RBITC conjugates is based on the finding that -the free 
isothiocyanate in 5ry~ ethanol has that extinction at 555 nm 
(Chen 1969) 
(c) TRITC : The determination of TRITC in conjugates remainl!l 
uncertain. While crystalline TRITC conjugates show one 
55 
stable absorbance peak at 555 nm, the amorphous conjugates 
exhibit two absorbance maxima in the regions 515-520 nm and 
550-555 nm with the relative intensities of these two maxima 
varying according to the conjugation ratio (Bergquist and 
Nilsson 1974). Thus, of the TRITC conjugates, only those 
labelled with crystalline TRITC can be assessed in terms of 
F:P ratio. Cebra and Goldetein (1965) had suggested that the 
"' 
ratio of absorbance measurements at 280/515 nm be taken as a 
measure of the degree of labelling of TRITC conjugates, and 
this had been accepted by Amante (1972) and Brandtzaeg (1973): 
TRITC-conjugated 
IgG (mg/ml) 
(with the protein ooncentration of oonjugated IgG based on 
,E:~o = 14.0). Bergquist .. and Nilsson (1974) had suggested 
using a 280/550 nm ratio instead, beoause they considered it 
undesirable to use a wavelength (515 nm) which represented 
low fluoresoenoe for oalculations. There is as yet no 
acoepted method available for the evaluation of amorphous 
TRITC conjugates. 
(d) RB200SC : It is not possible to obtain a molar absol.'ption 
coefficient for liss8IIIine rhodamine-B conjugates since the 
absorption spectrum varies with the extent of labelling 
(Chen 1969; Brandtzaeg 1973; Chadwick 1958) 
(e) DN8-CI : Results obtained by Chen (1968) showed that for 
the most aoourate work, no single absorption ooefficient 
oould be assumed for the dansyl group in oonjugates of all 
proteins. Data from Hartley and Massey (1956) and Ch en 
(1968) would suggest that a value of 3.4 x 103 M-1 cm-1 
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at ~40 nm should be a close approximation to the actual 
absorption coefficient in many dansyl conjugates. Chen 
(1968) also found that the value of 4.~ x 10~ M-1cm-1 
(Weber 1952b) generally employed to calculate the degree 
of labelling might result in large errors in the deter-
mination of the dansyl groups. 
(f)~Fluram and MDPF : Chen (1914) found that the molar absorp-
tion coefficient of a number of fluorescamine-conjugatcd 
amino acids at ~88 nm was 6450 100 M-1cm-1 : this valu~ 
was then used to calculate the dyelprotein (F:P) ratios of 
fluorescamine-conjugated proteins even though Chen recognised 
that there might be aome difference in the absorption of the 
fluorescamine conjugated to amino acids and proteins. 
Handschin and Ritschard (1916) investigated the 
individual molar absorption coefficients of MDPF and FL 
covalently bound to goat and rabbit gamma-globulins ana 
found that they were almost identical ( 3B' EMDPF -'Y- globulin = 
6 + 6 -1 -1 3B. 400 - 0 M cm ; E FL-'Y-globulln = 6~00 ± 100 M-1cni1). 
Furthermore, these values are not significantly different 
from those provisionally found by Weigele et al (1913) for 
FL-conjugated amino acids. The assumption was thus made 
that the average molar absorption coefficients of bound 
MDPF and FL are the same for a great number of proteins. 
(g) QJ'I I 'l'he degree of labelling of quinacrine conjugate is 
determined by measurement of absorbances at 425 nm and 280 
nm. At pH 1.4. the quinacrine mustard is found to have 
E425 c 1.8 x 103 M-1 cm -1 and E2BD = 4.56 x 104 M-1 cm-1 
(Chen 1916). If the absorbance of the conjugate is measured 
at 425 nm, the amount contributed by the label to the 
total absorbance at 280 nm can be calculated if it is 
assumed that the optical characteristics of quinacrine 
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mustard in the free and bound states are equivalent. The 
remainder of the absorbance at 280 nm is thus from the 
protein itself. Protein concentrations are than calculated 
using the extinction coefficients at 280 nm. 
" 
lh)' SITS : The molar absorption coefficient of SITS conjugates 
is assumed to be the sarns as that of SITS dissolved in 
water, which was found by Chen (1969) to be 3.7 x 104 'M-1cm-1 
at 345 nm, SITS reacts with 'Y -globulins to give conjugates 
with an absorption at 323 nm and a peak emission at 430 nm. 
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Table 1.10 Luminescence properties of some commonly used fluorophores 
Fluorophora -e/ns <1>, <l>b Xa/nm X,/nm E/M-'em-' X./nm Reference . 
FITC 4'5 0'85 493 ... 520 7·2 X 10
4 493 MeKlnney .al al,1964;' 
Chen,1969 
. 
RBITC 3 0·7 550 585 1'23 x t0
4 557 Chen, 1969; 
" 
Br .. ndlzaag, 1973,1975; 
MeKlnney,1975 
TRITC See Nota e 
RB200SC <1 0'04 530 595 S.a Nola d 
565 710 
DNS-CI 14· 0·2 0'3 340 480- . 3.4 X 103 340 Chen, 1968; 
520 
Har.lley el .',1956 
FL 7 0 0'1 -395 -485 6300! 100 385 Hand.ehln el ai, 1976; 
6450 t 100 38S Chan, 1974 
MDPF 0 0·1 -395 ... 485 6400 ± 60 385 Handsehln el .',1978 
OM 4 -f3 0-1 -0.3 250, _520 See Nole 
350. broad 
g 
450 
ANS ,. 0 0·9 385 471 Kenaoka, 1977 
NPM 100 0 340 375, W.llman el ai, 1973 
39. 
HBD-CI 468 530 1'29 X 104 468 G hosh, 1968; 
Hueng, 1975 
SITS 1·0- 1'3 323 430 3-7 X 104 345 Chen , 1969 
Anlhraeene -
3·04 X 103 ITC 29 0·6 357 460 357 Ibld; Harringlon al 'i, 
1956 
Abbreviations used are defined in Section 1.3.2 
<I>,,<I>bl quantum yield of free and bound fluorophore, respectively. 
~ I lifetime 
~ molar extinction coefficient of bound fluorophore at the 
absorption wavelength ". 
1.4 The Development of Energy Transfer Immunoassay Methods. 
Proposed Investigations. 
The principal intention of this project is to 
develop a number of energy transfer immunoassay (ETIA) 
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procedures, and to compare their sensitivity and ease of 
.application with those of existing immunoassays and other 
analytical techniques. 
In the first part of this work detailed studies will 
be performed to identify the experimental variables that 
affect the degree of energy transfer ( and hence the sensiti-
vity of the analysis) in a given assay system. }'or this 
purpose fluorescein and rhodamine aa donor-acceptor fluorescent 
labels will be used to de;elop an energy transfer assay for 
human serum albumin. The suitability of this label pair for 
other applications of the ETIA method will be evaluated, and 
the sensitivity of the energy transfer assay in the analysis 
of serum samples compared with the electroimmunoassa,y. 
Other potential donor-acceptor pairs will also be 
studied. These include (a) quinacrine and fluorescein; (b) 
quinacrine and rhodamine; (c) dansyl chloride and rhodamine; 
(d) fluorescamine and fluorescein; and (e) MDPF and fluorescein. 
The development of a single pair of labels which might be of 
value in the analysis of the widest possible range of materials 
would be very desirable, since it would permit the use of an 
extremely simple filter fluorimeter with filters providlng 
fixed exciting and emitting wavelengths. In practice, however, 
it seems more likely that a number of different systems 
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would be required to facilitate the labelling of antigens 
containing different functional groups. 
Upon the successful completion of the above 
investigations, a number of immunoassays for both low and high 
molecular-weight antigens will be developed, and comparisons 
made with other established immunochemical methods. In order to 
, 
increase the versatility of the ETIA method, different variants 
of the technique will also be developed, including homogeneous 
direct and indirect (or sandwich) ETIA, and heterogeneous solid-
phase ETIA. A principal advantage of the homogeneous ~'TIA method 
is its ease of automation because, in contrast to the heterogeneous 
aseay, the troublesome separation step ie not required. Flow 
injection analysis principles will be applied to the automation 
of an.energy transfer immunoaAsay. 
Experiments will also ,be carried out to determine 
the changes in the emission inetnsities when antigens labelled 
with various types of fluorophores are reacted with specific 
unlabelled antibodies. In particular, the fluram (and the analogous 
MDPF) enhancement effects will be studied in detail and applied 
to the development of FIA methods for the detennination of drugs 
and biological macromolecules. 
.. 
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CHAPTER 2 MATERIALS, INSTRUMENTATION, AND 
GENERAL EXPERlMENTAL PROCEDURES 
2.1 Materials (including purification and pretreatment steps) 
Materials 
Antibodies 
Purified immunoglobulin fractions 
of mono specific rabbit antisera to 
the following human proteins: 
Albumin; 
Colostrum immunoglobulin A, specific 
for a.-chains and secretory piece; 
Inununoglobul!n G, specific for "(-
chains \ 
11_2_Macroglobulin; 
Transferrin; 
Sheep anti-desmethylnortriptyline 
antiserum. 
Human proteins 
Albumin, lyophilised with 
electrophoretic purity 100 % 
Transferrin, lyophilised with 
min. purity 99 % and max. Fe 
concentration = 20 pg/g 
Standard human serum 
Source/Description 
DAKO-immunoglobulins Ltd., 
Mercia Brocades Ltd., 
Weybridge, Surrey. 
Guildhay Antisera, Surrrey 
Batch No.A HP/S/l (Gift 
from Prof.Dridges). 
Purification to yield IgG 
fraction of the antiserum 
is described below. 
Hoechst (UK) Limited, 
ltounslow, Niddlesex. 
Materials 
Human proteins 
Immunoglobulin A, lyophilised 
Immunoglobulin G, lyophilised 
. , 
Normal human serum samples 
Fatal road traffic accident 
blood sample 
Animal proteins 
:Bovine albumin, Fn V 
(powder). Purity 96-99% 
albumin. Assayed N = 15.4 % 
:Bovine 'Y-globul1n,Cohn :Fn n. 
Electrophorectic purity 99 % 
with <1 % NaCl. 
Assayed N= 15.0 % 
Tricyclic Antidepressants 
Deamethylnortriptyline 
Protriptyline 
Nortriptyline 
Amitriptyline 
Butriptyline 
Desipramine 
Imipramine 
Chlomipramine 
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Source/Deecription 
Calbiochem Ltd., Bishops, 
Stortford. 
Prepared from human colostrum 
from the method of Got (1965) 
Miles Laboratories Ltd., 
Stoke Poges, Slough. 
Donated by healthy laboratory 
workers. 
Home Office; Ref. CRE 2/79 
Sample was centrifuged to remove 
lysed cells, sand particles, etc. 
Sodium azide was added as preser-
vative to the serum. Stored 
frozen before analysis. 
Sigma (Lortdon) Chemical Co.Ltd., 
Poole, Dorset. 
Sigma (London) 
Gift from Prof. Bridges 
Gift from Dr. L.A.Gifford 
) 
Materials 
Chemicals, Reagents, etc. 
1_Dimethylaminonaphthalene-5-
sulphonyl chloride (DN8-CI) 
Rhodamine-B isothiocyanate,RBITC 
Fluorescein isothiocyanate 
isomer I (10 % on Celite) 
Fluram (Fluorescam:l:ne) 
MDPF 
Quinacrine mustard diRCl 
8_Anilino_1_naphthalene_ 
sulphonic acid, ANS 
(the ammonium salt) 
DEAE-Sephacel; DEAE-Sephadex A50; 
Sephadex G-25 (medium grade);--
Column PD-10 (G-25M) 
Immunobead Reagent Coupling Kit R 
containing immunobead matrix, 
control reagent, and EDAC. 
M-Partigen Immunodiffusion Plates 
for transferrin determination 
"Cellogel" Cellulose acetate 
Source/Description 
BDH Chemicals Ltd., 
P!lole, Dorset. 
Calbiochem Ltd., 
Roche Diagnostics Ltd., 
Welwyn Garden City 
Sigma(London) 
sigmalLondon) 
Pharmacia Ltd., 
Hounslow, Middlesex. 
BIO-RAn Laboratories, 
Watford, Hertfordshire. 
Hoechst (UK) Ltd. 
Whatman Labsales Ltd., 
Maidstone, Kent. 
All other buffer salts and reagents were of Analar or equivalent 
grade. 
'. 
Separation of sheep irnmunoglobulins on DEAE-Sephacel 
Buffer 1 : 0.0175M phosphate buffer pH 6.8 
Buffer 2 : O.OaM 
Buffer 3 : 0.3M 
Procedure : 
phosphote buffer pH 6.6 
phosphate buffer pH 6.5 
The methodolQgy of Mollieon (1972) was employed using 
., 
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DEAE-Sephacel instead of DEAE-celluloee. 2 ml of the sheep 
anti-nortriptyline antiserum were equilibrated on a Pharmacia 
PD-10 Sephadex G-25M column with buffer 1 • The dilution factor 
was ca. 1.5 • The equilibrated eample wae applied to a short 
• 
column (1.5 x 10.5 cm) of DEAE-Sephacel and then eluted with 
buffer 1 to obtain the first peak (eee Fig 2.1). SUbsequent 
etepwise elution with buffer 2 and 3 gave the second and 
third peak respectively. The flowrate of the elution was 0.28 
in- 1 mlm and each collected fraction contained 1.3 ml. 
.. 
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Figure 2.1 Fractionation of sheep serum immunoglobulins on"DEAE-Sephacel. Peak 1 
contained mainly IgG; peak 2 contained IgA with traces of IgG; and 
peak 3 contained mainly IgM. Arrows indicate the change of buffers 
used "in the stepwise elution. 
.30 
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2.2 Instrumentation 
The MPF-44B Fluorescence Spectrophotometer 
(Perkin-Elmer Ltd., Beaconsfield, ll11cks) fitted with a 
DCSU-2 corrected spectrum unit was used to record all 
corrected excitation and emission speotra. It was also used 
in addition to the Fluoricord Spectrofluorimeter (Baird-
" Atomio Ltd., Braintree, Essex) to record other uncorrected 
spectra. Quantitative fluorimetry was measured using both 
the MPF-44B and the Fluoripoint Spectrofluorimeter (Baird-
Atomic Ltd. ) fitted with an R928 side-on photomultiplier 
(Ilakuto International, Leigh-on-Sea, Essex) for improved 
long-wavelength sensitivity. Thermostatted 10 mm path 
length silica cuvettes were used in all fluorimetric measUre-
ments. In each case, the speotrofluorimeter used will be 
speoified. For flow~injeotion analysis work, the deteotor 
-, -
used was a Perkin-Elmer Model 1000M Filter Fluorimeter fitted 
wi th a flow-cell specially adapted with silica tubing of 
1 mm id. See chapter 8 
spectrophotometric absorption measurements were 
recorded using the pye-Unicam sp-600 UV spectrophotometer. 
Electroimmunodiffusion experiments were performed 
in water-cooled electrophoresis chambers powered by a Shandon 
Southern (Model Vokam S~ 2761) Power SUpply unit. 
All other equipment used will be described in the 
appropriate chapters. 
'. 
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2.} General Experimental Procedures 
2.}.1 Standard methods for the preparation of fluorescent 
protein conjugates 
The use of a purified homogeneous fraction of 
the protein to be labelled is a prerequisite for a 
standardized conjugation prooedure, regardless of the type 
of fluorophore. -,This is particularly true of antiserum which, 
if labelled without a prior purification step to remove non-
specific constituents, would yield fluorescent conjugates 
with both specific and non-specific binding properties 
(Brandtzaeg 197). A purified immunoglobulin fraction of the 
antiserum should therefore be used in the preparation of 
labelled antibody conjugates. Wood et al (1965) had reported 
that the relative homogene~ty in the isoelectrio point of 
isolated IgG moleoules was the basis for the charaoterization 
of labelled IgG conjugates by anionic exchange chromatography. 
However, the IgGmolecule which accounts for 7(]}6 or more of 
a large number of mammal serum immunoglobulins is among the 
most difficult to label (Brandtzaeg 197), and this hB(! been 
demonstrated earlier by the work of McKinney et a~(1964) and 
subsequently confirmed by White (1970). In order that labelled 
immune reagent's may be reproducibly prepared, labelling 
procedures and conditions must be optimized and standardized 
wi th respect to the following experimental parameters. 
(a) l10de of addition of label 
A number of approaches may be used: 
(1) 'I'he label in dry, finely divided form is added gradually 
and with efficient stirring to the buffered protein solution. 
'I'he method was first proposed by Marshal et al (1958) for 
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the preparation of fluorescein-labelled antibody. Reisber~ 
(1970) had reported that the reactivity of fluorescein was 
reduced after being dissolved, and so there is an advantage 
in some cases of adding the label as a dry powder directly 
to the protein solution. The method is simple and economical 
on label consumption but requires a good microbalance. Protein 
damage is minimal • 
" (2) The label is first dissolved in a small volume of organic 
solvent ego acetone, dioxane and DMSO, and then added 
gradually to the protein solution with continuous stirring. 
With this method, protein denaturation attributable to the 
organic solvents is inevitable. 
(3) The label is adsorbed on filter paper (Goldman 1957) or 
cellulose powder (Celite) (Rinderknecht 1962) from which it 
is gradually released into the protein solution. The method 
facilitates the weighing of small amounts of the label., \ 
(4) The protein solution is dialysedagalnst a solution of 
the label (Clark and Shepard 1963) 
(b) Buffer concentration and pH effect 
For all commonly used labels, a medium alkaline buffer 
ego carbonate or phosphate, ie ueed with the protein concentra-
tion generally kept between 10 - 60 mg ml-1(Dandliker and 
Portman 1971). Buffer concentration ueed is dependent on the 
label functional group involved in the conjugation reaction. 
For example, while a 0.05M buffer may be adequate for isocyanate 
and isothiocyanate, a buffer concentration of 0.5M may be 
required for the sulphonyl chloride group. 
69 
The effect of pH on conjugation reaction efficiency had 
been thoroughly investigated by McKinney et al (1964) in the 
case of labelling with fluorescein isothiocyanate. It was 
found that the speed of fluorescein labelling of serum 
proteins was increased with increasing pH within the range 
pH 6 to 10, with the optimal pH at 9.5. Thus, pH control 
(maintained by buffers or continuous adjustment with added 
" Na2C03 or NaOH) is an absolute prerequisite for the attain-
ment of standardized conjugation since it had been found 
(Goldstein and Morthland 1967) that even a pH drop from 9.5 
to 9.1 could reduce the efficiency of fluorescein-labelling 
by about 3C% 
(c) Effect of temperature and light 
The former practice was to keep the reaction 
temperature at O·C because of reduced protein denaturation. 
, 
However, results on the fluore~cein-labelling of serum proteins 
reported by Klugerman (1965) and McKinney et al (1964) showed 
that labelling at room temperature was many times faster 
without any disadvantages being apparent so long as organic 
solvents were absent. All labelling experiments described. 
below (section 2.3.1.1) for the preparation of fluorescent 
protein conjugates were carried out at room temperature, 
except where otherwise mentioned. Protection against light is a 
precaution necessary only insofar as the label and/or the 
conjugate are easily photo degradable. 
Isolation of labelled conjugates from unreacted label 
Before gel filtration became available, the methods. 
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used to remove unreacted label and other low molecular weieht 
substances from the labelled conjugate are time-consuming and 
often result in considerable protein loss and damage. These 
methods include charcoal and tissue powder adsorption, dialysis 
and solvent extraction. Gel filtration (on a column of Sephadex, 
for example) is now the preferred method be.cause it is (i) 
efficient in removing low molecular weight label and oreanic 
" 
solvent from the protein conjugate, (ii) gentle on proteins, 
(iii) rapid, and the protein recovery is high (Killander 1961; 
George 1961). 
Fractionation of conjugates with respect to the degree of 
labelling. 
With few exceptions, a labelling procedure usually 
" 
produces a heterogeneous population of labelled conjugates 
because of the differing reactivity of the macromolecular 
functional groups. The labelled conjugates, after having been 
separated from unreacted label by gel filtration, must there-
fore be further fractionated with respect to the degree of 
labelling by ion-exchange chromatography or electrophorectic 
methods. Even after this fractionation step, it is very likely 
that the resulting purified product still consists of a large 
number of isomers corresponding to the different conjugation 
points to which the label has been chemically bound. It has 
remarked ( O'Donnell and suffin 1979) that" the purification 
of labelled ligands is more art than science at present" even 
though recent developments in such analytical separation 
techniques as HPLC may help to reduce the tedium and labour 
involved in producing reproducibly pure labelled immune reactants. 
Methods for the determination of protein and label 
concentrations in conjugates 
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Label concentration can easily be assayed spectro-
photometrically using absorption or fluorescence measurements, 
though these methods are subject to a number of uncertainties. 
Thus, the original assumption (Creech and Jones 1940), that the 
extinction coefficients of the bound and free label were equiv-
alent, was found to be not valid by the work of Dandliker et al 
(1964) and Tengerdy and Chang (1966) who respectively found 
greater absorption by the free label compared to the protein 
conjugate by factors of 1.12 and 1.18 • Changes in the extinction 
·coefficient and shifts in the absorption maximum can occur when 
a label is chemically bound to a protein. Likewise, the fluore-
scence spectrum is also very dependent on the experimental condi-
tions and can undergo even greater changes than the absorption 
spectrum. An alternative and more accurate approach to the quanti-
tation of the bound label is to incorporate a radioactive tracer 
into the label. However, the work involved in radioactive labell-
ing of the fluorescent group may be laborious. 
Protein determination by absorp1;!on measurements is 
also subject to the same difficulties outlined above, but the 
effects on protein absorption are usually less significant than 
those on the label. Consequently, the determination of the protein 
content of the conjugate cell be obtained from the known (mOlar or 
specific) extinction coefficients of the proteins (Table 2.1), by 
nitrogen analysis ( eg.micro-Kjeldahl) , or some colorimetric 
method such as the Lowry or biuret method. Spectrophotometric 
determination of proteins based on absorbance measurements must 
be corrected for absorption by the dye at the wavelength of 
'. 
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measurement (usually 280 nm) as, well as the type of protein 
used. The Lowry method (Lowry et al 1951) for protein deter-
mination is based on the reaction between proteins and FOlin-
Ciocalteau reagent mediated by copper salts. The resulting 
colour reaction is recorded at 700 nm, which makes it a method 
of choice for fluorescent conjugates labelled with FITC, the 
rhodamines, DNS-CI ete because these do not aboorb near the 700 
nm region. Methods ~sed to characterize labelled conjugates with 
respect to protein concentration and fluorophore:protein (F:P) 
ratio include the following: 
(1) The protein content is determined by the Lowry method and 
the label is assayed spectrophotometrically using the molar 
absorption coefficients of the bound labels given in Table 
1.10 on page 58 
(2) Use of nomograph and formula. 
For fluorescein-Iabelled immunoglobulins, protein concentra-
, 
tion and molar F:P ratio can be found from the nomograph of 
Well et al (1966). A similar nomograph given by The and 
Feltkamp (19'70) or, alternatively, Brighton's formula 
(Brighton 1970) may also be used. (Refer also to Brusman(1971) 
for some theoretical and practical considerations in the 
spectrophotometric determination of fluorescein:protein ratlo.J 
(3) Other specific methods will be described where approprIate 
in section 2.,.1.1 
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Table 2.1 Molecular weights and extinction coefficients of 
. some human and animal proteins • 
Protein MW Ref. 
Human 
Albumin 66241 Putman(1975) 
19A 360000- White et al 
720000 (1978) 
19G 150000 White et al (1978) 
a-2-Macro- 725000 Putman( 1975) 
globulin 
Transferrin 76500 Putman(1975) 
Animal 
Bovine albumin 69000 Longworth 
(1971 ) 
Bovine 160000 Longworth 
'Y-globulin (1971 ) 
Rabbit 19G 140000 Mamet-Bratle 
(1970) 
Sheep 19G 145000 
a: pH 7.0 in 0.01M phosphate buffer 
b: apotransferrin 
c: Fe3+.Transf'errin 
E '%12801 Ref. 
'cm 
5.94a llerrens(1965) 
13.4 Grey(1972) 
13.8 GreY(1972) 
11.4b Feeney and 
Koma tsu ( 1966 ) 
14.3c Perkins( 1966) 
6.14a Berrens(1965) 
14.1 Lcngworth 
(1971 ) 
13.5 stevenson 
( 1970) 
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2.3.1.1 Preparation of fluorescent protein conjugates used 
in energy transfer immunoassay studies. 
Fluorescein-Iabelled conjugates. 
Proteins labelled: 
lyophilised human serum albumin (100% pure); 
mono specific rabbit immunoglobulins to human serum albumin, 
transferrin and IgG, and to human colostrum IgA; 
the IgG fraction of sheep anti-nortriptyline antiserum. 
Procedure: The method of Rinderknecht (1962) utilising 
fluorescein isothiocyanate isomer I adsorbed on Celite (10 %) 
was used to label the protein. CelHe was separated from the 
labelled solution mixture by centrifugation, and the unreacted 
dye was removed using a short column of Sephadex G-25 (medium 
grade) equilibrated with O.01M phosphate buffer pH 7.2 • The 
labelled protein was fractionated on a column of DEAE-Sephadex 
A-50 using a O.075M - 1.5M ~aCl gradient in 0.01M phosphate 
buffer pH 7.2 • (In the case of FITe-labelled sheep IgG, the 
salt gradient used was 0.025M - 1.5M NaCI ). 
The pro'tein content alld molar F:P of fluorescein-
labelled alltibodies were found from the nomograph of Well et 
al (1966). FOr fluorescein-labelled albumin the F:P ratio was 
detemined using the Lowry method to determine the protein 
concentration, and a value of 7.2 x 104 M-1cm-1 at 493 run for 
the molar absorption coefficient of the fluorescein 
thiocarbamide group (Chen 1969). 
Rhodamine-labelled conjugates 
Proteins labelled: 
lyophilised human serum albumin (100 % pure); mono specific 
rabbit immunoglobulins to human serum albwnin and IgG • 
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Procedure: Rhodamine conjugates were prepared by reacting the 
protein with an acetone solution of rhodamine-B isothiocyanate. 
The reagent solution was added, slowly and with stirring, to a 
solution of the protein maintained at pH 9.5 with solid sodium 
carbonate. After stirring for a further hour, excess reagent 
was removed and the conjugate fractionated by ion-exchange 
chromatography as described above for FITC-Iabelled conjugates. 
In determining th~ F:P ratios, the rhodamine group was assumed 
to have a molar absorption coefficient of 1.23 x 104 M-1cm-1 
at 557 nm (Chen 1969) 
Fluorescamine- and MDPF-Iabelled conjugates 
Proteins labelled: 
lyophilised human serum albumin , transferrin, IgG; 
mono specific rabbit immunoglobulins to human. colostrum IgA. 
Procedure:, The preparation of these conjugates was based on the 
methodology of Weigele et al (1973) with some modifications. The 
weighed protein (25 - }5 mg) was dissolved in 2 ml of 0.1M 
sodium phosphate buffer pH 9.5 • Depending on the molar F:P 
ratio required, 50 ~l portions of the fluorescamine or MDPF 
solution in acetone (3.0 -4.0 mg ml-1) were added (using a 
Hamilton nlicrolitre syringe) to the 'protein solution with 
stirring for one hour. Separation of the labelled conjugate 
from the hydrolysed products and acetone was performed on a 
column (1.5 x 15 cm) of Sephadex G-25 (medium grade) equilibrated 
with 0.01M sodium phosphate buffer pH 7.2 containing 0.145M NaCI. 
The Lowry method was applied to tile determination of the protein 
concentration of the conjugate. The bound label was assayed using 
a value of 6400 ± 60 M-1cm-1 and 6300 ± 100 M-1cm-1 at 385 nm for 
the molar absorption coefficients of the conjugated MDPF and FL 
groups, respectively (Handschin and Ritschard 1976). 
'. 
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Molar fluorophore:protein (F:P) ratio 
Trans-FL Trans-M 
Added Recovered % Added Recovered % 
2.0 1.85 92.5 2.7 2.6 96.3 
4.2 3.9 92.8 4.2 4.1 97.6 
7.2 7.0 97 .2 6.5 6.3 96.9 
10.0 9.79 97.9 9.0 8.8 97 .8 
12.8 12.6 
, 98.4 13.0 12.0 98.5 
av. 95.8 av.97 .4 
IgG-FL IgG-N 
Added Recovered % Added Recovered % 
8.5 6.6 77.6 11.2 6.8 60.7 
14.9 9.3 62.4 16.3 9.87 60.6 
22.8 16.7 73.2 25.0 16.0 64.0 
av. 71.1 av. 61.8 
Alb-FL 
Added Recovered % 
6.74 6.2 92.0 
10.7 10.0 93.5 
16.1 14.7 91.3 
av. 92.3 
Quinacrine-labelled human immunoglobulin G 
Procedure: Quinacrine mustard conjugates of human IgG were 
prepared by adding various amounts of the mustard dissolved in 
tri-distilled water to 1.0 -1.5 % w/v protein solutiono in 
0.1M NaHC03 • The mixture was vigorously agitated on a flask-
shaker for one hour. Labelled protein was separated from 
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! 
unreacted mustard on Sephadex G-25 (medium grade) equilibrated 
with O.OlM phosphate buffer pH 7.2 containing 0.145M NaCl. The 
protein concentration and molar F:P of the conjugate was found 
using the method described by Chen (1976). See page 56 
Dan~yl-labelled albumin 
Procedure: DNS-Cl dissolved in acetone l3 - 5 mg ml-1) were 
" added. slowly and with stirring. to the protein solution (16 -
20 mg dissolved in 2 ml 0.1M NaHC03) kept at ice-bath tempera-
ture. After mixing for 1, hours. the undissolved materials were 
removed by centrifugation and the solution allowed to come to 
room temperature. Organic solvent and unbound dye were removed 
by gel filtration on Sephadex G-25 (medium grade) eqUilibrated 
with O.OlM phoaphate buffer pH 7.2 • (Conjugate and unbound dye 
were easily visualized on the column). The protein content of 
the conjugate was measured by the Lowry method. and the bound 
DNS assayed spectrophotometrically assuming an E value of 
3.4 x 103 M-1cm-1 at 340 nm (Chen 1968). 
2.3 .. 1.2 Preparation of fluoreaoamine- and MDPF-labelled 
desmethylnortriptyline (DNT) 
Optimization of derivative formation prooedure 
(a) Fluorescamine-labelled DNT (DNT-FL) 
Prooedure 1 (pH effeot on the reaotion): 0.5 ml of 8.27 x 10-~ 
fluorescamine in acetone was rapidly added to 2.5 ml of 9.64 x 
10-6M DNT in 0.05M phosphate buffer of pH (7.5. 8.0. 8.5 ••••• 
12.0). The mixture was vigorously mixed on a vortex mixer and 
then equilibrated in the waterbath at 25°C for 5 minutes before 
fluorescence intensities 1f(485) were recorded in 10 nun path 
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length silica cuvette using the Baird-Atomic Fluoripoint 
Spectrofluorimeter with h = }90 nm and spectral bandwidth 
ex 
= 8 nm. In each case, final labelled product (DNT-FL) concen-
-6 tration was 8.0 x 10 M and the molar excess of added FL = 17.2 • 
Procedure 2 (Molar excess of FL for quantitative reaction): 
2.1 ml of 1.15 x 1O-5M DNT solution in 0.05M phosphate buffer 
pH 9.0 were rapidly and thoroughly mixed on vortex with various 
amounts of 1.37 x 10-3M FL in acetone. In each case, the appro-
priate amount of pure acetone was added to the reaction mixture 
to give the final total volume of 3 ml. This was to ensure that 
any changes in fluorescence intensity recorded were not the 
result of co-solvent polarity effects. The solutions were equili-
brated at 25'C for 5 minutes before fluorescence readings 
I f (485) were recorded usingthe same experimental conditions as 
-6 
above. Final concentration of DNT-FL = 8.0 x 10 M. 
~: In all subsequent experiments, solutions of DNT-FL were 
prepared with a 25-fold molar excess of the label in 0.01M 
sodium phosphate buffer at pH 9.0 • 
(b) MDPF-Iabelled DNT (DNT-M) 
Prooedure: The optimization experiments were performed as 
described above except that the molar excess of MDPF in the 
study of the pH effect was 20.}, and the solutions were buffered 
at pH 10.0 in the determination of the molar excess of MDPF 
required for quantitative reaction with DNT. 
". 
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Conditions of (a) pH and (b) molar excess of MDPF required for 
quantitative reaction between desmethylnortriptyline and MDPF. 
Molar ratio = MDPF : drug. 
'. 
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Table 2.2 Abbreviations used 'to denote fluorescent conjugates 
Protein/Ligand 
Antibody (Ab)a 
Albumin 
" 
Desmethylnortriptyline 
DNT 
Immunoglobulin G 
IgG 
Transferrin 
Label 
FITC 
li'luram 
RBITC 
DN3-Cl 
FITC 
Fluram 
MDPF 
RBITC 
Fluram 
MDPF 
Fluram 
MDPF 
'. Quinacrine 
Fluram 
MDPF 
Conjugate 
Ab-F 
Ab-FL 
Ab-R 
Alb-D 
Alb-F 
Alb-FL 
Alb-M 
Alb-R 
DNT-FL 
DNT-M 
IgG-FL 
IgG-M 
IgG-Q 
Trans-FL 
Trans-M 
a : The antigen for which the antibody is specific should be 
obvious from the context; where ambiguity may arise, 
subscript will be used to denote the specific antigen. 
Thus, AbX means antibody specific for antigen X. 
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2.3.2 Electroimmunodiffusion and Radial immunodiffusion 
Determination of albumin concentration by electro-
immunodiffusion was performed on Cellogel cellulose acetate 
strips containing anti-albumin antibodies (Dakopatts). 1 ~l 
samples of diluted serum standards (Hoechst) and appropriately 
diluted serum s~ples were applied on the Cellogel strip using 
1 pI microcap pipette. A barbiturate buffer pH 8.6, I = 0.02 
(barbitone 0.736 g 1-1 , sodium barbitone 4.12 g 1-1) was used 
in the electrophoresis which was carried out in a water-cooled 
electrophoresis chamber at a constant voltage of 120 V for 2 
hours. After the staining (Coomassie Blue RL, 0.25 % in 
methanol:acetic acid:water, 5:1:5 by volume) and destaining 
procedures to locate the rocket-shaped precipitill peaks, albumin 
, 
concentrations of the test samples were determined from the plot 
of rocket heights against concentrations of standards. 
M-Partigen Immunodiffusion plates (Hoechst) were used 
for the quantitative determination of sermn proteins. The 
procedure followed for the radial immunodiffusion experiments 
was as directed in the enclosed instructions. 
CHAPTER 3 ENERGY TRANSFER IMMUNOASSAY : A S'l'UDY OF THE 
EXPERll1ENTAL PARAMETERS IN AN ASSAY ~"'OH HUMAN 
SERUM ALBUMIN. 
3.1 Introduction 
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In the first description of energy transfer immuno-
assay (ETIA) by Ullman et al (1976), fluorescein (donor) and 
rhodamine (acceptor) were used in the development of assay methods 
for measuring both low molecular-weight (morphine, codeine) and 
high molecular-weight (human IgG) epecies with deteC'tability at 
levels above 100 pM. The Bame donor-acceptor fluorescent labels 
were also uBed in other applications of the method reported in 
subsequent papers from the same laboratory. These include assays 
for the quantitation of human IgA in samples containing from BO -
450 ~ dl-1 of the immunoglo~ulin (aodgers et al,1978), and IgM 
in the range 60 - 260 ~ dl-1 (Eimstad et al, 1978). All the above 
assays have made use of the competitive binding principle in the 
direct labelling method, or the sandwich assay principle in the 
indirect labelling method. In the former, purified or enriched 
antigen and antibody are respectively labelled with the donor and 
acceptor fluorescent groups. The average distance between donor 
and acceptor within the antigen-antibody complex formed should be 
sufficient to permit resonance energy transfer. This will lead to 
the quenching of the donor fluorescence and (possibly) the enhance-
ment of the acceptor fluorescence. These effects will be reversed 
by the inclusion of unlabelled antigens (present in standards and 
samples) in competitive reactions for the limited antibody binding 
sites. In the alternative sandwich assay, separate portions of the 
antibody are labelled with the donor and acceptor molecules. 
Unlabelled antigen causes the aggregation of the separately 
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labelled antibodies, and the effects of energy transfer are 
again observed. The sandwich assay does not require the use of 
purified antigens but a high degree of specificity is required of 
the antibodies so as to avoid the excessive fluorescence back-
ground due to inactive fluorescein-Iabelled prote.ins. Sandwiches 
cannot be made with hapten-antibody combinations, so the sandwich 
assay method is applicable to only multivalent ie. macro-molecular 
antigens. 
Since energy transfer from donor to acceptor involves 
a change in the fluorescence properties of one or both of the 
labels, the assay is homogeneous. That is, the separation of 
antibody-bound and free fractions of the antigen is not necessary, 
and hence this type of assay is easier to automate compared to the 
heterogeneous system. FUrthermore, the simUltaneous measurement of 
the quenching and enhancement effects gives a more accurate assess-
ment of the specific antigen-antibody combinations, and so offers 
a simple method for distinguishing genuine energy transfer effects 
from spurious environmental effects on the fluorescence intensity. 
In this chapter, the development of an energy transfer 
assay for low concentrations of human' albumin is described, and 
the suitability of fluorescein and rhodamine as fluorescent donor 
and acceptor labels in ETIA evaluated. The effects on the assay 
system of several experimental variables were investigated, includ-
ing (i) the fluorophore:protein (F:P) ratio, (ii) concentrations 
of labelled antigen and antibody, (iii) the fluorimeter spectral 
bandwidth, and (iv) whether, for greater resonance transfer 
efficiency, the donor tfluorescein) should be conjugated to the 
antigen or the antibody. The assay method was applied to the 
05 
analyses of test serum samples'and the results compared with 
those found by electroimmunoassay. studies on the specificity 
of the assay system as well as the stability of labelled immune 
reactants on storage will also be described. 
Human blood contains at least 100 individual proteins, 
and albumin which constitutes 60 per cent by weight is the most 
abundant. Its relatively small molecular size (molecular weight = 
66241; Putman,1975) confers upon it the important role of maintain-
ing through its osmotic pressure effect the circulating fluid 
within the vascular system. It binds with many physiological 
substances (eg. bilirubin, steroid hormones), drugs, antibiotics 
etc., and is therefore an important transport protein for many 
substances in blood. Albumin is synthesized in the liver and is 
a precursor for tissue protei.ns. 
In clinical laboratories, a simple, rapid and precise 
quantitative assay for albumin is essential for the diagnosis of 
vascular, cirrhotic and nephrotic defects, nutritional deficiencies 
of other proteins, aJld many other disease states. A summary of the 
different methods Which had been developed for the analysis of 
albumin in human blood plasma was given by Peters (1977). 
3.2 Experimental 
Quantitative fluorimetry was performed in thermo-
statted 10 mm path length silica cuvettes using the Eaird-Atomic 
Fluoripoint Spectrofluorimeter. All de terminations were made at 
37 C after srunples had been incubated at this temperature for 20 
minutes before measurement. Corrected excitation and emission 
I 
I· 
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spectra were recorded at 25 c., 
All fluorimetric measurements were corrected for the 
fluorescence background due to the buffer (saline(0.145M)-
phosphate buffer, pH 1.2, o.om) and added proteins. Contributions 
to the background from rhodamine-labelled antibodies were fOUIld 
to be negligible. 
" For stability studies, labelled protein solutions were 
stored in the dark at 4 C and examined for their fluorescent and 
immunological characteristics over periods of several months. If 
a labelled protein solution had turned turbid with precipitation, 
it was first centrifuged to remove the precipitates and the molar 
F:P of the recovered conjugates was then re-analysed as described 
in Section 2.3.1.1 • After re-standardization, such reagents were 
used ,in the usual way. 
3.3 Results and Discussion 
Energy transfer between fluorescein and rhodamine 
within the antigen-antibody complex was demonstrated by addition 
of rhodamine-labelled anti-albumin antibodies (Ab-R) to a fixed 
concentration of albumin-fluorescein (Alb-F). ~be degree of 
energy transfer was assessed by measuring the quenching of 
fluoresoein emission at 520 nm and the enhancement of rhodamine 
emission at 580 nm ( an excitation wavelength of 410 nm was used 
throughout). The resonance transfer efficiency of the fluorescein-
rhodamine system was expected to be high because there was signi-
ficant overlap between the fluorescein emission spectrum and the 
rhodamine excitation spectrum - see Fig.3.1 • However, the 
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Figure 5.1 Corrected excitation (E) and nuoreec'ence (F) spectra of 
albumin-nuorescein conjugate, label : protein ratio = 1. ~ : 1 ( " ), 
and of rhodamine-antibody conjugate, label: protein ratio = 7.5 : 1, 
(----). 
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magnitude of the energy transfer effects land hence the sensiti-
vity) of this particular assay system was found to depend on 
several other factors, including the molar ratio of labelled 
antigen and labelled antibody; the fluorophore:protein ratios of 
the labelled molecules; and whether the antigen was labelled with 
fluorescein and the antibody with rhodamine or vice-versa. These 
factors will be considered in turn. 
Fig. 3.2 shows that addition of increasing amounts of 
Ab-R to a fixed concentration of a lightly-labelled Alb-F (molar 
F:P = 1.3) caused fluorescein quenching and rhodamine enhancement 
to increase approximately linearly up to at least a 12-fold molar 
excess of antibody. At very low l < 0.5) antibody:antigen ratios, 
however, significant changes in fluorescence intensity were not 
observed. For any given mixt~re of Alb-F and Ab-H, the rhodamine 
enhancement was rather greater than fluorescein quenching. This 
re suI t may be .related to the small non-specific enhancement effect 
that occurred when unlabelled anti-albumin antibodies were added 
to fluorescein-Iabelled albumin ( Fig. 3.2), and which partially 
offsets the quenching due to energy-transfer. Ullman et al (1976) 
had also noted a similar slight increase in fluorescence intensity 
when unlabelled anti-morphine antibody was reacted with morphine-
fluoresce in molecules. Possibly, in both the cases, the enhance-
ment phenomenon is due to the change in the polarity of the medium 
within the environment of the bound antigen-fluorescein molecules. 
It is also clear from Fig. 3.2 that observations of rhodamine 
enhancement, as well as of fluorescein quenching, may be feasible 
in this type of fluorescence immunoassay, although in the present 
work the absolute intensity of the rhodamine fluorescence was 
found to be generally low. However, the background fluorescence 
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of blood serum and other biological fluids has been found 
(Soini et aI, 1919) to be generally greater at shorter wavelengths, 
so interferences from this cause will be reduced if, instead of 
measurement of fluorescein quenching at 520 nm, the rhodamine 
enhancement at 580 nm is measured. All previous studies on energy 
transfer (Ullman et aI, 1916; Rodgers et al 1978; Eimstad et. aI, 
1918) have made use of only fluorescein quenching measurements 
The figure also shows that the magnitude of the quench-
ing and enhancement effects is strongly dependent on the number of 
rhodamine molecules bound to the antibody molecules, with heavily-
labelled conjugates producing the largest effects especially at 
high antibody : antigen ratios. The effect of the degree of 
rhodamine labelling on the quenching of albumin-fluorescein 
fluorescence by excess labelled antibodies can be related to the 
greater probability of one or more rhodamine groups beIng attached 
. ' 
close to the antigen-binding site: energy transfer is thus more 
efficient because of the lower mean distance between the fluores-
cein and rhodamine groups. 
Legends for Figures 
Fig. 3.2 Enhancement of rhodamine fluorescence (580 nm) and 
quenching of fluorescein fluorescence (520 nm) when increasing 
amounts of rhodamine-labelled antibody are added to an albumin-
fluorescein conjugate (label:protein ratio = 1.3:1). The degree 
of labelling of the antibody is indicated by the n values: 
n = moles of rhodamine per mole of antibody. The dotted line 
shows the slight enhancement of fluorescein fluorescence (520 nm) 
when unlabelled antibody is added to the same albumin-fluorescein 
conjugate. Pure solutions of fluorescent conjugates have arbitrary 
fluorescence intensities of 100. Excitation wavelength: 410 nm. 
Fig. 3.3 Effects of adding rhodamine-labelled antibody to an 
albumin-fluorescein conjugate (label:protein ratio = 4:1). other 
details as in Fig. 3.2. 
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Comparison of Figures ,.2 and ,.3 shows that the degree of 
labelling of the albumin-fluorescein molecule is also an 
important factor. For a given rhodamine-labelled soluUon, and 
a given antibody:antigen ratio, the effioiency of resonance 
transfer from fluoreecein to rhodamine is less for an albumin-
fluorescein with a molar F:P of 4.0 than for a conjugate in 
which the molar F:P is only 1.,. That is, the more heavily-
labelled albumin"conjugate is less susceptible to quenching by 
the energy transfer mechanism than the lightly-labelled one. The 
principal reason for this effect is likely to be that, in the 
heavily-labelled conjugates, fluorescein-fluorescein energy 
transfer occurs in competition with fluorescein-rhodamine energy 
transfer. The corrected excitation and emission spectra of an 
albumin-fluorescein conjugate overlap to a considerable degree, 
(Fig. ,.1). The fluorescein~fluorescein energy transfer is thus 
likely to be quite efficient. i~ese results show that the optimum 
conditions for the observation of large proportional changes in 
the fluorescence intensities of fluorescein and rhodamine labels 
include the use of lightly-labelled fluorescein (donor) conjugates, 
and heavily-labelled rhodamine (acceptor) conjugates. A few 
experiments were al~o performed in which the labels were reversed 
ie. an antibody solution lightly labelled with fluorescein (label: 
protein ratio = 1.4:1) was the donor of energy, and a heavily-
labelled albumin-rhodamine conjugate (label:protein ratio = 8.0:1) 
was the acceptor. Results of all these experiments show that the 
measured quenching and enhancement effects were substantiallY 
less than those found using albumin-fluorescein and antibody-
rhodamine conjugatee. It is naturally possible that the opposite 
result will be obtained with a different antigen. 
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The sensitivity of the assay, system was found to be dependent 
on the total concentration of the labelled reactants. Fig. 3.4 
shows that in an assay system where the concentration of albumin-
fluorescein was 4.8 x 10-9 and the molar labelled, antibody: 
labelled antigen 14.6, albumin concentrations of 10-9M and 
below could be detected. (This is well below the concentration 
of albumin in normal urine - ca. 10-7M, so the energy transfer 
assay might be s~itable for this application - Cf. Woo et al,1979) 
When both labelled 'albumin and labelled antibody were present at 
10-fold higher concentration, however, the sensitivity of the 
assay is much reduced. In the latter conditions, not only was a 
higher concentration of sample albumin necessary to dissociate 
labelled albumin-labelled antibody complexes, but inner-filter 
effects would also reduce the observed fluorescence intensity 
changes. If the labelled immune reactants were present in very 
low concentrations, however, the maximum instrunlent gain setting 
(producing worsening signal to noise ratios) had to be used to 
measure the fluorescence signals: in this work, the limi.t of 
detecti.on of albumin in pure solution was found to be ca. 4.5 x 
10-10M • The sensitivities of different fluorimeters differ 
substantially in practice, so an instrument specially designed 
to give optimum results with fluorescein-labelled speceis might 
be ,able to improve on this detection limit considerably. 
A further important limitation on the sensitivity of 
a fluorimeter in this assay is the spectral bandwidth. Fig. 3.5 
shows that the largest energy transfer effects, measured by 
determining the quenching of fluorescence of labelled a.lbumin, 
were observed when both the excitation and emission monochrcmators 
on the instrument were used with narrow bandwidths. In the 
illustrated experiment, the quenching observed with excitation 
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Changes in fluorescence intensity at 520 nm when unlabelled albumin· 
ie added to mixtures containing (a) 4.8 x 10~ albumin-fluorescein 
conjugate (label: protein ratio 1.3 I 1) and 7 x 10-7M antibody-
rhodamine conjugate (label: protein ratio 12 I 1), and (b) the 
same conjugates each at one-tenth the concentrations in (a). 
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32 
Effects of speotral bandwidths on the effioienoy of energy transfer 
(measured at 520 nm) between an albumin-fluorescein oonjugate . 
(9.6 x 10-9M; label:protein rat~o, 1.3:1) and an antibody-rhodamine 
oonjugate (1.6 x 10-7M; label:protein ratio, 16.5:1). The albumin-
fluorescein conjugate alo~e has a fluorescence intensity of 100 • 
• • -= emission bandwidth 12 nm, excitation bandwidth varied; 
~ = emission bandwidth 32 nm, exoitation bandwidth varied; 
• • • excitation bandwidth 12 nm, emisllion bandwidth varied; 
-().--O-= exoitation bandwidth 32 0lIl, emission bandwidth varied. 
Exoitation wavelength, 470 nm. 
'. 
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and emission bandwidths of 8 and 12 nm respeotively was 51.5 %; 
when both monoohromators were used with bandwidths of 32 nm, the 
observed quenching was only 35 %. This effect ooours beoause the 
exoitation speotrum of the rhodamine label partially overlaps 
that of the fluoresoein label (Fig. 3.1). Thus, when the fluori-
meter is used with large bandwidths some direct excitation of the 
rhodamine occurs at a nominal exciting wavelength of 470 nm, in 
addition to and in ~ompetition with the energy transfer excitation. 
This problem has been previously noted during other studies of 
energy transfer phenomena (Schiller, 1975) : one practical effect 
in the present application is to reduce the value of filter fluori-
meters in fluoresce in-rhodamine energy transfer assays. 
The excellent specificity of the assay is exemplified 
in Fig. 3.6. Addition of human IgG to a mixture of fluorescein-
labelled albumin and rhodamine-labelled anti-albumin produced'no 
significant changes in fluorescence intensity. Furthermore, ' 
excellent agreement between the energy-transfer method ( using 
fluorescein quenching measurements) and the electroimmunoassay 
method was obtained when four diluted serum samples were studied 
(Table 3.1). The energy-transfer assay also showed excellent 
precision, particularly when the serum samples were diluted 500 
times to minimise fluorescent background interference. 
The development of a useful fluorescence immunoassay 
requires that the fluorescent labelled reagents are reasonably 
stable both under measurement conditions and on storage. A long 
shelf-life for such reagents will facilitate long-term assay 
standardization and is indeed one of the major potential 
advantages of fluorescence i,rununoassay methods compared to 
isotopic assays. In this work, fluorescein-Iabelled proteins 
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Effects of adding albumin (-o~-) .and human immunoglobulin G 
(. .) to a solution containing an albumin-fluorescein 
conjugate ( 4.8 x 10-9M ; label:protein ratio, 1.311) and an anti-
albumin-rhodamine oonjugate ( 5 x 10-BM ; label:protein ratio, 
8.111). The albumin-fluoresoein oonjugate alone has arbitrary 
fluorescence intensity of 100. Exoitation wavelength, 470 Ilm; 
bandwidths, 12 nm. 
Sample Dilution 
for E-T 
assay 
1 xSO 
2 xSO 
3 xSOO 
4 xSOO 
Table 3.1 
Determination of· albumin in·diluted human serum samples: 
comparison of energy-transfer and electroimmunoassay methods 
Energl-Transfer (E-T~ Assal Elcctroimmunoassay 
Same day (n=10) Different days (n=lO) Same dax- (n=lO) 
Concentration cv Concentrat~on cv Concentration cv 
mg. dl- l \ mg. dl- l % mg. dl- l % 
3370±130 3.8 3180±220 6.9 3300±160 5.0 
3400±110 3.1 3S70±230 6.4 3700±260 7.0 
3970±120 3.0 4070±160 4.0 4100±180 4.4 
3S10±80 2.3 3620±180 4.9 3700±120 3.3 
'0 
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stored in the dark at 4 C were found to be stable ( in respect 
of fluorescent and immunological characteristics) over periods 
of several months. Rhodamine-labelled antibody solutions, on the 
other hand, exhibited turbidity and precipitation after only a 
few weeks in the same storage conditions. Heavily-labelled 
fractions (F:P 10j were particularly vulnerable to such losses. 
Thus, a preparation of rhodamine-labelled wlti-albwnin, with ruJ 
initial rhodamine:protein ratio of 13.0 was found, ai'ter storage 
" 
at 4 C for 12 weeks, removal of precipitate by centrifugation, 
and analysis, to have a rhodamine:protein ratio of only 9.3. 
After re-standardization, such rhodamine-labelled samples were 
still usable but the sensitivity of the assay was thus reduced, 
so such reagents are clearly not ideal. 
From these results it is apparent that, while energy-
transfer immunoassays using·fluorescein and rhodamine as the 
donor and acceptor labels are perfectly practicable, these, 
fluorophores are by no means ideal for use in such assays. 
Particular disadvantages include the poor stability of rhodamine-
labelled antibodies, and the overlap of the fluorescein and 
rhodamine absorption spectra. In addition, the stokes shift for 
fluorescein is relatively small, sO .interference from scattered 
light may limit the sensitivity of the assay in biological 
samples; and in the present work the intensity of the rhodamine 
emission at 580 run was too feeble to permit its routine use in 
a sensitive assay. Results of the investigations performed to 
identify pairs of labels that overcome most of these disadvantages 
are discussed in the next chapter. 
". 
CHAPTER 4 EVALUATION OF OOMF) PO'l.'ENTIAL DONOR-ACCEPTOR 
FLUORESCENT LABELS APPLICABLE IN ENERGY 
TRANSFER IMMUNOASSAY 
4.1 Introduction 
All the applications of ETIA so far reported 
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(Ullman et al 1976; Rodgers et al 1978; Eimstad et al 1978) 
"-have made use of fluorescein as the donor label because of its 
high absorption coefficient and fluorescence quantum yield, 
and rhodamine as the acceptor label because of its good spectral 
overlap with the fluorescein emission maximum. An evaluation of 
these two labels described in Chapter 3 has shown that they are 
not an ideal pair of labels for use in such assays. The 
principal deficiencies of the fluorescein-rhodamine energy 
transfer assay system can lie attributed to I 
(i) the small Stokes shift of the fluorescein molecule (ca 30 nm) 
which makes fluorimetrio measurements at the emission maximum 
wavelength (520 nm) very liable to interferences from Rayleigh 
(and possibly Raman) scatter especially in assays of biological 
samples; 
(ii) the partial overlap of the absorption spectra of fluores-
cein and rhodamine which reduces the assay sensitivity when 
large spectral bandwidths for fluorescein excitation at 490 nm 
are used; and 
(iii) the poor stability of the rhodamine-labelled protein 
solutions on storage, which prevents long-term assay standardi-
zation. 
To date, most fluorescence immunoassays tFIA) have 
utilized fluorescent molecules which were originally developed 
". 
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for other applico.tions. For example, fluorescein which is 
perhaps the most commonly used fluorophore in FlA (eg.Aalberse 
1973; Watson et ai 1976; Smith 1977; Shaw et al 197'7; McGregor 
et 0.1 1978; etc) was initially employed by Coons et al (1942) 
in immunofluorescence microscopy as a topographical marker for 
the localization of antigens or antibodies in tissue cells. Not 
surprisingly, a large number of the commonly ( and commercially) 
available fluorescent labels have been found to be unsuitable 
, 
for specific applications in FlA. The special requirements of a 
fluorescent label for use in FIA severely limit the choice to 
only a few fluorophores. A further limitation is imposed by the 
specific requirements of the energy transfer assay method which 
requires, amon'gst other conditions, the optimum spectral overlap 
of the donor emission spectrum with the acceptor excitation 
spectrum. 
This chapter describes the preliminary investigations 
which were performed to identify sui table donor-acceptor pairs 
amongst the many commonly available fluorescent labels. The 
development of a single pair of labels applicable to the widest 
possible range of materials would be very desirable, although in 
practice it is more likely that a number of different donor-
acceptor systems would be required to facilitate the labelling 
of a range of ligands with different chemically active groups. 
The following donor-acceptor pairs were studied: 
(a) quinacrine and fluorescei,n 
(b) quinacrine and rhodamine 
tc) dansyl chloride and rhodamine 
(d) fluorescamine and fluoresceln 
(e) MUFF and fluorescein (to be described in 
Chapters 6 and 7) 
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Of the above, only (d) and (e), were found to be suitable donor-
acceptor pairs. Fluorescamine (donor) and fluorescein (acceptor) 
were used to develop an energy transfer assay for human albumin 
in an evaluation of their applicability to the development of 
similar assays for other analytes. The general methodology used 
in the albumin assay was later extended to the development of 
assays for nortriptyline and related tricyclic antidepressants 
(Chapter 5), human serum transferrin (Chapter 6), and human , 
immunoglobulin G and A (Chapter 1) 
Experiments were also performed to investigate the 
changes in the fluorescence intensities when unlabelled specif1.c 
antibodies were reacted with antigens labelled with different 
types of fluorophores (quinacrine, DNS, fluram and MDPF). In 
these studies, albumin-fluoreacamine conjugates in particular 
were found to exhibit large increases in the fluorescence 
intensity when excess unlabelled anti-albumin antibodies were 
added. Further investigations (to "be described in subsequent 
chapters) confirm that the fluram enhancement phenomenon is a 
general effect observed with all the fluorescamine-labelled 
antigens studied in this work. 
4.2 Experimental 
The donor-acceptor pairs listed above were studied 
using the following labelled proteins (see Table 2.2 for 
abbreviations used). 
(a) IgG-Q and Ab-F 
(b) IgG-Q and Ab-R 
(c) Alb-D and Ab-R 
(d) Alb-~'.L and Ab-F 
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Quantitative fluorimetric studies of fluorescamine-
fluorescein energy-transfer were performed with a Baird-Atomic 
Fluoripoint Spectrofluorimeter. The MPF-44B Fluorescence 
Spectrophotometer was used in experiments to evaluate other 
donor-acceptor pairs. Thermostatted 10 mm path length silica 
cuvettes were used in all fluorescence measurements at 35 C 
after preincubation of the reagents at the same temperature for 
60 minutes (for experiments on (a) and (b) ) or 45 minutes ( for 
" 
experiments on (c) and (d) ). Corrections were made for the 
background fluorescence contributed by the buffer, added proteins 
and labelled antibodies. The buffer used in all the experiments 
was 0.01M phosphate buffer, PI! 7.2, containing 0.145M NaCI. 
The spectra shown in Figure 4.10 were recorded with 
a Baird-Atomic Fluoricord spectrofluorimeter connected to a Model 
27000 chart recorder; other spectra were recorded in the 
corrected mode using the MPF-44B together with the ~Iodel 56 
recorder. 
4.3 Resul ts and Discussion 
The condition of maximum"spectral overlap ( the J_ 
v 
factor in Equation (1.11) ) is an important prerequisite for 
efficient energy transfer by the resonance mechanism. In a gh'en 
donor-acceptor system where this condition amongst others is 
fUlfilled, the transfer efficiency can be expected to be high; 
at the same time, the observation of the energy transfer effects 
can be complicated by other factors rolated to the spectral 
characteristics of both the donor and acceptor labels. ~bis is 
exemplified in Figure 4.1(b) which shows the good spectral 
, 
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Figure 4.1(a) Corrected excitation (E) and fluorescence (F) spectra of an 
Ig~quinacrine conjugate (label: protein ratio, 1.9:1). Instrument gain setting 
was reduced 3.3 times when recording from 200 to 300 nm. 
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Figure 4.1(b) Corrected excitation (E) and fluorescence (F) spectra 
of a fluorescein-labelled anti-IgG conjugate (la'bel:protein ratio, 
1.5:1) ( ). Fluorescence spectrum of an IgG-quinacrine conjugate 
(label:protein ratio, 1.9:1) is shown by dotted linea. 
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overlap of fluorescein with the quinacrine emission spectrum. 
This desirable condition for the observation of energy transfer 
between quinacrine and fluorescein is offset, however, by the 
broad spectral bandwidth of the quinacrine fluorescence spectrum, 
which also overlaps the fluorescein emission spectrum to a 
considerable degree. One practical limitation of this result in 
the study of quinacrine-fluorescein energy transfer will be the 
difficulty of measuring accurately the enhancement of fluorescein 
and the quenching of quinacrine emission intensities. Clearly, 
these.two labels are not suitable for use as donor-acceptor 
labels in ETIA. 
In'order to overcome the shortcomings of fluorescein 
as the acceptor label in the above system, rhodamine as an 
acceptor of energy was investigated as a potential replacement 
for fluoresce in. Even though the spectral overlap between 
quinacrine emission and rhodamine excitation spectra is less 
than optimum (Fig. 4.2), rhodamine was nevertheless employed in 
this investigation because, if efficient energy transfer from 
quinacrine to rhodamine could occur, then the measurement of the 
rhodamine enhancement intensity at 585 nm would be more convenient 
. compared to the measurement of the fluorescein emission intonsi ty 
at'520 nm (for reasons already discussed in Chapter 3). The 
efficiency of quinacrine-rhodamine energy transfer was investi-
gated by addition of rhodamine-labelled anti-IgG conjugates to a 
fixed concentration of IgG-quinacrine. The resultant energy 
transfer effects were assessed by measuring the quenching of 
quinacrine emission at 500 nm mId the rhodamine enhancement at 
585 nm ( an excitation wavelength of 425 nm was used). Figures 
4.3 and 4.4 show that in the reaction between a lightly labelled 
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Figure 4.2 Corrected excitation (E) and fluorescence (F) spectra of 
a rhodamine-labelled anti-IgG conjugate (label:protein ratio, 0.3:1 ) 
( ). Fluorescence spectrum of an IgG-quinacrine conjugate (- - - ) 
reproduced from Fig. 4.1(b). 
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Figure 4.3 (a) and (b) are respeotively the emission spectra 
of IgG-quinacrine conjugate (8.95 nM; label:protein ratio,1.9:1) 
and rhodamine-labelled anti-IgG conjugate (22.9 nM; label:protein 
ratio, 8.3:1). (c) is the emission spectrum of a mixture contain-
ing both the conjugates at the concentrations stated. 
Excitation wavelength, 425 nm ; bandwidths, 10 nm • 
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Figure 4.4 AB in Fig. 4.3 • except that the rhodamine-
labelled anti-IgG conjugate concentration is 1.07 x 10-7M. 
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IgG-quinacrine conjugate (label:protein ratio, 1.9:1) and its 
specific antibody heavily labelled with rhodamine (label:protein 
~ ratio, 8.3:1), no significant changes in the fluorescence inten-
sities of quinacrine and rhodamine were observed either at low 
(2.56) or high (12.8) molar labelled antibody:labelled antigen 
ratios. The negligible transfer effects observed in this case 
was at first thought to be due to the low degree of labelling in 
the IgG-quinacrine molecules, but similar negligible transfer 
" effects were again observed when more heavily labelled IgG-
quinacrine conjugates (label:protein ratios, 4.211 and 8.6:1) 
were used with the same preparation of rhodamine-labelled anti-
IgG conjugates. Furthermore, the accurate determination of quina-
crine quenching effect at 500 nm was made more difficult by the 
overlapping Raman scatter peak (Fig. 4.5); a small increase (ca 
. 20 % ) in the IgG-quinacrine emission intensity was also noted 
when" excess unlabelled anti-IgG antibodies were added (Fig. 4.5). 
The latter effect would have more than nullified whatever small 
decreases in quinacrine emission caused by energy transfer. 
These results demonstrate clearly that quinacrins is not a 
suitable donor label for use in ETIA studies. 
Legend for Figure 4.5 
Emission spectra showing the changes in the fluorescence intensity 
of mixtures containing a fixed concentration of Igr~quinacrine 
conjugate (1.79 x 10-BM ; label:protein ratio, 1.911) ruld increas-
ing amountB of unlabelled anti-IgG antibodies. 
B = emission spectrum of buffer alone; the Raman scatter peak 
occurs at 500 nm. 
(0= emission spectrum of IgG-quinacrine conjugate alone. 
1 =(1) - B. All other spectra were corrected for the added Ab. 
2, (AbIAg ratio, 3.8:1) ; 3,(7.6:1) ; 4,(11.3:1) ; 5,(15.0:1) ; 
and 6,(18.9:1). Excitation wavelength, 425 nm; bandwidths, 10 nm. 
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Figure 4.6 corrected excitation (E) and fluorescence (F) spectra 
of a rhodamine-labelled anti-albumin conjugate (- - - ) (label: 
protein ratio, 7.5:1), and of an albumin-dansyl conjugate ( ) 
(label:protein ratio, 16:1) 
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The overlap of dansyl emission and rhodamine 
excitation spectra is shown in Figure 4.6. The efficiency 
of energy transfer in the dansyl-rhodamine system was assessed 
by adding rhodamine-labelled anti-albumin conjugates to a fixed 
concentration of dansylated albumin ldansyl:protein ratio, 16:1),. 
and measuring the decrease in the dansyl emission intensity at 
530 nm and the relatively small increase in the rhodamine 
emission intensity at 585 nm (excitation wavelength, 340 nm). 
, 
See Figure 4.7. At more than a 12-fold molar excess of labelled. 
antibody conjugates, the quenching of the dansyl emission inten-
sity amounted to no more than 30 per cent in the two cases where 
the degree of rhodamine labelling was 7.1 (Fig. 4.7a) and 11.6 
(Fig. 4.7b).(A small increase in the dansyl emission intensity 
was also observed when excess unlabelled anti-albumin was added 
to a same concentration of the albumin-dansyl conjugate - Fig.4.6; 
this effect may partially offset the quenching of dansyl emission 
intensity by rhodamine-labelled antibodies). Interestingly, in 
all these studies, there did not seem to be a proportional 
increase in the rhodamine enhancement intensity at 565 nm 
comparable to the observed decrease in the dansyl emission inten-
sity at 530 nm. A possible explanation for this observation is 
likely to be that, in this particular system, the nonradiative 
deactivation processes are highly efficient in competitively 
diminishing the sensitized rhodamine fluorescence intensity. A 
few experiments were also performed using lightly labelled 
albumin-dansyl conjugates ( dansyl:albumin ratios, 4.6:1 and 
6.0:1). Results relating to the energy transfer effects observed 
in these studies were not at all satisfactory because the feeble 
fluorescence signals from low concentrations of these lightly 
labelled conjugates required the use of maximum gain setting 
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in the fluorimeter: this inevitably produced worsening 
signal to noise ratios. It is apparent from the above results 
that while energy transfer from the dansyl to the rhodamine 
group can take place within the labelled antibody-labelled 
antigen complex, the magnitude of the transfer effects was not 
sufficiently large to permit its application to the development 
of a sensitive assay for albumin. It is naturally possible that 
a greater magnitude of the transfer effects may be obtained 
using a different antigen, although it is quite likely that 
even in such an assay system the rhodamine enhancement signal 
at 585 nm will be too feeble to be utilized for accurate 
fluorimetric measurements. Moreover, the excitation and 
emission spectra of dansyl chloride overlap those of serum and 
other biological fluids (Soini et al,1979), and so fluorimetric 
measurements of the dansyl emission intensity at 530 nm are 
very liable to fluorescence background interferences in assays 
of biological materials. 
Legend for Figure 4.7 
Emission spectra showing the changes in the fluorescence inten-
sity of miXtures containing a fixed conceptration of albumin-
dansyl conjugate (5.85 nM ; dansyl:albumin ratio, 16:1) and 
increasing amounts of antibody-rhodamine conjugates (label: 
protein ratiOS, (a) 7.1:1 ; (b) 11.6:1 ). 
R : emission spectrum of albumin-dansyl conjugate alone 
Fig. 4.7(a) 1,(Ab:Ag ratiO, 3.5:1) ; 2,(7.0:1) 3,(10.6:1) 
4,(14.1:1) ; 5,(17.1:1). 
Fig. 4.7(b) 1, (Ab:Ag ratio, 2.6:1) ; 2,(5.1:1) ; 3,(7.7:1) ; 
4,(10.2:1) ; 5,(12.8:1). 
Emission spectra of added antibody-rhodamine conjugates alone 
are indicated by numerals within circles. Excitation wavelength, 
340 nm ; bandwidths, 6nm. 
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Figure 4.8 
Emission speotra showing the ohanges in the fluoresoenoe 
intensity of mixtures oontaining a fixed oonoentration of 
albumin-dansyl oonjugate (5.85 nM; dansyl:albumin ratio, 
16:1) and inoreasing amounts ~f unlabelled anti-albumin 
antibodies. 
B : emission speotrum of phosphate buffer alone. 
R : emission speotrum of albumin-dansyl oonjugate alone. 
1,(Ab:Ag ratio, ~.7:1) ; 2,(7.5:1) ; ~,(11.2:1) ; and 
4,(14.9:1). Excitation wavelength, ~40 nm; bandwidths, 6 nm. 
----- -----------------------
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Figure 4.9 shows that the maximum of the fluorescamine 
emission spectrum overlaps strongly the maximum of the fluores-
cein excitation spectrum. Transfer of energy from fluorescamine 
to fluorescein can therefore be expected to be efficient, and 
this is exemplified in Figure 4.10 by the quenching of fluores-
camine and the enhancement of fluorescein emission intensities. 
Quantitative fluorimetric studies of fluorescamine- fluorescein 
energy transfer w~re performed by adding increasing amounts of 
fluorescein-labelled anti-albumin antibodies to a fixed concen-
tration of albumin-fluorescamine conjugate (label:protein ratio, 
10.0 : 1), and measuring the decreases in fluorescamine emission 
intensity at 485 nm and the simultaneous increases in fluorescein 
emission intensity at 535 nm (an excitation wavelength of 390 nm 
was used). Figure 4.11 shows the changes in intensities of 
fluorescamine and fluorescein emission at various molar labelled 
antibody : labelled antigen ratios. In the two cases where the 
degrees of fluorescein labelling were 1.4:1 (Fig. 4.11a) and 
3.2:1 (Fig. 4.11b), the decrease in fluorescamine emission 
intensity varied approximately linearly with the added antibody 
conjugates. At a 6-fold molar excess of labelled antibody conju-
gates, the overall quenching effect in both the cases amounted 
to no more than 20 per cent. In the same conditions, the observed 
proportional enhancement of the fluorescein emission intensity 
was considerably greater, amounting to more than 110 per cent 
increase. The most likely cause for this apparent disparity 
between the quenching and enhancement effects can be related to 
the exceptionally large increases in the albumin-fluorescamine 
conjugate emission intensity when excess unlabelled anti-albumin 
was added (Figure 4.12). The figure also shows that the enhance-
ment phenomenon, termed the "fluram enhancement effectll in this 
". 
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thesis, was strongly dep~ndent on the number of fluorescamine 
molecules bound to the albumin, with heavily-labelled conjugates 
producing the largest effects. Neither the addition of non-
specific bovine gammaglobulins to a solution of albumin-
fluorescamine conjugate, nor the addition of unlabelled anti-
albumin antibodies to a solution of albumin-fluorescein conjugate 
produced any significant increases in the fluorescence intensities 
of the conjugates (Fig. 4.12). Experiments performed using other 
antigens labelled with fluorescamine also gave results similar to 
those obtained with albumin-fluorescamine conjugate, thus confirm-
ing that the fluram enhancement phenomenon is indeed a general 
effect (see Chapters 5,6 and 7). A probable mechanism for this 
effect has been described by Miller (1979). 
An ETIA for albumin based on the fluorescamine-
fluorescein label pair would have to make use of only the fluores-
cein enhancement measurements because the quenching of the 
fluorescamine emission intensity by energy transfer is counter-
acted simultaneously by the fluram enhancement effect. In the 
assay for albumin, the optimum conditions required include the use 
of heavily labelled albumin-fluorescamine conjugate (label:protein 
ratio, 10:1) and the antibody lightly labelled with fluorescein 
(label:protein ratio,1.5:1). The molar excess of labelled antibody 
to labelled antigen in the assay should preferably be not too 
large ( < a 6-fold molar excess of labelled Ab) because at high 
concentrations of the antibody-fluorescein conjugates, the magni-
tude of the energy transfer effects observed will be diminished by 
inner fH ter effect. The standard curves shown in ]'igure 4.13 
permit low concentrations of albumin (sub-nanomolar levels) in 
pure solution and in serum samples to be detected. SUbsequent 
chapters will describe the applications of the fluorescamine-
fluorescein label pair to the development of ETIA's for other 
analytes. 
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Figure 4.9 Corrected excitation'(E) and fluorescence (F) spectra 
. of an albumin-fluorescamine conjugate (label:protein ratio, 5.8:1) 
( ), and of an antibody-fluorescein conjugate (label:protein 
ratio, 3.2:1) (- - - ). ' 
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Emission spectra of (a) an albumin-Duorescamine conjugate 
(1.5 x 10-7M ; label:protein ratio, 6.2:1) ; (b) an antibody-
fluorescein conjugate (4.67 x 10-7M ; label:protein ratio, 
1.4:1) ; and (c) a mixture containing both the conjugates at 
the concentrations stated. )\ex = 390 nm ; bandwidths, 12 nm 
". 
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Legends for Figures 
Figure 4.11 
Quenching of fluorescamine emission intensity If(465) and the 
enhancement of fluorescein emission intensity I f (535) as 
increasing amounts of antibody-fluorescein conjugates (label: 
protein ratio, (a) 1.4:1 ; (b) 3.2:1) are added to a fixed 
concentration of albumin-fluorescamine conjugate (5.1 x 10-6M ; 
label:protein ratio, 10:1). Corrections were made for contri-
butions to the background fluorescence by added labelled 
antibodies. Excitation wavelength, 390 nm ; bandwidths, 10 nm. 
Figure 4.12 
The Fluram Enhancement Effect. 
Increases in fluorescamine emission intensities I f (465) of 
albumin-fluorescamine conjugates when unlabelled anti-albumin 
antibodies are added: 
6 -6 
.2 x 10 M Alb-FL ; label: protein ratio, 6.2: 1 ( • • .-) 
7.4 x 1O-6M Alb-FL label: protein ratio, 10: 1 ( U It .. ) 
-6 Alb-FL label: protein ratio, 14.7: 1 (-0-0-0 -) 7.0 x 10 M • ,
Effect on the fluorescamine emission intensity at 465 nm when 
non-specific bovine gammaglobulins are added to an albumin-
fluorescamine conjugate ( 1.4 x 10-6M ; label:protein ratio, 
10:1) is shown by ( A A A ), Excitation wavelength used for 
all the above measurements, 390 nm; bandwidths, 10 nm. 
Changes in the fluorescein emission intensity at 530 nm when 
unlabelled anti-albumin antibodies are added to an albumin-
fluorescein conjugate ( 4.6 x 10-6M ; label:protein ratio,1.3:1) 
are indicated by ( 0 0 0 ). Excitation wavelength, 470 nm 
bandwidths, 6 nm. All fluorescent conjugates alone have 
arbitrary intensity of 100. 
Figure 4.13 
Changes in the fluorescence intensity at 535 nm when unlabelled 
albumin in pure solutions (-x-x-) and in standard serum (-t-t-) 
is added to mixtures containing 2.3 x 10-6M Alb-FL (label:protein 
ratio,10:1) and 1.4 x 10-7M Ab-F (label:protein ratio, 1.4:1). 
A~x'" 390 nm ; bandwidths, 10 nm • Error bars are standard 
deviations for 4 measurements. 
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CHAPTER 5 DEVELOPNENT OF FLUORESCENCE IMl1UNOASSAY NETHODS FOR 
NORTRIPTYLnfE AND RELATED TRlCYCLIC ANTIDEPRESSANTS 
5.1 Introduction 
In view of the widespread use of tricyclic, antidepressants, 
TAD,(see Table 5.1) for the alleviation of depression, there exists 
in the clinical laboratories a need for a rapid, sensitive and 
precise method for the quantitative measurement of these exogenous 
compounds in human blood serum and urine. Reported analytical 
techniques for measuring tricyclic antidepressants in biological 
fluids have been based on spectrophotometric (Wallace et al,1967), 
isotopic (Hammer et al,1967), chromatographic (Borga et al,1972 ; 
Braithwaite et al,1971 ; Faber et al,1974), and immunochemical 
procedures including a radioimmunoassay (Aheme et al,1976 ; 
Naguire et al, 1978) and a double-antibody enzyme immunoassay 
(Al-Baesam et al,1978) for nortriptyline. 
This chapter describes the development of two 
fluorescence immunoassay methods for the determination of 
nortriptyline in human blood serum : an energy transfer assay in 
which fluorescamine is used as the energy donor and fluorescein 
as the acceptor, and a fluorescence enhancement immunoassay in 
which the fluram enhancement effect is utilized. An eValuation of 
fluorescamine and fluorescein as donor-acceptor labels applicable 
in ETIA was described in the last chapter. It was found that the 
fluorescamine-fluorescein energy transfer within the albumin-
antibody complex was efficient. A large increase in the 
fluorescein emission intensity at 535 nm and a relatively small 
decrease (offset by the fluram effect: see Section 4.3) in the 
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fluorescamine emission intensity.at 485 nm were observed. FOr 
the foregoing reason, the energy transfer assay that was 
developed for albumin made use of only the fluorescein 
enhancement measurements. 
In several respects, fluorescamine and fluorescein are 
superior to fluorescein and rhodamine as donor-acceptor 
fluorescent labels in ETIA. Compared to fluorescein as the donor 
label, fluorescamine has a large Stokes shift of ca. 100 nmi and 
so with the excitation wavelength of fluorescamine set at 390 nm, 
the fluorimetric measurement of the fluorescein enhancement 
emission at 535 nm will be less susceptible to scatter inter-
ferences. FUrther, large fluorimeter slit widths for greater assay 
sensitivity may be used because, in contrast to the fluorescein-
rhodamine system, the effect on the fluorescamine-fluorescein 
energy transfer of the fluorimeter spectral bandwidth is 
negligible. Fluorescamine derivatives of proteins and other 
analytes containing the primary amine group can be easily prepared 
witho~t the need to separate the labelled conjugates from excess 
unreacted fluorescamine molecules which are rapidly hydrolysed to 
non-fluorescent products (Udenfriend et al,1972). And compared to 
rhodamine-labelled protein conjugates, fluorescein-antibody 
conjugates are more stable, being usable and free from turbidity 
or precipitation after storage for several months in the dark at 4C 
". 
5.2 Experimental 
Quantitative fluorimetric stUdies were performed in 10 mm 
path length silica cuvettes using a Fluoripoint fluorimeter fitted 
with a temperature-controlled cell compartment. All reagents were 
were incubated at 30 C for 30 minutes before measurements were 
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recorded at the same temperature. Desmethylnortriptyline and the 
immunoglobulin G fraction of sheep anti-nortriptyline antiserum 
were labelled with fluorescamine and fluorescein respectively as 
described in Section 2.3.1. Fbr studies on serum samples, the sera 
were diluted 1:1 v/v with saline (0.145 M)-phosphate buffer, pH 
9.0, 0.01M, containing known concentrations of drugs. The spiked 
sera were then further diluted 50-fold prior to analysis. 
Studies on the fluram effect of nortriptyline-
fluorescamine conjugate made use of the IgG and IgM fractions of 
the sheep antiserum (Figure 2.1). A value of E18~ = 15 was used 
to calculate the protein concentrations of the sheep immunoglobulins. 
Assumed molecular weights for sheep IgG and IgM molecules are 
145000 and 900000 respectively. 
In all fluorimetric measurements, corrections were made 
for the background fluorescence from added proteins, labelled 
antibodies, serum and buffer. Tricyclic antidepressants were found 
not to contribute to the background. The following non-standard 
abbreviations are used to denote the drugs studied in this work. 
AT Amitriptyline DP : Desipramine 
BT : Butriptyline IP Imipramine 
CP : Chlomipramine NT Nortriptyline 
DNT Desmethylnortriptyline PT Protriptyline 
DNT-FL : Desmethylnortriptyline-fluorescamine 
conjugate 
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Table 5.1 Some Trleyelle Antldepre .. anta (TAD) 
Amitriptyline Rt = CH3 RZ = CH3 
Nortriptyline " R, = CH3 R2 = H 
Desmathylnortrlptyllne R, = H R2 = H 
~ ~ 
N 
§ R2 
'J /CH3 H2CH2CH2N, R, 
Chlomlpramlne R, = CH3 R2 = Cl 
Desipramine R, = H R2 = H 
Imipramine R, = CH3 R2 = H 
BUlrlplyllna 
Protrlptyllna 
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5.3 Results and Discussion 
The fluram enhancement effect of DNT-FL conjugate was 
first investigated by measuring the changes in the fluorescamine 
emission intensity at 485 nm as increasing amounts of unlabelled 
sheep anti-nortriptyline IgG molecules were added to a fixed 
concentration of DNT-FL conjugate (7.5 x 10-7M); an excitation 
wavelength of 390 nm was used in this work. FiGure 5.1 shows that 
, 
in the presence of a 14.3-fold molar excess of unlabelled sheep 
IgG , the DNT-FL conjugate emission intensity increased by more 
than 170 per cent. The absence of non~specific enhancement effect 
is also illustrated in the figure which shows that when a 
comparable molar excess of non-specific human IgG, in lieu of the 
sheep IgG, was added to a solution of DNT-FL conjugate, the 
measured increase in the fluorescamine emission intensity of the 
conjugate was less than 2 per cent. This relatively small increase 
in the fluorescence intensity can be attributed to the viscosity 
change in the solution medium when protein was added., The 
specificity of antibody binding of DNT-FL conjugate was 
demonstrable by the observation that addition of excess unlabelled 
DNT caused the labelled DNT-antibody complex to dissociate, and 
consequently the fluram enhancement effect to be reversed. The 
effects of addition of DNTon the fluorescence intensity of a 
~ ~ 
solution containing 1.5 x 10 M DNT-FL conjugate and 1.16 x 10 M 
sheep IgG molecules are shown in Figure 5.2. These standard graphs 
permit the detection of DNT at concentrations as low as 3.5 nM 
in aqueous solution and 6.5 nM in spiked sera. 
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Figure 5.1 
Changes in the fluorescence intensity at 485 nm of a solution of 
desmethylnortriptyline-fluorescamine conjugate (7.5 x 10-7M) when 
sheep anti-nortriptyline 19G (graph A) and non-specific human 19G 
molecules (graph B) are added. Excitation wavelength,390 nm; 
bandwidths, 20 nrn. 
'. 
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Figure 5.2 
Fluorescence intensity changes at 485 nm as increasing amounts of 
unlabelled desmethylnortriptyline in pure solution ( ! f ) and 
in spiked sera (~) are added to a reagent mixture containing 
desmethylnortriptyline-fluorescamine conjugate (1.5 x 10-8M) and 
unlabelled sheep immunoglobulin G molecules (1.16 x 10-7M). 
Fluorescence intensity of the reagent mixture without unlabelled 
desmethylnortriptyline is assigned an arbitrary value of 100. 
Excitation wavelength, 390 nm ; bandwidths, 20 nm. 
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Experiments were also performed to investigate the 
changes in the fluorescence intensity when the IgM fraction of 
the same sheep antiserum was added to a solution of DNT-FL 
conjugate. Results of these investigations are given in Table 5.2. 
Comparison of the tabulated results with Figure 5.1 shows that a 
greater fluram enhancement effect was observed with the IgM 
molecules than with the IgG molecules at comparable immunoglobulin 
to DNT-FL conjugate molar ratios. It is naturally possible that 
a standard curve for DNT similar to that shown in Figure 5.2 
could be obtained using a reagent mixture containing IgM molecules 
and fluorescamine-labelled DNT conjugate. Since a greater fluram 
effect was observed with the IgM molecules, an improvement on 
the detection limits by several orders of magnitude might be 
attainable if IgM-containing reagents were used in the assay. 
Due to a lack of IgM protein. available, investigations into these 
possibilities were not performed. 
Table 5.2 
Fluram enhancement effect of DNT-FL conjugate when IgM 
molecules are added. 
I f (485) % Increase 
7.5 x 10-7M DNT-FL 40 
IgM/DNT-FL (mol/mol) 
0.34 58 45 
0.69 85 112 
1.38 168 320 
2.75 182 355 
4.14 182 355 
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Figure 5.} 
Corrected excitation (E) and fluorescence (F) spectra of a d.esmethyl-
nortriptyline-fluorescamine conjugate (---), and of a sheep anti-
nortriptyline IgG-fluorescein conjugate (label:protein ratio, 3.5:1) 
(- - - -) 
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The corrected spectra (Fieure 5.3) of the 
fluorescamine derivative of desmethylnortriptyline showed, 
excitation and fluorescence maxima at 390 nm and 490 nm, 
respectively. The excitation and fluorescence maxima of 
fluorescein-sheep anti-nortriptyline IgG conjugate were at 495 nm 
and 520 nm respectively. There is therefore the required 
excellent overlap between the fluorescence spectrum of the donor 
label (fluorescamine) and the excitation spectrum of the 
acceptor (fluorescein). Further, the overlap between the 
excitation spectra of the two labels is negligible: the 
efficiency of the observed energy transfer is thus undiminished 
even when large spectral bandwidths are used in the fluorimeter. 
Filter fluorimeters can therefore be conveniently used in this 
ETIA, in contrast to the case of fluorescein-rhodamine label 
pair (see Chapter 3). 
Energy transfer was demonstrated by adding fluorescein-
labelled antibodies (fluorescein to protein ratio, 7.5:1) to a 
40 nM solution of fluorescamine-labelled desmethylnortriptyline. 
The degree of energy transfer was assessed from the quenching 
effect of the fluorescamine emission at 480 nm and tbe enhancement 
of the fluorescein emission at 530 nm. A 3.4-fold molar excess of 
labelled antibody reduced the intensity of the fluorescamine 
derivative emission by 60 per cent and produced a 4.5-fold 
enhancement of the fluorescein enhancement (Fieures 5.4(a) & (b) ). 
As noted in previous stUdies of energy transfer using antigens 
labelled with fluorescamine as the donor label, the observed 
proportional reduction of the fluorescamine emission intensity, 
being partially offset by the fluram enhancement effect, was very 
much less than the corresponding proportional increase of the 
I 
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Figure 5.4(a} 
Quenching of fluorescamine (at 480 nm) and enhancement of 
fluorescein (at 530 nm) emission intensities when fluorescein-
labelled antibody conjugate (label:protein ratio, 7.5:1) are 
added to a fixed concentration of deemethylnortriptyline-
fluorescamine conjugate (4.0 x 10-~). Excitation wavelength, 
390 nm ; bandwidths, 20 nm. Molar ratio, labelled Ab:labelled Ag. 
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Figure 5.4(b) 
Same as in Figure 4.5(a) except that a value of 100 has been 
arbitrarily assigned to the fluorescence intensity of the 
fluorescamine derivative alone. 
-! 
-
137 
fluorescein fluorescence. In practice, this would mean that 
fluorimetric determinations in this type of ETIA can make use 
of only the fluorescein enhancement measurements. Figures 
5.4(a) and (b) also show that the fluorescence of both labels 
changed approximately linearly as the molar ratio of fluorescein-
antibody to fluorescamine-nortriptyline increased from 0.7 to 3.4. 
Addition of unlabelled desmethylnortriptyline reversed these 
effects, producing, for example, a reduction in the fluorescsin-
" 
antibody conjugate fluorescence at 530 nm. This reduction was used 
to set up standard graphs for the determination of tricyclic 
antidepressants in pure solutions and in spiked sera (Figure 5.5). 
In these assays the ratio of labelled antibody to labelled antigen 
was 2.;:1. The limit of detection of desmethylnortriptyline was 
about 2 oM (0.5 ng ml-1) in pure solution and about 6 oM in 
spiked sera. The precision of the assay was high (mean coefficient 
of variation = 1.1 %) 
'OO·r---~r--=--'-----------------------------------------------~ 
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Figure 5.5 Changes in the fluorescence intensity upon combining· 
DNT in pure solution ( 4-) and in spiked sera (-?-) with 
4.8.10·BMDNT-FL conju/>ate and 1.1 x 10·'M IgG-fluorescein conju/>ate 
(fluorescein:protein ratio, 7.5:1). Excitation wavelength, 390 nm; 
bandwidths, 10 nm. 
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Figure 5.6 Changes 
DNT and 
in the fluorescence intensities upon combining 
other tricyclic antidepressants 
-8 
containing 4.0 x 10 M DNT-FL conjugate 
wi th mixtures 
and 1.1 x 10-7M 
IgG-fluorescein conjugate. A value of 100 is arbitrarily 
assigned to the fluorescence intensity of the reagent 
mixture alone ie. without any unlabelled drug. 
Excitation wavelength, 390 nm; bandwidths, 12 nm. 
Cross-reactivity studies (~'igure 5.6) showed that 
nortriptyline, amitriptyline, imipramine and protriptyline 
generated fluorescence changes similar to those found for 
desmethylnortriptyline. Desipramine showed little reactivity in 
the assay, while ch10mipramine and butripty1ine showed partial 
reactivity. An enzyme immunoassay (A1-Bassam et a1,1978) for 
tricyc1ic antidepressants, using antiserum from the same source 
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as this work, showed similar cross-reactivities; such effects 
do not preclude the use of the assay in practice as these drugs 
are normally administered singly. Other immunoassay studies of 
nortriptyline showed that the major metabolite, 10-hydroxy-
nortriptyline, would not substantially interfere in the assay 
although present in greater amounts than nortriptyline itself 
(Maguire et al,1978; Ziegler et al,1976b). 
, 
The fluorescence immunoassay methods described 
provide several advantages over other heterogeneous assays for 
nortriptyline and tricyclic antidepressants (Maguire et al,1978; 
Al-Bassam et al,1978). The sensitivities of both fluorescence 
assays (from 0.5 - 1.5 ng ml-1 ) are more than adequate for the 
routine measurement of nortriptyline and other TAD's in plasma 
samples. The normal plasma levels of nortriptyline lie in the 
range 50 - 250 ng ml-1 (Ziegler et al,1976a). Desmethylnortrip-
tyline-fluorescamine conjugates required for use in both the 
assays can be prepared very easily and quickly immediately 
prior to the assay. The fluorescence assay methods are homo-
geneous, so the need for the troublesome separation step 
required in heterogeneous assays is eliminated. Finally, the 
prior extraction of plasma sample is not required, thus allowing 
for a more rapid assay. 
CHAPTER 6 HOMOGENEOUS FLUORESCENCE IMMUNOASSAY METHODS FOR 
HUMAN SERUM TRANSFERRIN. 
Comparative Studies of Fluorescamine and MDPF as 
Labels in Fluorescence Immunoassays. 
6.1 Introduction 
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6.1.1 Properties and clinical significance of transferrin. 
It was found by Holmberg and Laurell (1945;1947) 
that iron was principally transported in human blood plasma by 
the specific iron-binding ~,-g1obulin which they named 
transferrin (also called siderophilin). There are a.bout 20 
genetic variants of transferrin (Giblett, 1969), all apparently 
compatible with good health. At a normal blood pH, each 
transferrin molecule (molecular weight, 76500) can bind two 
atoms of Fe(III) to form a pink complex, although under normal 
circumstances the transferrin bindiQg sites are only one third 
saturated. The concentration of transferrin in human blood 
plasma is normally in. the range 200 - 400 mg dl-1 which may be 
decreased in cases of nephrosis (where there is a loss of 
transferrin in the urine), malignant neoplasia, or when there 
is a hereditary deficiency of the protein as in patients with 
a severe hypochromic anemia (Heilmeyer, 1964). Increased serum 
transferrin levels are observed in iron deficiency anemia and 
in the last months of pregnancy. Estrogenic substances such as 
those found in oral contraceptives can also cause an increase 
in the concentration of transferrin as well as other transport 
proteins in plasma (Laurell et al, 1968). 
" 
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6.1.2 Detennination of transferrin. 
Transferrin levels may be measured directly by 
immunological techniques or indirectly by measuring the maximum 
amount of iron the serum can bind, ie. the total iron-binding 
capacity (TIBC). The indirect technique overestimates transferrin 
by 10 - 20 % because the metal binds to proteins other than 
transferrin when the fatter is more than half saturated (van der 
Heul et al, 1972). Transferrin may be quantitated immunochemically 
by the radial immunodiffusion, electroimmunodiffusion qr.i~nuno­
nephelometric methods. Data comparing the immunochemical, radio-
isotopic and colorimetric procedures for the measurement of total 
iron binding capacity and transferrin appear in recent literature 
(Buffone et al, 1978, and references 1 to 4 cited therein;Daigneault· 
et al,1978). In this work,two fluorescence immunochemical methods 
for determining low concentrations of transferrin in serum samples 
have been developed. The first method is based on the enhancement 
in the fluorescence intenaitiea of the.fluorescamine and MDPF 
derivatives of transferrin on binding to anti-transferrin antibodies 
(fluorescence enhancement assays). The second method is an energy 
transfer ass~y in which either fluorescamine or MDPF as the energy 
donor is used in conjunction with fluorescein as the acceptor. 
The excellent sensitivities attainable in the energy 
transfer assays for human albumin (Chapter 4) and nortriptyline 
(chapter 5) show that the fluorescamine-fluorescein label pair are 
suitable for use in other applications of this ETIA method. Likewise, 
the sensitive fluorescence assays that were developed also for 
albumin and nortriptyline demonstrate clearly that the fluram 
enhancement effect can be Generally applied to the analysis Df both 
". 
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low and high molecular-weight antigens. MDPF resembles fluoresca-
mine in many respects: molecular structure, chemical reactions and 
luminescence characteristics (page 49). However, some workers 
(Handschin et al, 1976; Weigele et al, 197~a) have reported that 
MDPF provides several advantages over fluorescamine, including the 
greater .fluorescence stability of the MDPF conjugates over a wide 
pH-range. This stability has been attributed to the lack of a free 
carboxylic group, which in fluorescamine derivatives may give rise 
to an intramolecular nonfluorescent lactone (Weigele et al,1973a). 
The additional availability of MDPF to complement (if not to 
substitute for) fluorescamine in these FIA methods will cer:ta:!.nly. 
enhance the versatility of these fluorogenic reagents and enlarge 
the rather limited number of useful fluorophores for fluoroimmuno-
logical techniques. 
This chapter describes the experiments carried out to 
examine the comparative merits of fluorescamine and MDPF as 
fluorophores for specific applications in FIA. The bases for 
comparison include (a) the efficiency of the fluorophores as donors 
of energy (together with fluorescein as the acceptor) in ETIA; 
(b) the magnitude of the fluram and MDPF enhancement effects; (c) 
the accuracy and precision of the assay methods in the analyses 
of serum samples; and (d) the stability of the fluorescent conju-
gates under storage conditions. 
6.2 Experimental 
The Baird-Atomic Fluoripoint fluorimeter was used to 
record all quantitative fluorimetric measurements. The reagents 
were incubated at 30 C for at least 30 minutes before measurements 
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were made in 10 mm path length silica cuvettes thermostatted at 
the same temperature. Corrections were made for fluorescence 
background contributed by the phosphate buffer (0.01M, pH 7.2, 
containig 0.145M NaGl) , added proteins including se~m samples, 
and labelled antibodies. Corrected spectra were recorded,at 25 C 
using the Perkin-Elmer MPF-44B fitted with the DCSU-2 corrected 
spectra unit. 
Radial immunodiffusion was performed using M-Partigen 
Transferrin Immunodiffusion plates according to the recommendations 
of the manufacturer (Behringwerke AG, Marburg/Lahn, West Germany-
through Hoechst (UK) Ltd.). Zone diameters were measured after a 
48-hour inCUbation at room temperature. 
Serum samples were diluted 5- and 500-fold, 
respectively, p~ior to analysis by the immunodiffusion and energy 
transfer assay methods. Standard human serum (Behringwerke AG) 
was used as a standard. 
All fluorescent protein solutions were kept in the 
dark at 4 C. After six weeks in storage conditions, MDPF- and 
fluorescamine-labelled transferrin conjugates were found to be 
usable. Furthermore, no significant difference in the fluorescence 
properties between the two transferrin conjugates was evident. A 
solution of antibody-fluorescein conjugate, after four months in 
the same storage conditions, was found to be usable although a 
very slight precipitation of the conjugate was also noted. This 
was easily removed by centrifugation and the recovered sample was 
found not to have suffered any significant loss in immunological 
or luminescence properties. 
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6.3 Results and Discussion 
As noted above, the two fluorogenic reaeents (MDFF 
and fluorescamine) have many properties in common, and so in 
analogy with the fluram enhancement effect of fluorescamine 
derivatives, it can reasonably be expected that a similar enhance-
ment effect will also be observed with MDPF-labelled derivatives. 
This expectation i~ indeed borne out by experimental results. 
Figure 6.1 shows that the increases in the emission intensities 
at 465 nm of transferrin-fluorescamine (Trans-FL) and transferrln-
MDPF (Trans-M) conjugates are strongly dependent on the TIlolar 
excess of the added antibodies and the fluorophore:transferrin 
ratios of the conjugates. In all the transferrin conjugates 
examined, a greater magnitude of the enhancement effect was 
obtained with a more heavily-labelled conjugate than a liglltly-
labelled one. However, the results available are not sufficient 
to enable one to conclude which of the two transferrin conjugates 
(Trans-FL or Trans-M) exhibited the greater enhancement effect, 
even though it would appear from Figure 6.1 that the fluram 
enhancement effect was more pronounced compared to the MDPF 
enhancement effect. An accurate determination of the relative 
magnitude of these two effects would require the use of 
transferrin conjugates with the same degree of fluorescrunine and 
MDPF labelling. The effect on the fluorescence spectrum of a 
transferrin-fluorescamine conjugate on binding to increasing 
amounts of unlabelled antibodies is shown in Figure 6.2. Except 
for a general increase in the fluorescence intensity of the 
transferrin conjugate with added antibodies, no spectral 
distortion is evident and there is no shift in the m"ission 
spectrum maximum. 
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Figure 6.1 
Changes in the fluorescence intensities at 485 nm of mixtures 
containing a fixed concentration of transferrin-fluorescamine or 
transferrin-MDPF conjugates and increasing amounts of unlabelled 
antibodies: 
6 -8 ( )() x 10 M Trans-M conjugate label:protein ratio,2.8:1 --0---0-; 
6 1 -8 " t ( t" t" 6 ) ( ) x 0 M Trans-M conJuga e label: pro el.n ra l.0, .4: 1 ..; 
9 x 10-8M Trans-FL conjugate(label:protein ratio,3.7:1) (-0---0-); 
9 x 10-8M Trans-FL conjugate(label:protein ratio,7.8:1) ~ • . ). 
The changes in the fluorescence intensity of mixtures containing a 
fixed concentration of Trans-FL conjugate and increasing runounts of 
non-specific human 19G molecules are shown by (-x--x--). Pure solu-
tions of fluorescent conjugates have arbitrary fluorescence intensity 
of 100 • .\ •• ,390 nm; bandwidths, 8nm; molar ratio = Ab:Ag 
I, . 
, ' 
c 
440 500 560 620 nm 
Figure 6.2 
Spectra showing the changes in the fluorescence intensities 
of mixtures containing a fixed concentration of Trans-FL conjugate 
(7 x 10-8M; label:protein ratio, 7.8:1) and increasing amounts of 
antibodies: (a) without antibody; (b) Ab:Ag molar ratio, 5.2:1); 
(c) Ab:Ag molar ratiO, 9.1:1). Excitation wavelength, 390 nm; 
bandwidths, 8 nm. 
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Figure 6.1 also shows that the addition, of a 10.6-
fold molar excess of non-specific human IgG to a solution of 
transferrin-fluorescamine conjugate (label:protein ratio, 3.7:1) 
produced only a 12 % increase in the fluorescamine emission 
intensity at 485 nm, thus confirming that the fluram (and by 
analogy, the MDPF) enhancement phenomenon is a consequence of 
specific antigen-antibody combinations, and not of spurious 
environmental effec~s on the fluorescence intensity. 'rhe specificity 
of antibody binding of the fluorescent transferrin conjugates wa.s 
further demonstrated by the reversal of the enhancement effects 
when unlabelled transferrin molecules (in serially diluted 
standard serum samples) were added to dissociate the fluorescent 
antigen-antibody complex. The resultant decreases in the fluores-
cence intensities of transferrin-fluorescamine and transferrin-
MDPF conjugates were used to set up standard graphs for the 
determination of serum transferrin concentrations (Figure 6.3). In 
these assays, the molar excess of unlabelled antibodies were 12:1 
in 3 x 10-8M Trans-FL conjugate (label:protein ratio, 7.8:1), and 
11.8:1 in 3.4 x 10-~ Trans-M conjugate (label:protein ratio,7:1). 
The limits of detection in both assays are comparable (5nM = 
4 mg dl-1). 
Comparison of Figures 6.4 and 6.5 shows that the 
corrected excitation and fluorescence spectra of the fluorescamine 
and MDPF derivatives of transferrin are almost identical: the 
excitation and fluorescence maxima of both conjugates occur at 
390 nm and 490 nm, respectively. The corresponding maxima for a 
fluorescein-labelled antibody conjugate occur at 495 nm and 525 nm, 
respectively. The condition of optimum spectral overlap between 
the donor (FL or MDPF) emission and the acceptor (fluorescein) 
, 
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Figure 6., Fluorescence intensity changes at 485 nm as increasing amounts 
of unlabelled transferrin molecules (in serially diluted standard serum samples) 
are combined with mixtures containing (a) , x 10-8M Trans-FL conjugate (label: 
protein ratio, 7.8:1) and 3.6 x 10-711 antibody molecules ( ! ! ); 
(b) 3.4 x 10-8M Trans-M conjugate (label:protein ratio, 7:1) and 4 x 10-7M 
antibody molecules ( ~ ). Reagent mixtures without added unlabelled 
antibodies have arbitrary fluorescence intensity of 100. Error bars represent 
standard deviations for 3 measurements. Excitation wavelength,390 nm; bandwidths,6 nm. 
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Figure 6.4 corrected excitation ·(E) and fluorescence (F) spectra of a 
transferrin -fluorescamine conjugate (label:protein ratio, 
~.9:1) ( ), and of an antibody-fluorescein conjugate 
(label:protein ratio, 2.7:1) (- - - - ). 
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Figure 6.5 Corrected ~xcit~tiori (E) and fluorescence (F) spectra of a 
transferrin-MDPF conjugate (label:protein ratio, 3.2:1)(-----). 
Spectra 01 an antibody-fluorescein conjugate (- - - ) 
reproduced from Figure 6.4. 
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excitation spectra obtains, and therefore a high degree of 
energy transfer in the fluorescamine-fluorescein as well as in 
the MDPF-flu~rescein systems can be expected. 
Experiments to study the energy transfer effects of 
the two donor-acceptor pairs were performed by adding increasing 
amounts of antibody-fluorescein conjugates to solutions containing 
( -8 a fixed concentratioh of Trans-M conjugate 3 x 10 M; label: 
protein ratio,13.2:1), and also to solutions containing a fixed 
concentration of Trans-FL conjugate (7 x 10-8M; label:protein 
ratio, 13.9:1). The degrees of energy transfer were assessed by 
measuring the decreases in the donor (FL or MDPF) emission 
intensities at 485 nm and the concomitant increases in the 
acceptor (fluorescein) emission intensity at 530 nm ( excitation 
wavelength, 390 nm). Figures 6 •. 6 and 6.7 show that addition of 
increasing amounts of the labelled antibody molecules to the 
transferrin conjugates caused the quenching and the enhancement 
effects in the two donor-acceptor systems to increase approximately 
linearly up to a 4-fold molar excess of labelled antibodies. 
Thereafter, while the fluorescein emission intensities continued 
to increase linearly up to an antibody:antigen molar ratio of 6:1, 
the fluorescamine as well as the MDPF emission intensities 
appeared to be less susceptible to the quenching effect. In 
addition, for a given antibody:antigen molar ratio, the propor-
tional increase in the enhancement effect was rather greater than 
the proportional decrease in the quenching effect. As noted and 
explained previously in other stUdies of the fluorescamine-
fluorescein energy transfer (Chapters 4 and 5), this apparent 
disproportionality between the quenching and enhancement effects 
can be related to the counter-acting fluram and MDPF erihancement 
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• 
• 
. Figure 6.6 Enhancement of fluorescein fluorescence (530 run) and 
quenching of MDPF fluorescence (485 nm)-when increasing amounts of 
fluorescein-labelled antibody molecules are added to solutions 
containing a fixed concentration of Trans-M conjugate (3 x 10-~; 
label:protein ratio, 13.2:1). The degree of labelling of antibody 
is indicated by the "nil values: n = moles of nuorescein per mole 
of antibody. An arbitrary value of 100. is assigned to the fluorescence 
intensity of a pure solution of transferrin-MDPF conjugate. 
Excitation wavelength, 390 nm; bandwidths, 8 nm. 
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Figure 6.7 
As in Figure 6.6 except 
conjugate was used (7 x 
• 
" 
• n=6'4 
Ab-Fn 
Trans-FL 
• 
that a transferrin-fluorescamine 
-8 10 M; label:protein ratio, 13.9:1) 
effects which partially offset the quenching of the fluorescamine 
and MDPF emission intensities caused by resonance energy transfer, 
As shown in the same figures, the magnitude of the energy transfer 
effects in the two donor-acceptor systems is also dependent on the 
degree of fluorescein labelling of the antibody conjugates. The use 
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of a more heavily-labelled antibOdy-fluorescein conjugate 
appeared to cause the quenching effect to be increased more than 
the enhancement effect. An explanation for this observation is 
likely to be that in the condition of a higher concentration of 
fluorescein molecules, the observed enhancement in the fluoresce~n 
emission intensity would be much diminished by inner filter.effects 
due to the high background fluorescence. These results suggest that 
the optimum conditions required in the assays for transferrin 
, 
should include the use of heavily-labelled fluorescamine- or MDPF-
transferrin conjugates (label:protein ratiO, ca. 12:1) (donor) and 
a lightly-labelled antibody-fluorescein conjugate (label:protein 
ratio,:;; 4: 1) (acceptor). The molar excess of labelled antibody in 
the assay should be kept low (labelled Ab:labelled Ag molar ratio, 
ca.4:1). These conditions are essentially similar to those required 
in the energy transfer assay for albumin described in Chapter 4. 
Typical standard graphs for the determination of transferrin in 
pure solution and in serum samples are shown in Figures 6.8 and 6.9. 
The excellent specificity_of the assays was demons-
trated by the absence of cross-reactivities when two of the major 
constituents of serum proteins, albumin and IgG, were included in 
the assay medium (Figure 6.10). Furthermore, good agreement between 
the energy transfer assays and the immunodiffusion method was 
obtained when four serum samples were analysed for their transferrin 
contents. These results are summarized in Table 6.1. The precision 
of the two ETIA methods was comparable (mean CV = 6.6 %). 
Transferrin concentrations found in the three samples taken from 
healthy donors all lie within the normal range (200-400 mg dl-1). 
On the other hand, the blood sample taken from the victim of a 
road traffic accident was found to have a very low transferrin 
!. 
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Figure 6.8 
standard graphs for transferrin determination. 
Changes in the fluorescein fluorescence intensity at 530 nm when 
unlabelled transferrin molecules in aqueous solutions are added to 
. 8 
reagent mixtures containing (a) 5 x 10- M Trans-M conjugate (label: 
protein ratio,13.2:1) and 1.8 x 10-7M Ab-F conjugate (label:protein 
ratio,4:1) (--t-+ ) ; (b) 4 x 10-8M Trans-FL conjugate (label: 
protein ratio, 13.9:1) and 1.8 x 10-7M Ab-F conjugate (label:protein 
ratio,4:1) ( 1 ! ). 
Excitation wavelength, 390 nm; bandwidths, 12 nm. Error bars 
represent standard deviations for 4 measurements. 
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Figure 6.9 As in Figure 6.8 except that serially diluted 
standard serum solutions were used as standards. 
concentration. Bacterial degradation, as evidenced by the putrid 
smell emitted from the sample, might have been the cause for this 
low level of transferrin. 
It is apparent from these results that both 
fluorescamine-fluorescein and MDPF-fluorescein are suitable donor-
acceptor labels for use in other applications of the WrIA method. 
There is no significant difference in properties between 
fluorescamine and MDPF when these are used as donors of energy 
together with fluorescein as the acceptor. In the assessment of 
the relative magnitude of the fluram and MDPF enhancement effects, 
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it was found that such effects are strongly dependent on the 
fluorophore:protein ratios of the conjugates as well as the 
molar excess of unlabelled antibodies added. So an accurate 
determination of the comparative magnitude of these two enhance-
ment effects must make use of transferrin conjugates with the 
same degree of fluorophore labelling. However, in view of the 
close similarities between the two fluorogenic labels, it seems 
reasonable to assume that, all other conditions being equal, the 
fluram and MDPF enhancement effects are about comparable in 
magnitude. Thus, for applications in FIA, the choice between 
these two fluorophores would be dictated by the simple economic 
consideration of cost and availability. 
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Figure 6.10 Effect of adding transferrin (-0-0-), albumin 
(-6-tr-) and human IgG (-0--0-) to a solution mixture containing 
4.0 x 10-8M Trans-FL conjugate (labellprotein ratio,13.9:1) and 
1.8 x 10-7M Ab-F conjugate (label:protein ratio,4:1). An arbitrary 
value of 100 is assigned to the fluorescence intensity of the 
solution mixture without any added proteins. 
Excitation wavelength, 390 nm; bandwidths, 12 nm. 
Sample 
1 
2 
3 
RTA sample 
Table 6.1 
Determination of Serum Transferrin 
Radial immunodiffusion 
n = 5 
220 ± 16.5 
255 ± 13 
135 ± 6.8 
(n = 4) 
Energy Transfer Immunoassay 
FL as donor 
n = 5 
250 ± 18 
260 ± 17.5 
290 ± 16 
152 ± 9.4 
(n = 4) 
MDPF as donor 
n = 5 
240 ± 16 
215 ± 18 
285 ± 20 
All concentrations in mg dl-1 The serum samples were diluted 5- and 500-fold prior 
to analysis by the immunodiffusion and energy transfer assay methods, respectively. 
RTA = Road Traffic Accident .... 
VI 
0> 
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CHAPTER 7 DEVELOR1ENT OF FLUORESCENCE IMMUNOASSAY METHODS 
FOR HUMAN IMMUNOGLOBULIN G AND A 
7.1 Introduction 
7.1.1 The immunoglobulins G and A. Properties and clinical 
significance, 
The immunoglobulins are a family of structurally 
and functionally related serum glycoproteins whioh exhibit 
antibody activity. The basic structure of the immunoglobulin 
molecule oonsists of two identical heavy polypeptide chains 
and two identical light polypeptide chains joined together 
by interchain disulphide bonds and noncovalent forces 
(Edelman 1973; Porter 1973). There are, however, variations 
which account for the class and subclass differences and 
their varying antigen-binding capacities. Based on differences 
in heavy chain composition and molecular weights, the immuno-
globulins are classified into five classes, namely, 
immunoglobulin (Ig) G, IgA, IgM, IgD and IgE. Heterogeneity 
within classes allows for subclasses (Refer, for example, 
White et a1 (1978), p 930 ). 
The relative concentrations of serum immuno-
globulins change at various stages of growth and abnormalities 
are found in many disease states. These abnormalities 
generally fall into three categories I (i) decreased levels 
in two or more immunoglobulins as found in immunologic 
deficiency diseases; (ii) increased levels of two or more 
immunoglobulins as in cases of chronic infections; and (iii) 
large increase in the level of one of the immunoglobulins as 
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may occur in cases of myeloma •. 
Human IgG comprises 15 per cent of the total Sel'Uffi 
immunoglobulins with a mean adult serum concentration of 990 -
-1 1300 mg dl depending on the geographical factors. Its concen-
tration Is found to be raised in patients suffering from auto-
immune dineases (Sunderman 1964; Sherlock 1970) and in cases of 
IgG myelomas (Cohen 1968; Nah 1911). Decreased levels in serum 
"-
IgG are encountered in cases of congenital and acquired hypo-
gammaglobulinemia, some malabsorption syndrome and during 
excessive protein loss (Cohen 1968). Maternal IgG is the only 
class of illununoglobulin that is normally transferred across the 
placenta to the -foetus. 19G is, however, the last of the irnmuno-
globulins to be produced after an antigenic challenge or 
immuniza tion. 
Sensitive techniques which have already been developed 
for the quantitation of IgG in human serum and other biological 
fluids are summarized in Table 1.1. 
Table 7.1 Techniques for 19G quantitation 
Technique References 
Radial immunodiffusion 
Electroimm noassay 
lmmunoelectrophoresis 
Radioimmunoassay 
N.ephelometry 
Mancini et al (1965); Fahey et al(1965). 
Laurell (1966;1972); Perry et al (1974). 
Ghan ta and Hiramo to (1974). 
Salmon et al (1969); Cawley et al(1974); 
Woo et al (1979) 
Killingsworth and Savory (1972); 
Markowitz et al (1972); Deaton et al(1976). 
Enzymeimmunoassay Engvall and Perlrnann (1971); 
Halliday and Wisdom (1978). 
Fluorescence immunoassay Blanchard and Gardner (1978). 
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Ji'1lI1OJ1 immunoglobulin A, with a concentration of 200 mll' % 
in nOl.maJ uerum (Hobbs 1971), constitutes approximately 20 % of 
the serum immunoglobulins. As the major immunoglobulin in body 
seCreUOtlfl such as saliva, mucus, colostrum, etc., it provides 
protection for linings of the digestive, respiratory, excretory 
and n'productive passages (Gabl and Wachter, 1961). Secretory 19A 
contains an additional structural unit called the secretory piece 
(Hansen and Johanssen, 1967). 
Serum'lgA concetration is found to be raised in patients 
suffering from Wiscott-Aldrich syndrome and 19A multiple myeloma 
(Cohen 1960; Nah 1971), in some stages of auto immune disease, and 
in mmlY cases of hepatic cirrhosis (SUnderman, 1964). Decreased 
levels of serum 19A are found in cases of nephrotic syndrome, 
gastrointestinal disease associated with severe protein loss and 
certain leukemias. Extremely low concentrations of IgA have also 
been encountered in cases of ataxia telangiectasia and congenital 
affammaglobulinemia (Cooper et aI, 1973). 
7.1.2 Development of fluorescence immunoassay methods for 
immuIloglobulin G and A. 
This chapter describes the FlA methods that have been 
developed in this. work for the quantitation of 19G and 19A. The 
fluorescrunine-fluorescein label pair are again applied to the 
development of a direct ETlA for 19G and an indirect (sandwich) 
ETlA for 19A. The methodology used in the direct energy transfer 
assay for 19G is as previously described for nortriptyline and 
transferrill (Chapter 5 and 6 respectively). In the sandwich assay 
for 19A, separate portions of the rabbit anti-lgA mltibodies are 
labelled 'Ilth fluorescrunine (donor) and fluorescein (acceptor) 
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respectively. Addition of unlabelled IgA molecules causes the 
aggregation of the separately labelled antibodies. '1'he mean 
distance between the donor and acceptor groups within the 
"sandwich" immune complex formed should be sufficient for 
resonrolcc energy transfer to occur. The consequent quenching of 
the donor and/or enhancement of the acceptor emission intensities 
can be related to the amount of the IgA present. In this method, 
the use of purified or enriched antigens is not necessary. 
studies on the Duram and MDPF enhancement effects of IgG 
, 
conjugates show that such effects can also be applied to the 
development of fluorescence assays for the determination of 19G. 
7.2 Experimental 
Quantitative fluorimetric measurements were performed 
in thermostatted 10 mm path length silica cuvettes using the 
MPF-44B Spectrofluorimeter. All determinations were made at 35 C 
after reagents had been incubated for one hour at the same 
temperature. Corrections were made for fluorescence background 
contributed by the buffer (0.01M phosphate, pH 7.2, containing 
O.145M NaCl) and added proteins including standard serum and test 
serum samples. The fluorescence background due to the added 
labelled antibodies was also subtracted from all measurements in 
the quantitative study of the energy transfer effects between 
IgG-fluorescamine conjugates and added antibody-fluorescein 
molecules. All spectra were recorded in the corrected mode. For 
the detennination of IgG concentrations in test serum samples, the 
sera were diluted 400-fold prior to analysis by the energy transfer 
and the Duram enhancement assay methods. 
7.~ llesultn and Discussion 
7. ~.1 FlA methods for 19G determination 
Experiments were first performed to study the fluram 
and HDPF enhancement effects of 19G-fluorescamine and 19G-
HDPF conjugates. Figures 7.1 and 7.2 show respectively the 
changes in the emission spectra of a solution of 19G-FL 
conjugate (7.8~x 10-8M; label:protein ratio, 6.6:1) and of 
a solution of 19G-MDPF conjugate (2.3 x 10-8M; label:protein 
, 
ratio, 6.8:1) when increasing amounts of unlabelled rabbit 
anti-IgG antibodies were added. A notable feature of these 
spectra is that, except for a general enhancement of the 
fluorescence in the 400 - 600 nm range, no significant shift 
in the emission maxima at 495 nm was evident. The magnitude 
of the fluram and MDPF enhancement effects is also very 
dependent on the fluorophore:protein ratios of the conjugates, 
with l,eavily-labelled conjugates ,exhibiting the largest effects 
(see Figure 7.3). This finding had previously been noted when 
such effects were encountered in transferrin conjugates 
(Chapter 6). The specificity of antibody binding of the 
fluorescent 19G conjugates was illustrated by the reversal of 
the enhancement effects on combining unlabelled 19G molecules 
(in pure solutions and in serially diluted standard serum) with 
(a) 1.1 x 10-8M 19G-FL conjugate (F:P ratio, 10.8:1) solution 
containing a 12.4-fold molar excess of unlabelled antibodies -
see Figure 7.4 ; and (b) 9.5 x 10-9M 19G-MDPF conjugate (F:P 
ratio, 9.9:1) solution containing a 14.3-fold molar excess of 
unlabelled antibodies - see Figure 7.5. These standard graphs 
permit the quantitation of 19G in pure solutions and diluted 
serum samples at nanomolar levels and below. 
'. 
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400 500 600 nm 
F il,'1lre 7. 1 
Spectra showing the changes in the fluorescence intensity of a 
solution of IgG-FL conjugate (1.85 x 10-8M; label:protein 
ratio, 6.6:1) upon adding increasing amounts of unlabelled 
rabbit anti-IeG antibodies: 
(a) without antibody; (b) Ab:IgG-FL molar ratio, 0.65:1 ; 
(0) 1.3:1 ; (d) 1.95:1 ; (e) 2.6:1 ; (f) 3.25:1 ; (g) 3.9:1 ; 
(h) 6.55:1 ; (i) 9.82:1 ; (j) 13.1:1 • 
Note the overlapping Raman scatter peak at ca. 465 run which 
appeareu as a shOUlder in spectra (a) - (d). Excitation 
wavelength, 390 run; bandwidths, 8 run. 
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• 
" 
400 500 600 nm 
Figure 7.2 
spectra showing the changes in the fluorescence intensity of 
a soluLion of IgG-MDPF conjugate (2.3 x 10-6M; label:protein 
ratio, 6.6:1) upon adding increasing amounts of unlabelled 
rabbit anti-IgG antibodies: 
(a) without antibody; (b) 1.5:1 ; (c) 2.0:1 ; (d) 6.9:1 ; 
(e) 14.6:1. 
spectra were recorded with "blank" (ie. added unlabelled 
antiboules) subtractions. Hence the absence of the overlapping 
Immrul scatter peak at 465 nm in all the spectra. Cf. Figure 7.1. 
ExoitaLion wavelength, 390 nm; bandwidths, 6 nm. 
166 
200 
1~U 
100~0--~~----~4----~----~8-----J----~1~2----~ 
MOLAR RATIO 
Figure 'r. 3 
Changes in the fluorescence intensity at 485 nm of Inixtures 
containing a fixed concentration of 19G-FL or 19G-MDPF 
conjugates and increasing amounts of unlabelled anti-leG 
antibodies. 
1.9 x 10-0M 19G-M conjugate (label:protein ratio, 9.9:1)(-0--0-); 
3.4 x 1O-8M 19G-M conjugate (label:protein ratio, 16:1) ('" .. ); 
-8 1.9 x 10 M 19G-FL conjugate (label:protein ratio, 9.3:1)(-0--0-); 
,·IJ )( ) 2.2 x 10 M 19G-FL conjugate (label:protein ratio,16.7:1 ~X-. 
Pure solutions of fluorescent 19G conjugates have arbitrary 
emission intensity of 100. Excitation wavelength, 390 nm; 
bandwidUw, 8 nm. 
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Figure 7.4 Fluorescence intensity changes at 490 nm upon combining IgG molecules in 
pure solutions (A) and in serially diluted standard serum (B) with 1.1 x 1O-8}! IgG-FL 
conjugate (F:P ratio, 10.8:1) and 1.4 x 10-7M anti-IgG ffiolecules. Reagent mixture 
without any added ll.'llabelled IgG has arbitrary fluorescence intensity of 100. Error 
bars represent standard deviations. Excitation wavelength, 390 nm; bandwidths, 12 nm. 
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Figure 7.5 Fluorescence intensity changes at 490 r~ upon combining unlabelled IgG 
molecules in pure solutions with 9.5 x 10-9M IgG-MDPF conjugate (F:P ratio, 9.67:1) 
and 1.4 x 10-7M anti-IgG molecules. Other details as in Figure 7.4. 
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Tile corrected spectra of Figure 7.6 show once 8{;ain that 
there is excellent spectral overlap between the fluorescamine 
(donor) emission and the fluorescein (acceptor) excitation 
spectra. NI efficient energy transfer between IgG-fluorescrunine 
and wltibouy-fluorescein molecules can therefore be expected to 
occur within the antigen-antibody complex. Studies of the energy 
transfer effects were performed by adding increasing amounts of 
antibody-fluorescein molecules to solutions containing a fixed 
, 
concentration of IgG-fluorescamine conjugate. ~'he magnitude of the 
transfer (lff';cts was assessed by measuring the decreases in the 
fluorescamine emission intensity at 485 nm and the simultaneous 
increaseD in the fluoreocein emission intensity at 530 nm 
( excitation wavelength, 390 nm). Results obtained are summarized 
in Ficurcn 7.7(a), (b) and (c). The general conclusions to be 
drawn from these results are similar to those already discussed in 
Chapter 6. In particular, the observed disproportionality between 
the quenching and enhancement effects can again be related to the 
counteracting fluram enhancement effect which partially offset the 
quenching of the fluorescamine emission by energy .tranefer. The 
optimum conditions required for the development of an energy 
transfer assay for IgG are also similar to those found for the 
assays of albumin (Chapter 3) and transferrin (Chapter 6). These 
include the use of a heavily-labelled IgG-fluorescrunine conjugate 
(label:protein ratio, 12:1) and a lightly-labelled antibody-
fluorescein conjugate (label:protein ratio, < 2:1). Exrunples of 
standard graphs for the assay of IgG in pure Bolutions. and in 
serum samples are shown in Figure 7.8. 
Resul ts of the analyses of 3 test serum sampl.es by 
the enercy transfer assay and the fluorescence enhancement assay 
methods are summarized in Table 7.2 : good agreement between the 
two methods is obtained. 
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Figure 7.6 Corrected excitation (E) and fluorescence (F) spectra of an 
IgG-fluorescamine conjugate (label:protein ratio, 10.8:1) ( - ), 
and of an aritibody-fluorescein conjugate (label:protein ratio,1.5:1) 
(- - - - ). 
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Figure 7.1 (a) 
Enhancement of fluorescein fluorescence (530 nm) and quenching of 
fluorescamine fluorescence (485 nm) when increasing amowlts of 
fluorcscnin-labelled antibody conjugate (F:P ratio, 1.5: 1) are 
added to solutions containing a fixed concentration of IgG-FL 
-8 ) conjugate (9.2 x 10 M; F:P ratio, 10.8:1 • 
Excitation wavelength, 390 nm; bandwidths 10 nm. 
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As in Figure 7.7(a) except that antibody-fluorescein 
molecu.les with label:protein ratio, 2.5:1 are added to 
2.2 x 10-8M IgG-fluorescamine conjugate (label:protein 
ratio, 9.3:1) 
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Figure 1.1(c) 
AB in Figure 1.1(a) except that antibody-fluoreacein 
molecules with label:protein ratio, 2.511 are added to 
2.2 x 10-8M IgG-fluorescamine conjugate (label:protein 
ratio, 16.1:1). 
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Figure 7.8 standard graphs for 19G determination 
Changes in the fluorescein fluorescence (5}0 nm) when unlabelled 
19G molecules in pure solutions (A) and in serially diluted 
standard serwn (B) are combined with 2.2 x 10-8M 19G-FL conjugate 
(F:P ratio, 10.8:1) and 1.0x 10-7M antibody-fluorescein conjugate 
(F:P ratio, 2.5:1). Fluorescence intensity of reagent mixture 
without any added unlabelled 19G is assigned an arbitrary value of 
100. Error bars represent standard deviations. Excitation wavelength, 
}90 nm; band.widths, 8 nm. 
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Table '( .;> Detennination of IgG 
Fluorescence immunoassay methods 
Srunl,le ETIA "Fluram" enhancement assay 
A 1260 ± 106 (5) 1195 ± 96 (5) 
B 1078 ± 93 (5) 1020 ± 80 (4) 
c 1130 ± 98 (4) 1200 ± 92 (4) 
COl1<'entrations in mg dl-1• Figures in brackets refer to the 
number of detenninations. 
Experiments were also perfonned in an attempt to 
develop fl solid-phase energy transfer assay for IgG based on 
on!., of the reaction schemes outlined below. 
Scheme I. Competitive binding assay with labelled antigen (IgG*) 
on solid-phase 
* ** I-IgG + IgG + Ab 
* Scheme ll. Noncompetitive sandwich assay with Ab on solid-phase. 
** 
I- IgG ~<:=~" f-Ab!..IgG Ab ) * *.)(-\--Ab-IgG-Ab 
Scheme III Competitive binding assay with Ab** on solid-phase. 
f- ** * :. *-M- * f-'Ab~IgG Ab + IgG + IgG 
... 
f-Ab-IgG + 
I- = solid-phase 
* = donor label (eg. fluorescamine) 
** = 
acceptor label (eg. fluorescein). 
Attempts to immobolize the fluorescent protein conjue,ates onto 
the lJIlNUUOBEADS (the solid-phase) have so far not yielded 
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satisio'.,l.ory results. The observed fluorescence signal from the 
inullobilbed conjugates was found to be too feeble to permit Hs 
use in the development of a solid-phase energy transfer assay. 
7.3.2 Dflndwich ETIA for 19A determination 
In the sandwich ET!A method for 19A determination, 
separato portions'uf the rabbit anti-lgA antibodies were labelled 
with f1uore~camine and fluorescein respectively. The corrected 
excitation and fluorescence spectra of these conjugates are 
shown ill Figure 7.9. Since the 19A molecule is multivalent (MW of 
mOllomerJc !gA = 180000), the reaction of the differently labelled 
antibody fractions with the antigen should bring the donor and 
acoppior label groups wi thin close proximity, and therefore 
resonruJec energy transfer can be expected to occur within the 
molecular- dimension of the sandwich immune complex formed. ,In 
order to first establish the optimum conditions required for the 
devulop'oent of a sandwich energy transfer assay for 19A, a 
nwnber of preliminary experiments were performed. 
The change in the fluorescence intensity upon 
adding wl1abelled 19A molecules to antibody-fluorescamine (Ab-E'L) 
conjugate was first investigated. Results are summarized in 
Table 7.5. Addition of 19A to a solution of Ab-FL conjugate 
(2.4 x 10-8M; label:protein ratio, 14.7:1) resulted in a small 
enhancement of the fluorescence up to a maximum of 19 per cent. 
This enhancement effect, though small in magnitude, is 
nevertheless analoGOus to the fluram enhancement effect 
encouniered in previous stUdies of fluorescamine-Iabelled 
antigens. 
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Figure 7.9 Corrected excitation (E) and fluorescence (F) spectra of 
a fluorescamlne-labelled anti-IgA conjugate (label:protein ratio, 
14.7:1) ( ), and of a fluorescein-labelled anti-I&! conjugate 
(label:protein ratio, 2.3:1) (- - - - - ). 
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Table 7.3 
Changes in the fluoresoamine fluoresoenoe (at 490 nm) upon 
binding 19A moleoules with antibody-fluorescamine conjugate 
(label:pJ'otein ratio, 14.1:1). Excitation wavelength, 390 nm. 
-8 2.4 x 10 M Ab-FL 
19A : Ab-FL 
(molar ratio) 
2.3 
4.' 
6.8 
9.1 
11.4 
54.0 
60.0 
60.0 
60.0 
The Ab-FL concentration was then varied while 
keeping the concentration of unlabelled 19A constant at 
at 2.73 x: 10-9M and 5.45 x 10-8M. Fluorescence measurements 
(at 490 urn) were made both without the inclusion of unlabelled 
antIbody (~'igure 7.10) and with the addition of an amount of 
unlabelled antibody sufficient to maintain a constant total 
antibody concentration of 2.4 x 10-8M (see Figure 7.11). In 
both the cases (Figures 7.10 and 7.11) it was found that the 
enhancement produced by the 19A moleoules beoame significant 
only in very low conoentrations (4.8 x 10-9M) of Ab-FL 
containing a large excess of the 19A molecules (5.45 x 10-BM). 
In the absence of unlabelled antibody, no signifioant enhanoe-
ment ill the fluorescence was evident in the oase when the IgA 
cOlleentration is low (2.73 x 1O-9M) - see curve B in Figu.re 7.10. 
However, in the presence of the unlabelled antibody, a small 
..... 
'. 
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increas,~ ( ca. 8 % ) in the fluorescence intensity was noted at 
low concentrations of Ab-FL containing 2.73 x 10-9M IgA - see 
curve B in Figure 7.11. 
The above experiments were repeated using fluorescein-
labelled antibody (Ab-F) conjugate (label:protein ratio, 2.3:1) in 
place of the unlabelled antibody and with the concentration of IgA 
kept constant at 5.46 x 10-9M. Fluorescence measurements at 490 nm 
(fluorescamine emission) and at 530 nm (fluorescein emission) were 
, 
made. The re suI ts are shown in ~'igure 7.12. In contrast to the 
erulrulcement in fluorescence (at 490 nm) noted above, a reduction 
in the fluorescamine emission at 490 nm and a simultaneous 
ellilanc6ment in the fluorescein emission at 530 nm were observed as 
the Ab-F/Ab-FL molar ratio was varied from 0.7 to 4.0. There did 
not seelfl to be any signific~t change in the fluorescence 
intensi ties when the Ab-F/ Ab-FL molar ratio < 0.7. On the basis 
of these results, 1.5/1 and 4.0/1 mixtures of Ab-F and Ab-FL were 
incubated with increasing amounts of IgA and the fluorescence 
intens.LUes at 490 nm and 530 nm were recorded. These results are 
summarized in Figures 7.13 and 7.14. At very low concentrations 
of the IgA (~55 nM), an increase in the fluorescein emission 
at 530 nnl was accompanied by a reduction in the fluorescamine 
emission at 490 nm. However, as the IgA concentration was 
increased, not only was there an ellilancement in fluorescein 
emission but the reduction in the fluorescamine emission appeared 
to be offset by a counter-acting ellilancement effect (cf. fluram 
enhancement effect). Addition of comparable wnounts of nonspecific 
bovine serum albumin (RSA) and bovine gammaglobulin(BGG) to the 
labelled antibody mixtures resulted in only a small enhancement 
in fluorescence which can be attributed to the viscosity effect. 
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An explanation for these observations seems likely to be that, 
as the IgA concentration in the assay mixture is increased, the 
fluram enhancement effect (refer Table 7.3) becomes so pronounced 
to the extent that it can more than offset the quenching of the 
fluorescamine emission caused by energy transfer. In practice 
this would mean that the assay must utilize only the fluorescein 
emission measurements. In the assays developed, IgA at nanomolar 
concentrations can be detected. However, a seriolls drawback is 
the narrow concentration range in which these assays are applicable. 
It is proposed as suggestions for further work that experiments 
be performed to optimize the assay conditions along the lines 
described above. 
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Ratio of the fluorescence intensities (at 490 run) of Ab-FL 
conjugate (label:protein ratio, 14.7:1) solutions measured 
in the presence and absence of IgA whose concentration is 
kept constant at (A) 54.5 nM ; and (B) 2.73 riM. 
Excitation wavelength, 390 nm; bandwidths, 6 nm • 
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Figure 7.11 
Ratio of the fluorescence intensities (at 490 nm) of Ab-FL 
conjugate (label:protein ratio, 14.7: 1) solutions measured in 
the presence and absence of (A) 54.5 oM IgA and (B) 2.73 rnl IgA 
plus sufficient unlabelled antibody to maintain a total 
constant antibody concentration of 2.4 x 10-~. 
Excitation wavelength, 390 nm; bandwidths, 6 nm. 
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4 
Ratio of the fluorescence intensities (at 490 nm and 530 nm) 
of mixtures containing Ab-FLconjugate (label:protein ratio, 
14.7:1) and Ab-F conjugate (label:protein ratio, 2.3:1) in the 
presence and absence of 5.46 nM IgA. The composition of the 
separately labelled antibody fractions is varied but the total 
-8 antibody concentration is kept constant at 2.4 x 10 M. 
Excitation wavelength, 390 nm; bandwidths, 6 nm. 
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Figure '7. 13 
Effect of IgA on the fluorescence of a 1.5/1 mixture of Ab-F 
conjugate (labellProtein ratio, 2.3:1) and Ab-FL conjugate 
(label:protein ratio, 14.1:1) having total antibody concentration = 
4.8 x 1Q-8M• Intensity changes at 530 nm ars indicated by (.....:-.- ); 
at 490 nm by (x x x ). Effect of nonspecific bovine serum albumin 
and gammaglobulin on the fluorescence of the mixture is indicated 
by (.) and ( A. ) respectively. Excitation wavelength, 390 nm; 
bandwidths, 6 nm. 
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Figur'e 7. 14 
As In Figure 7.13 except that a 4/1 mixture of Ab-F and 
Ab-FL conjugates is used. Other details same. 
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CHAP'l'lm 8 AUTOMATION OF AN ENERGY TRANSFER D1MUNOASSAY BY USING 
Sl~PPED-FLOW INJECTION ANALYSIS WITH MERGING ZONES 
8.1 In troduction 
Since its introduction in 1974 by Ruzicka and Hansen 
(1975), and by Stewart et al (1974), flow injection an,uysis 
has been applied 'to the. automation of a number of de terminations 
(reviewed ~y Betteridge,1978). These analyses have been 
performed by injecting precisely measured sample zones into a 
reagent-containing carrier stream; by varying the design of the 
flow system, a wide range of interfacial gradients Call be 
exploited. This approach is less well-suited to analyses in 
which the reagent is a biological macromolecule such as an 
antibody or enzyme, since such reagents may be costly and are 
often available only in small quantities: published applications 
include the use of readily-available enzymes to the analysis of 
. , 
glucose (Hansen et al,1977) and urea (Ruzicka et al,1979b) in 
serum. lwo additional principles recently applied to flow 
injectIon analysis have, however, opened up new potential 
applications of the technique. It has been shown (Ruzicka and 
Hansen,1978) that "stopped flow" analyses are feasible ie. that 
the dispersion of a sample zone in the carrier stream will 
remain constant if the flow rate of the stream is reduced to 
zero. nlis principle is of great value in kinetic assays (Ruzicka 
and Hansen, 1978 & 1979a) and in analyses where an inCUbation 
period is required before the sample zone reaches the detector. 
In addl.lion, economies of sample and of reagent can be achieved 
by usIu(; the "merging zone" approach, in which small volumes 
of sample and reagent are injected into inert carrier streams 
18"1 
and lI'org" before reacting and being carried to the detecto.r. The 
merging zone principle has been applied to a number of analyses 
(Bergamill nt aI, 1978; Zagatto et al, 1979) including, in 
conjunction with the stopped-flow principle, the enzymatlc assay 
of serum rslucoes (Ruzicka and Hansen,1979a). 
This chapter describes the application of flow 
injection analysis in the field of immunoassay. The stopped-flow 
and merging-zone principles are applied to the automation of a 
, 
homogeneous energy-transfer immunoassay for albumin described in 
Chapter 3. In this assay fluorescein and rhodamine were used aB 
the donor - acceptor fluorescent labels, though as pointed out ill 
Chapter 3, these groups are far from ideal. Since the phenomenon 
of ener/:,"Y transfer involves a change in the fluorescence 
properties of one or both of the labels on antigen-antibody binding, 
the analyais is homogeneous (ie. no separation step is required) 
and very sui table for automation. Previous stUdies have shown 
that a fluorimetric detector can be combined successfully w.i th 
flow injection analysis in the determination of albumin by a dye-
binding procedure using anilinonaphthalene (Braithwaite and Niller, 
1979). A modification of that assay using the merging zono 
principle will also be described. 
8.2 Experimental 
Flow injection analysis was performed using the 
arrangement shown in Figure 8.1. The pump was a Gilson Minipuls 
IIP-4 8-charmel instrument and the double-injection valve 
(Figure U.2) was obtained from BlFOK (Sollentuna, Sweden) 
through I~.D.T. Research Ltd., London (Cf. Ruzicka and Hansen,1979o.). 
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Flow-injection analysis arrangement. (B) Bypass; (n) fluorimetric 
detector; ~I) injector valve; (1) reaction coil; (Q) pump; 
(R) reagent; (S) sample; (T) 3-way valve; (W) waste. 
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Figure 8.2 Double-injection valve 
The rotor (2) of the double-injection 
valve is sandwiched between two stators 
(1 and 3) and the whole system is 
clamped together and held in place by a 
bolt. Two volumteric bores in the rotor 
allow precisely measured volumes of the 
sample and reagent to be introdu.ced. into 
the carrier stream. The diagram shows a 
volu.metric bore of the rotor filled with 
the sample solution (shown sha~ed) before 
sampling; the carrier stream enters 
through the bottom stator at "b" and 
bypasses the rotor through a shunt. 
During sampling the rotor moves in the 
direction indicated by the shruied arrow 
and introduces the precisely measured 
sample zone into the carrier stream. The 
shunt is being bypassed during sampling 
because of its higher hydrodynamic flow 
resistance. 
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Po1yethy1ene tubing was used throughout and was connected using 
the manifold system shown in Figure 8.3. The lengths and diameters 
of the tubing used were as follows: a = b = 250 mm. long, 0.5 mm. 
i.d. c = d 150 mm. long, 0.5 mm. i.d. ; e = 100 mm. long, 0.7 mm. 
i.d. bypass (B) = 320 mm. long, 0.7 mm. i.d. The reaction coil, 
L, was made of 0.7 mm. i.d. tubing and was 650 mm. long for the 
dye-bindill/l' assay and 950 mm. long i'or the immunoassay. 'rhe detector 
was a Perkill-E1mer Model 1000M filter fluorimeter, with a flow cell 
specially adapted with silica tUbing of 1 mm. i.d. (Figure 8.4). 
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Figure 8.4 Flow cell 
The illuminated volume of the cell was ca. 16 III • Excitation 
and emission wavelengths were 364 and 410 run respectively for 
the dye-binding assay, and 410 and 541 nm respectively for the 
immunoassay. The fluorimeter was connected to an Omniscr.ibe 10 mV 
recol'tler (Houston Instruments). 
The carrier stream was a phosphate buffer (0.067M, 
pH 7.0 for the dye-binding assay; 0.01M, pH 1.2, containing 
0.14;;H NaCl for the immunoassay). The 8_anilino_1_naphthalene 
sulphonic acid (ANS: Sigma) was used at a concentration of 15 
-1 mg 1 • Pure human serum albumin and purified rabbit anti-
albumin antibodies were labelled with fluorescein isothiocysnate 
and rhodamine isothiocyanate respectively as described in 
I 
20 • 
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Section 2,).1. Electroirnmunoassay was done on "Cellogel" 
cellulose acetate membrane (Section 2.3.2 ). Individual serum 
samples were obtained from healthy laboratory workers. 
8.3 Renuli;s 
8.3.1 ANS binding procedure 
This assay, previously performed using conventional 
flow-injection procedures (Braithwaite and Miller, 1979), was 
successfully adapted to the merging zone approach. A flow rate of 
1 1 · -1 .03 m m1ll was used. The volumes of sample and reagent injected 
(determined by injecting an air-bubble into the carrier stream) 
were 10.4 ~l. This represents a substantial saving in reagent 
compared with the previous method. The merge time, sampling time, 
and residual time (non-stop) were 9.8 s, 3.0 s, and 23.6 s 
respectively. A linear relationship was obtained between the 
fluorimeter response (fluorescence of protein-bound ANS) and 
albumin concentration in the range 0 - 200 mg dl-1 (Figure 8.5) 
[al bUMin]/(me/100ml) 
Ficure 0.5 Standa.rd graph for albumin determination using 
ANS binding procedure. 
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Using dilnted standard serum the coefficient of variation was 
01 -1 of -1 was 2., 70 at 18 mg dl and 2.1 70 at 180 mg dl • The coefficients 
of variation using diluted test sera were somewhat higher, averag-
ing 4.5 96. The albumin concentrations of four test sera were 
determined, the results being given in Table 8.1. 
8.,.2 EnerGY Transfer Immunoassay 
, 
Initial attempts to automate this assay using 
conventional ~low injection procedures gave unsatisfactory results. 
Not only was the consumption of labelled albumin and labelled 
antibody unacceptably high, but the high background fluorescence 
of the carrier stream (a mixture of the labelled species) severely 
restricted the precision and the sensitivity of the assay. These 
objections were overoome using the stopped-flow, merging zone 
method. The injected reagent was a solution containing 2.4 x 1O-7M 
fluorescein-labelled albumin (fluorescein:albumin ratio, 1.4:1) 
-6 ( and 4 x 10 M rhodamine-labelled antibody rhodamine: antibody 
ratio, 16.5:1). Previous stUdies (Chapter ,) had demonstrated that 
this combination of lightly-labelled antigen and heavily-labelled 
antibody, with a large excess of the latter, produced optimum 
results when the assay was performed without automation. n.l.luted 
serum srunples were injected at S (Figure 8.1). The flow rate used 
was 3.8 ml min-1, giving a merge time of ,.2 s, a non-stop residual 
time of 16 s and sample and reagent volumes of ,6 ~l. A stopped-
flow incubation time of 6 minutes was used: during this period, the 
three-way valve, '1', was used to divert the carrier stream through 
the bypass, and the recorder chart was switched off. The recorder 
was re-started as '1' was turned to re-start the flow of the sample. 
In the analysis of unlabelled (sample) albumin 
" 
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concentrations, the fluorescence of the fluorescein label was 
detennined (the fluorescence of the rhodamine label was too 
feeble in practice to provide a sensitive assay - see Chapter 3). 
Fluorescence intensities were related to the emission from a 
2.4 x 10-7M labelled albumin solution, arbitrarily assib~ed a 
value 0.1' 100. The results obtained in this way were satisfactory. 
Readily-measurable fluorescence peaks were obtained (.Ficure 8.6): 
the coefficient of~ariation of the results using diluted straldard 
sera was 2.5 % at an albumin concentration of 5 x 10-~,nnd 2.3 % 
, 
at a concentration of 10-7M. The standard curve obtained (Figure 
8.7) showed that albumin concentrations of 10-7M and below could 
be determined. The values obtained from four test sera are shown 
in Tabl (' 8.1, along with the results of the ANS binding nnd 
electroillununoassay techniques: agreement between the three methods 
was genu'ally good. 
8.4 Discussion 
The results demonstrate clearly the suitability of 
stopped-flow merging zone flow injection analysis for tile 
automation of homogeneous immunoassays: they also confinn the 
usefulneas and senaitivity of a fluorimeter as a detector fol' 
flow injcc tion methods. In the present assay the flow injec tion 
approach had several substantial advantages over the staUc 
analysis described in Chapter 3. These included smaller saJnpleo, 
a considerable economy in labelled reagents and a shorter 
incubation period. The incubation period of six minutes was 
perfectly adequate in the albumin assay, but there would be no 
technical objections to the use of longer periods if required in 
other assays. ~'he use of a flow cell of narrow bore precluded 
any interference by inner filter effects, and the background 
-. 
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fluorescence of the diluted serum was negligible compared with 
the fluorescein emission. 'I'he detection limit of the assay was 
more than adequate for the determination of albumin in diluted 
serum saH'ple,j' and in urine (Cf. Woo et al, 1978). Improved 
detection limits could almost certainly have been achieved by the 
use of a spectrofluorimeter, rather than a fH ter fluorimeter, as 
the detec lor: detailed studies of the fluorescein-rhodamine energy-
transfer pair show that larger quenching and enhancement effects 
occur at narrow spectral bandwidths (Chapter 3). 
, 
The 'relatively low sampling rate available in this 
stopped-flow assay can be improved upon by modifications to the 
manifolds (Ruzicka and Hansen, 1978) and in any event provides a 
faster throughput of samples than the manual method. 'l'wo further 
small problems were noted, the first being the need to carry out 
frequent checks (by injecting air-bubbles) to ensure synchronous 
merging 01' the sample and reagent: very small adjustments in the 
flow rate could be achieved by means of a screw clip attached to 
a short length of thin-walled tubing inserted in one of the 
channels (cg. in tube "a" in Figure 8.1). The second problem was 
the tendency of air bubbles to form in the carrier strerunm this 
effect could be avoided by equilibrating the srunples and the 
reagents at 37 C before beginning an analysis. 
A wide variety of other homogeneous immunoassays are 
suitable for automation using flow injection analysis, including 
fluorescence quenching, enhancement and polarization assays. The 
present energy trannfer approach can also be applied to the 
analysis of many other macromolecules and low molecular-weight 
species such drugs and hormones. Flow injection techniques will 
increasincJ Y used in thin branch of clinical and biochemical annl ysis. 
". 
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Figure 8.6 Exampl<;!s of recorder responses obtained during 
the energy transfer immunoassay of serum albumin in diluted 
standard serum. The albumin concentrations were: (A) 1.1 x 10-6M; 
(B) 5.5 x 10-6M; (c) 1.1 x 10-~. 
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Figure 8.1 
standard curve for the energy transfer immunoassay for serum 
albumin. Error bars represent standard deviations. 
, 
Table 8.1 
Determination of albumin in serum samples 
MS-binding Energy-transfer 
immunoassay - FIA* 
Electroimmunoassa}' 
Sample * FIA method 
I (100) 3700 t 180 [10] 
2 (100) 3600 t 170 [10] 
3 ( 40) 4380 t ISO (10] 
4 ( 75) 3675 ± 200 [ 8] 
-1 All concentrations in mg.dl. 
FIA * : Flow injection analysis 
(lOO) 
(500) 
(500) 
(lOO) 
method methcd 
, 
/ 
3860 t 200 [8] (150) 3800 t 
3320 t 170 [8] (150) 3680 t 
4810 t ISO [8] (150) 4500 ± 
3460 t 220 [4] (150) 3080 ± 
Figures in round brackets are the factors by which serum samples were 
diluted before study; figures in square brackets are numbers of 
measurements used in calculating standard deviations. 
140 [5] 
80 [8] 
140 [7] 
80 [5] 
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CHAPTER 9 CONCLUSION 
In contrast to other fluorescence immunoassay (FIA) 
methods, energy transfer immunoassay (ETIA) requires the 
simultaneous use of two different types of fluorescent labels, 
the donor and acceptor, attached respectively to the antigen and 
antibody in the direct assay method, or to separate portions of 
the antibody in the indirect (or sandwich) assay method. The 
'" 
direct and indirect assays that have been developed and deocribed 
in this thesis demonstrate clearly that ETIA is a general 
immunochemical method applicable to the analysis of both haptens 
(eg. nortriptyline) and macro-molecular species (eg. IgG, IgA, 
transferrin, etc ). Tile principal merits of the energy transfer 
assay technique can be summarized as follows. 
(a) Sensitivity 
In the assays developed in this work, detection 
limits in the sub-nanomolar range were attainable. For maximum 
assay sensitivity, it has been found necessary to optimize a 
given assay system with 'respect to a number of experimental 
variables including the degrees of labelling of antigen and 
antibody, the total concentration and the relative compositi,on 
of the labelled antibody and antigen in the assay, the 
fluorimeter spectral bandwidth, etc. 
(b) Specificity 
The sirnul taneous observation of the quenching and 
enhancement effects of the energy transfer phenomenon pennito 
specific antigen-antibody combination to be distinguished 
from spurious environmental effects on the fluorescence 
intensity. 
(c) Wide applicability 
The same donor-acceptor labels may be applied to 
.. 
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the analysis of a wide range of materials. The instrumentation 
required in this case is a relatively simple fluorimeter ,~ith 
filters providing fixed exciting and emitting wavelengths. 
(d) Speed of analysis 
Relatively short incubation times are required 
(cf. immunoprecipitation methods). An incubation time of one 
hour at a temperature of 35 C had been found to be adequate for 
the analyses performed in the present study. Furthermore, the 
assay is homogeneous and hence can dispense with the troublesome 
separation step required for the heterogeneous assays. This has 
permitted the successful application of the flow injection 
analysis principles to the automation of an energy transfer 
immunoassay for albumin (Chapter 8). With the trend towards 
increasing use of microprocessor-based technology in analytical 
instrumentation and the rece~t introduction of image detection 
in fluorimetry (Talmi et al, 1978), it seems likely that the 
next few years will witness rapid developments in the field of 
fluorescence immunoassay automation which will in turn 
contribute to increasing the speed of analysis by the ETIA 
method. 
(e) Stability of labelled reagents 
The labelled immune reactants were found to be 
generally stable both under measurement conditions and on storage. 
In the case of fluoresc:amine-Iabelled antiGens, the preparation 
of the conjugates can be easily performed immedietely prior to 
the analysis. 
All the applications of ETIA so far described in . 
this thesis as well as in the pUblished works have utilized only the 
-, 
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fluorescein-rhodamine and the fluorescamine-fluorescein label pairs. 
These pairs of labels are by no means ideal or adequate for the wide 
applicability of which the ETIA technique is capable. ~'here is there-
fore. a need to develop new fluorescent. labels specially desiglled for 
specific applications in energy transfer assays. 
A principal requirement of the ET!A technique is 
the need to use purified homogeneous antigens and antibody with a 
high degree of specificity in order to avoid the excessive 
fluorescence background due to the non-specific fluorescence-labelled 
proteins. Recent advances in in vitro mouse myeloma cell fusion 
techniques have made possible the increasin(l' commercial availability 
of monoclonal antibodies in gram quantities (Koprowski et al, 1977). 
It can be expected that the use of these highly enriched immune 
reactants in the assay system will further increase the sensitivity 
and specificity of the ET!A technique. 
Attempts to develop a solid-phase ETIA method have 
so far not yielded satisfactory results primarily because the 
fluorescence sigaal from the immobilized fluorescent conjugates was 
too feeble to permit its application in an assay. Much work is 
therefore needed to overcome this problem before a number of possible 
solid-phase ETIA's can be developed based on the reaction schemes 
outlined on PUB'e 175. 
Detailed studies of the fluram and the analogous 
MDPF enhancement phenomena have revealed that such effects might 
also be encountered with many other fluorescamine- and NDPF- labelled 
antigens. A more thorough theoretical understnnding of the mechanisms 
underlyil1(l' these phenomena is required in order to exploit these 
effects for the development of a &Snerally-applicable fluorescence 
enhancement assay. 
----------------------------_._---
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